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Abstract 
The Gram positive anaerobic bacterium, Clostridioides difficile, is one of the 
leading causes of hospital associated diarrhoea world-wide. An opportunistic 
pathogen, C. difficile colonises the gut during intestinal microbial dysbiosis, 
causing Clostridioides difficile infection (CDI). Treatment of CDI is 
complicated by the increasing numbers of recurrent infections.  
C. difficile has demonstrated its ability to produce composite, adherent 
multicellular communities, or biofilms, in vitro. In vitro biofilms offer the 
bacteria within increased resistance to a range of environmental stresses 
including antibiotics and oxygen stress. However the mechanisms underlying 
C. difficile community formation are poorly understood. In other bacteria, 
quorum sensing, a process mediated by small signalling molecules that 
accumulate in the extracellular environment, coordinates biofilm formation. 
In several bacteria, the metabolic enzyme LuxS, produces the signalling 
molecule autoinducer-2 (AI-2), which plays a key role in quorum sensing. AI-
2 is considered to be a cross-species signalling molecule and for many 
bacterial species AI-2 has been shown to have a signalling role during biofilm 
formation and development. 
 
Here we show C. difficile luxS mutants (LuxS) are defective in biofilm 
formation and demonstrate the ability for chemically synthesised AI-2 to 
partially restore the biofilm defect of LuxS. Through RNA-seq analysis we 
show that LuxS/AI-2 quorum sensing likely influences C. difficile prophage 
expression, affecting levels of extracellular DNA present within the biofilm. 
Additionally we show that Bacterioides fragilis has an inhibitory effect on C. 
difficile, with increased levels of inhibition observed in WT compared to LuxS. 
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By utilising dual species RNA-sequencing we propose a number of possible 
mechanisms responsible for the observed inhibition.         
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Chapter 1  INTRODUCTION 
Clostridioides difficile  
Clostridium difficile is an anaerobic, Gram positive bacterium belonging to 
the phylum Firmicutes. It exists in two forms: the motile, rod-shaped, 
vegetative cell and the endospore (spore) (Hall and O'Toole, 1935). The 
vegetative bacteria are metabolically active and capable of reproduction 
whilst spores are metabolically dormant, allowing the bacteria to survive for 
long periods in unfavourable conditions such as: extreme temperatures, 
oxygen and harsh physical or chemical environments (Setlow, 2007). As 
proposed by Lawson and Rainey (2015) recently, Clostridium difficile was 
reclassified to the new genus of Clostridioides (Lawson et al., 2016), in order 
to restrict the genus Clostridium to Clostridium butyricum and related 
species,  
 
It is interesting to note that initial knowledge of Clostridiodies difficile and C. 
difficile Infection (CDI) stem from three separate lines of study spanning an 
80-year period (Bartlett, 1994). The earliest known studies were on 
pseudomembranous colitis (PMC), a condition first described in 1893 by John 
Finney (Finney, 1893) and characterised by pseudomembranous lesions of 
the intestinal tract. However, relatively little was known about PMC until the 
1950s, when it became a relatively common complication of antibiotic usage 
(Bartlett, 1994). At the time, Staphylococcus aureus was suspected to be the 
pathogen responsible, due to recovery of this organism from patient stools 
(Bartlett, 1994). Nonetheless, with the benefit of hindsight it is clear that C. 
difficile was the most likely cause (Bartlett, 1994). 
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Research on C. difficile itself, did not to begin until its isolation in 1935.  
Formerly named Bacillus difficilis from the Latin ‘difficilis’, which means 
difficult or obstinate, due to the “unusual difficulties” encountered in its 
isolation and study (Hall and O’Toole, 1935). C. difficile was originally 
described as a component of the normal intestinal microbiota of newborn 
infants (Hall and O'Toole, 1935). Whilst not harmful to neonates, it was 
shown that C. difficile produced a toxin that was highly lethal to guinea pigs 
(Hall and O'Toole, 1935).  
 
A third line of study began during the Second World War with the creation of 
a rodent model to investigate the potential benefits of penicillin for 
treatment of gas gangrene (Hambre M, 1943). During the study, guinea pigs 
were inoculated with Clostridium perfringens and treated subcutaneously 
with penicillin. It was found that many of the guinea pigs developed typhlitis, 
which proved more lethal than C. perfringens-induced gas gangrene 
(Hambre M, 1943, Bartlett, 1994). The cause of this was to remain elusive 
until 1978, when these separate lines of study were finally linked and C. 
difficile was implicated as the causative agent of PMC and antibiotic-
associated diarrhoea (Bartlett, 1994). 
 
It is now known that C. difficile is an opportunistic pathogen of both humans 
and animals causing a toxin-mediated intestinal disease, more commonly 
known now as C. difficile infection (CDI) (Smits et al., 2016) (also known as C. 
difficile associated disease or CDAD). The symptoms of this infection can 
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range from mild diarrhoea to severe conditions such as PMC and toxic 
megacolon.  
 
Since the 1970s, C. difficile has been well studied, with a lot of emphasis 
placed on the role of two large toxins, toxin A and toxin B, which were 
quickly recognised as the main virulence factors (Voth and Ballard, 2005). In 
recent years recurrent infections have become a significant problem affecting 
20-36% of patients  (Aslam et al., 2005, Zar et al., 2007) leading to greater 
research focus on other processes important to pathogenesis such as 
colonization and sporulation.  
 
1.1 C. difficile infection  
C. difficile is transmitted by spores that can be readily isolated both in 
healthcare settings and at low levels in the environment and food supply, 
allowing for both nosocomial and community transmission (Dubberke et al., 
2007, Otter et al., 2015, Lund and Peck, 2015). Whilst carriage of C. difficile is 
most commonly asymptomatic (as is the case for neonates [Hall and O’Toole, 
1935]), in susceptible individuals colonisation by C. difficile can lead to 
disease formation, with symptoms ranging from mild self-limiting diarrhoea 
to severe, relapsing and potentially fatal pseudomembranous colitis  (Smits 
et al., 2016). CDI is recognised to be one of the leading causes of infectious 
diarrhoea in the healthcare setting (Rupnik et al., 2009) with elderly patients 
undergoing treatment with broad-spectrum antibiotics at the highest risk of 
infection (Goorhuis et al., 2008, Vardakas et al., 2012).  
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Although the precise mechanisms for colonisation resistance are yet to be 
deduced, disruption to the intestinal microbiota, usually due to antibiotic 
use, increases the availability of nutrients and alters the production of 
secondary metabolites that are inhibitory to C. difficile germination and 
outgrowth (Theriot et al., 2016). Once ingested, the C. difficile spores survive 
the gastric acid and digestive enzymes of the stomach passing through to 
the duodenum where they germinate and proliferate  (Smits et al., 2016). The 
vegetative cells associate in the caecum and colon, where they are thought 
to adhere and quickly establish itself as a dominant species within the gut of 
susceptible individuals (Rupnik et al., 2009, Dubberke and Olsen, 2012). 
 
The early 2000s marked the beginning of an epidemic, with hospitals around 
the world reporting dramatic increases in the number of severe instances of 
CDI over the next several years (Rupnik et al., 2009), with about 450,000 
cases and 29,000 deaths each year, in the United States alone (Lessa et al., 
2015). Isolates from this period were sequenced and subsequently known as 
BI/NAP1/027 (McDonald et al., 2005). This strain is characterised by high-
level fluoroquinolone resistance, efficient sporulation, and high toxin 
production. Although there is no clear explanation for the dramatic increase 
in instances of CDI, a number of theories have been proposed, including a 
growth advantage observed for C. difficile, in the presence of trehalose, a 
food supplement that became widely used at around the same time period 
(Collins et al., 2018b).  
 
The most important risk factor for CDI remains antibiotic use, with broad 
range antibiotics such ampicillin, amoxicillin, cephalosporins, clindamycin and 
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fluoroquinolones most frequently associated with CDI (Ananthakrishnan, 
2011, Owens et al., 2008, Pepin et al., 2005). The risk and severity of CDI 
increases with age (Rupnik et al., 2009). Whilst the majority of cases are 
thought to be hospital acquired, C. difficile is now recognised as a cause of 
community-associated diarrhoea. Furthermore, the PCR ribotypes of strains 
isolated from patients within the community have a significant overlap with 
strains isolated from patients with CDI in hospitals, suggesting a common 
source of C. difficile (Hensgens et al., 2014, Eyre et al., 2013). Interestingly, 
more than 30% of patients experiencing CDI within the community do not 
have the typical risk factors i.e. recent antibiotic treatment (Hensgens et al., 
2011, Wilcox et al., 2008). Studies have also suggested that the use of proton 
pump inhibitors could be a risk factor, however the underlying rationale for 
this is unclear (Janarthanan et al., 2012, Kim et al., 2012).  
 
Outbreaks of CDI are particularly disruptive, often resulting in patient 
isolation, ward closures and in some cases, hospital closures (Cartman et al., 
2010). Treatment for C. difficile is complicated by its intrinsic antibiotic 
resistance which is attributed to the large number of mobile elements 
containing antibiotic resistance genes, within the bacterium’s genome 
(Sebaihia et al., 2006). For mild, single occurrences of CDI associated with 
antibiotic-induced alterations to the gut microbiota, treatment can simply 
involve withdrawal of antibiotics, which allows the gut microbiota to recover 
(Rupnik et al., 2009). In severe or recurrent infections however, treatment is 
more challenging. Patients experience high levels of recurrence ranging from 
20% after an initial episode to 60% after multiple recurrences. Recurrent 
infections are often caused by re-exposure to or reactivation of C. difficile 
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spores in patients with an impaired immune system or weakened barrier 
function of the colonic microbiota (Marsh et al., 2012). Patients with multiple 
recurrences respond to treatment with metronidazole or vancomycin initially, 
but symptoms return days or weeks after the treatment is stopped (Rupnik et 
al., 2009). 
 
Historically vancomycin and metronidazole were the only available 
antibiotics for C. difficile, with CDI patients being treated with pulse dosing 
of vancomycin every other or third day. The hope of this was to enable the 
normal gut biota to re-establish, whilst preventing C. difficile from re-
growing (Leong and Zelenitsky, 2013). In 2011, fidaxomicin, a poorly 
absorbed antibiotic with activity against specific anaerobic gram-positive 
bacteria, was approved by the food and drug administration (FDA) for the 
treatment of CDI. Fidaxomixin has been shown to have a similar cure rate for 
acute infections as vancomycin, however, it substantially lowers the risk of 
recurrence compared to vancomycin (Cornely et al., 2012, Louie et al., 2011). 
Despite this, the high cost of fidaxomycin has curtailed its use (Vaishnavi, 
2015).  
 
In recent years, the most effective treatment for severe multiple occurrences 
of CDI has been the replenishment of the normal gut biota by means of a 
faecal transplantation, a procedure first reported in 1958 (Aas et al., 2003).  
Although successful in 90% of patients experiencing recurrent infections 
(Rohlke and Stollman, 2012), this treatment has some risks associated with it. 
Not only have changes to the gut microbiota been associated with certain 
types of cancer (Zackular et al., 2013), but there is also the risk of disease 
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transmission from the faecal donor to the recipient. The precise organisms 
responsible for providing resistance against C. difficile, and the mechanisms 
involved are not yet known, but multiple studies have indicated that both the 
Bacteroidetes and Firmicutes  may play important roles (Seekatz and Young, 
2014). As the Bacteroides have been shown to be nutritionally diverse, 
capable of utilising a wide variety of carbon sources, these organisms may 
simply be better adapted to surviving in the gastrointestinal tract. 
Additionally, these organisms have been shown to play an important role in 
the biotransformation of primary bile acids into secondary bile acids (Theriot 
and Young, 2015). Some secondary bile acids such as taurocholate, have 
been shown to promote C. difficile germination, whilst others such as 
deoxycholate have been shown to inhibit C. difficile outgrowth. This ability 
for secondary bile acids to both enhance and inhibit C. difficile germination 
and outgrowth is thought to play an important role in the restoration of 
colonisational resistance.      
 
Finally if all treatments fail to stem the infection, the only life-saving 
alternative is for the removal of the colon (Lamontagne et al., 2007). 
 
1.2 Virulence Factors 
The diarrhoeagenic phenotype of CDI is accredited to the toxins produced by 
C. difficile (Vedantam et al., 2012). The main toxins produced by the 
organism are TcdA and TcdB, with an additional toxin, Clostridioides difficile 
transferase (CDT), found in some strains, most notably ribotypes 027 and 
078. All naturally occurring diarrhoeagenic strains produce TcdB with most 
strains also producing TcdA (Vedantam et al., 2012).  
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As the majority of C. difficile strains associated with CDI are toxigenic, the 
two large clostridial toxins TcdA and TcdB are the most well characterised C. 
difficile virulence factors (Borriello et al., 1990, Voth and Ballard, 2005, Warny 
et al., 2005). Nonetheless, a number of other factors are needed for the 
disease to take hold e.g. Colonisation of the host, adhesion to the gut 
mucosa, and dissemination (Vedantam et al., 2012). However, the late 
development of molecular tools for C. difficile hindered the study of these 
other non-toxin virulence factors (Vedantam et al., 2012). Whilst studies are 
now focusing on these gaps in our knowledge, little is known about the role 
these virulence factors play during infection. 
 
1.2.1 Toxins 
1.2.1.1 Toxin A and toxin B 
The two large toxins TcdA and TcdB produced by C. difficile (Voth and 
Ballard, 2005), have long been shown to cause the symptoms of the disease, 
triggering intestinal damage and the release of nutrients from the damaged 
colonic epithelium (Voth and Ballard, 2005). Both toxins glucosylate Rho 
family GTPases, leading to the disruption of the actin cytoskeleton, cell death 
and a strong inflammatory response (Just et al., 1995, Voth and Ballard, 2005, 
Carter et al., 2012).  
 
Both toxins are encoded in the 19.6 kb Pathogenicity Locus (PaLoc) (Figure 
1). The PaLoc is very stable and conserved amongst toxigenic strains (Cohen 
et al., 2000). Although nontoxigenic strains lack the PaLoc, they are still 
capable of colonising the gut (Cohen et al., 2000, Curry et al., 2007). 
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Figure 1: PaLoc locus encodes C. difficile Toxins  
The 19 kb pathogenicity locus (PaLoc) encodes both toxin A and toxin B (TcdA and 
TcdB). In non-toxigenic strains PaLoc is replaced by a 115 bp sequence (Rupnik et 
al., 2009). Reproduced with permission from Springer Nature. 
 
The PaLoc encodes five genes: tcdA, tcdB, tcdC, tcdE and tcdR. Both genes 
encoding toxins tcdA and tcdB are separated by an intervening sequence, 
tcdE (Voth and Ballard, 2005). TcdE shares homology to phage holin, a 
protein with pore-forming activity used to release the phage from the host 
cell. It has been demonstrated that TcdE is important for the release of TcdA 
and TcdB from R20291 cells (Govind and Dupuy, 2012, Govind et al., 2015). 
However its function is less clear in 630 (Olling et al., 2012). 
 
TcdR, an alternative sigma factor, directs transcription from both TcdA and 
TcdB promotors as well as its own promotor, while TcdC is an anti-sigma 
factor that negatively regulates TcdR. Genes within the PaLoc are expressed 
during stationary phase and it has been demonstrated that the expression of 
the toxin genes is regulated by the global gene regulator CodY (Dineen et al., 
2007). When nutrients are in abundance, CodY binds to the promoter region 
of tcdR thus repressing toxin gene expression. When environmental nutrients 
are lacking, CodY disassociates from tcdR thus enabling expression of both 
large toxins (Voth and Ballard, 2005, Dineen et al., 2007, Carter et al., 2012). 
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TcdA and TcdB are both glucosyltransferases and transfer glucose from UDP-
glucose to small GTPases such as Rho, Rac and Cdc42 in the host cell. 
Glucosylation deforms these small proteins, disrupting the signalling 
pathways that they are involved in. This results in alterations to the actin 
cytoskeleton leading to disruption of tight junctions and loosening of the 
epithelial barrier, disruption of barrier function, and eventually, cell apoptosis 
(Figure 2a) (Abt et al., 2016). The net effect of these alterations is rapid fluid 
loss into the intestinal lumen, manifesting as diarrhoea (Voth and Ballard, 
2005, Carter et al., 2012, Vedantam et al., 2012).  
 
In addition to the direct cytotoxic effects of TcdA and TcdB, both toxins have 
also been demonstrated to provoke inflammatory responses to which the 
additional tissue damage may lead to serious clinical conditions such as 
pseudomembranous colitis (Ng et al., 2010). 
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Figure 2: Mechanism of action of C. difficile toxins in epithelial cells.  
(A) the repetitive oligopeptides (CROPS) domain of TcdA binds to carbohydates on 
the apical surface of epithelia cells, whereas TcdB binds to a poliovirus receptor-like 
3 (PVRL3) expressed on colonic epithelial cells. Both toxins are internalised, where 
the acidification of the endosome enables the CROP domain to embed into the 
endosomal membrane. The cysteine protease domain (CPD) and the glucosyl 
transferase domain (GTD) are consequently transported into the cytosol. The 
cysteine protease is activated by inositol hexakisphosphate (IP6) to release the toxin 
glucotransferase. RHO or RAC GTPases are inactivated by glucosylation, which 
results in the breakdown of tight junctions and epithelial integrity. (B) C. difficile 
transferase (CDT) is internalised by binding to the lipolysis-stimulated lipoprotein 
receptor (LSR). The CdtB subunit creates pores in the acidified endosome releasing 
the CdtA subunit into the cytosol. The ADP-ribosyl transferase activity of the CdtA 
subunit inhibits actin polymerisation near the cell membrane. This enables the 
fibronectin microtubules to elongate and protrude through microvilli enhancing C. 
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difficile adherence to the epithelium (Abt et al., 2016). Reproduced with permission 
from Springer Nature. 
 
Structural analyses of both TcdA and TcdB have shown both toxins to be 
single stranded proteins, each possessing four structural domains, including: 
(i) an amino-terminal glucosyltransferase domain (GTD), (ii) an autoprotease 
domain (APD), (iii) a pore-forming and delivery domain, (iv) the combined 
repetitive oligopeptides (CROPS) domain. Although receptor binding occurs 
at the CROPS domain located at the C termini of both toxins, a number of 
studies have demonstrated the ability for the toxin to bind to cells in the 
absence of the CROP domain (Olling et al., 2011, Goy et al., 2015, Manse and 
Baldwin, 2015). Activation of the APD by eukaryotic inositol hexakisphophate 
releases the GTD into the cytosol of the host cell resulting in toxin activity 
(Abt et al., 2016).   
 
Another important C. difficile toxin is CDT which is an actin-specific ADP-
ribosylating toxin encoded by cdtA-cdtB (Figure 3) (Carter et al., 2007, Rupnik 
et al., 2009). The ADP-ribosyl transferase activity of the CdtA subunit inhibits 
actin polymerisation, inducing morphological changes in the host intestinal 
epithelial cells (Figure 2B) (Abt et al., 2016). Thus facilitating increased 
adherence of the organisms possessing this toxin (Schwan et al., 2014). 
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Figure 3: Clostridioides difficile transferase locus. 
Clostridioides difficile transferase (CDT) is encoded on a separate region of the 
chromosome on the CDT locus which comprises three genes (Rupnik et al., 2009). 
Reproduced with permission from Springer Nature. 
 
The contributions of both TcdA and TcdB to disease progression remains a 
matter of debate with two laboratories separately obtaining conflicting 
results with regard to the role of TcdA in the hamster model. One study 
showed that both toxins could individually cause severe disease, whilst the 
other found that TcdB alone was required for virulence (Lyras et al., 2009, 
Kuehne et al., 2010, Kuehne et al., 2011).   
 
1.2.2 Sporulation 
 
When bacteria exist as spores they are highly resistant to a range of 
environmental factors including extremes of heat, pH and chemical stresses. 
C. difficile spores are no exception; additionally being resistant to mechanical 
forces and aerobic conditions (Borriello et al., 1990). Due to their 
morphological and physiological features these spores can persist for large 
amounts of time on hospital surfaces as well as in the air, resisting 
conventional disinfection protocols (Lawley et al., 2009).  The ability of the 
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spore to endure in the environment is crucial to both acquisition and 
transmission of CDI (Deakin et al., 2012). 
 
Upon ingestion, the spore is able to tolerate the low pH environment of the 
stomach, passing through to the intestinal tract where it germinates. Patients 
with CDI excrete large numbers of spores into the environment leading to 
transmission of the disease (Deakin et al., 2012). However, a small number of 
spores may remain in the intestinal tract. As the antibiotics used to treat CDI 
do not kill spores, they are able to germinate and recolonise the intestinal 
tract once treatments are stopped (Sarker and Paredes-Sabja, 2012). 
 
During sporulation, external factors trigger the signal cascade of sigma 
factors causing the vegetative form of the bacterium to be transformed into 
a highly resistant spore. One of the most common signals to induce 
sporulation is starvation (Setlow, 2007). The initial stages of sporulation are 
evolutionarily conserved between Bacillus subtilis and C. difficile with sigma 
factors remaining the key regulators of the pathway. Although it should be 
noted that the sigma factors controlling sporulation behave quite differently 
in both species, activating at different times (Pereira et al., 2013).  
 
The master regulatory protein Spo0A, which is activated by phosphorylation, 
governs entry into sporulation (Molle et al., 2003, Deakin et al., 2012, Pereira 
et al., 2013). As Spo0A regulates several other cell processes including 
biofilm formation, the concentration of phosphorylated Spo0A present 
within the bacterial cell is used to control which cell process becomes 
activated, with higher levels of phosphorylated Spo0A committing the cell to 
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sporulation and repressing other vegetative cell functions (Piggot and 
Hilbert, 2004).   
 
1.2.3 Surface Virulence Factors 
S-layer 
Surface layer proteins (SLPs), also called the S-layer, are surface associated 
paracrystalline arrays, formed by identical subunits of glycoproteins or 
proteins. Present in most prokaryotes (Sara and Sleytr, 2000), the function of 
the SLPs are far reaching and includes: acting as molecular sieves, protective 
factors against parasitic attack, virulence factors, adhesion sites for 
extracellular proteins and, maintaining the cell envelope integrity. Roles for 
SLPs have even been observed in cell division, biofilm formation and 
swimming (Sara and Sleytr, 2000). In C. difficile the S-layer appears to be 
important for growth. As such, research into its function has been seriously 
hampered by a lack of slpA mutants (Dembek et al., 2015). 
 
The S-layer of C. difficile is mainly composed of two proteins, a high-
molecular-weight (HMW) SLP of 40kDa and a low-molecular-weight (LMW) 
SLP of 35 kDa (Cerquetti et al., 2000). Both the HMW and LMW SLPs are 
derived from the same precursor, SlpA. The SlpA pre-protein contains a 
signal peptide directing translocation of the protein across the cell 
membrane. Once across the membrane, SlpA is cleaved by the cysteine 
protease Cwp84, to form both the HMW and LMW SLPs (Calabi et al., 2001, 
Fagan et al., 2009). The SLPs are then tightly linked by a non-covalent 
complex, with the HMW SLP localised to the bacterial cell wall and the LMW 
SLP displayed as the external surface of the bacterium (Fagan et al., 2009) 
(Figure 4). As the LMW SLP is immunologically variable (Cerquetti et al., 2000, 
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Fagan et al., 2009), it has been suggested that this may play a part in evasion 
of the immune system (Vedantam et al., 2012). However, a recent study by 
Kirk et al. (2017) noted that the LMW SLP is the binding site for 
bacteriophages suggesting this antigenic variation could be a result of 
selective pressure to change the bacteriophage receptor (Kirk et al., 2017). In 
other studies it has been found that C. difficile chemically stripped of SLPs 
show a diminished adherence in both animal models and human HeLa cells, 
demonstrating a role of the SLP in adhesion to the host (Takeoka et al., 
1991). 
 
 
Figure 4: C. difficile cell wall model. 
 (A) Two types of surface layer proteins are presented. High MW SLP are shown as 
light grey molecules, and low-molecular-weight SLP shown as dark grey. Two-lobed 
structures (white) represent other minor cell wall proteins with thevertical black bars 
representing putative cell wall polymers. (B) The precursor protein SlpA, the 
cleavage sites producing the signal peptide is indicated by th dark arrow head and 
the mature HMW SLP and LMW SLP by thelight arrow head (Fagan et al., 2009) 
Reproduced with permission from John Wiley and Sons. 
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1.2.4 Cell wall proteins 
Genetic studies have also demonstrated the presence of 28 paralogs of SlpA 
within the C. difficile 630 genome. Collectively known as cell wall proteins 
(CWP), these proteins were all found to contain three copies of the Pfam 
04122 motif, a complex cell wall binding motif characteristic of the SLPs. It 
has been proposed (Karjalainen et al., 2001) that this motif mediates the 
binding of these proteins to the underlying cell wall. Many of these proteins 
also carry a second variable motif.  
 
The best characterised examples of CWPs are Cwp66, a putative adhesin 
(Waligora et al., 2001), Cwp84 (Janoir et al., 2007), a cysteine protease that 
mediates the cleavage of the SlpA precursor (Kirby et al., 2009, Dang et al., 
2010) and the degradation of a variety of host cell extracellular matrix 
proteins (Janoir et al., 2007), and CwpV, a phase-variable protein that 
provides anti-phage protection to C. difficile (Emerson et al., 2009, Sekulovic 
et al., 2015). 
 
1.2.5 Flagella 
For many species, the flagella not only provides force-driven motility, but 
have also been implicated in promoting adherence to host cells, facilitating 
the translocation of virulence factors across cell membranes, and in 
promoting biofilm formation (Harshey, 2003, Duan et al., 2013). Naturally 
occurring nonflagellated strains were reported to demonstrate a 10-fold 
reduction in adherence to tissue in the mouse cecum (Tasteyre et al., 2001). 
Recent studies have investigated specific genes in the flagellar operon, 
  
18 
 
although the role of flagella during infection remained undefined. (Stevenson 
et al., 2015).   
 
Inactivation of either the flagellin (fliC) or flagellar cap (fliD) results in 
complete loss of flagella and motility of C. difficile (Dingle et al., 2011). 
Recent studies in strain R20291 have also implicated a role for the flagella in 
the later stages of C. difficile biofilm formation with a fliC mutants displaying 
decreased biofilm formation at 5 days (Ðapa et al., 2013). Contradictions 
within the literature, regarding the role of the flagella in colonisation likely 
stem from difference between strain 630 and R20291. 
 
1.4 Biofilm 
Biofilms are communities of surface-associated microorganisms, encased in a 
self-produced extracellular matrix. First appearing in the fossil record, 
between 3.2-3.4 billion years ago (Rasmussen, 2000, Westall et al., 2001), 
formation of a biofilm is a common feature amongst bacteria and can be 
found to occur on practically any natural or artificial surface. In the past few 
decades it has become established that biofilms are ubiquitous in nature, 
likely being the prevalent form of bacteria living in the natural setting (Hall-
Stoodley et al., 2004).  Biofilms are known to play an important role in 
disease, as biofilm formation greatly influences the ability of several 
pathogens to colonise and establish an infection (Nobbs et al., 2009, Allsopp 
et al., 2010), Biofilms provide an enclosed environment for bacteria within to 
escape immune responses as well as providing increased resistance to 
antibiotics (Mah and O'Toole, 2001, Beloin et al., 2008). 
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1.4.2 Structure 
Bacterial cells within a biofilm are morphologically and physiologically 
different from planktonically cultured cells (Vlamakis et al., 2008). The three-
dimensional structure of the biofilm provides variations in the concentration 
of nutrients within the biofilm, this in turn enables genetically identical 
bacteria within the monoculture biofilm to simultaneously express different 
genes, resulting in the production of subpopulations containing functionally 
different cell types (motile cells, matrix producing cells and spores) (Vlamakis 
et al., 2008).  
 
One of the best studied organisms for biofilm formation is Bacillus subtilis. 
For this organism to form a biofilm, planktonic cells must first adhere to a 
surface to produce a microcolony. The bacteria within the microcolony use a 
form of cell-cell communication, known as quorum sensing (QS), to co-
ordinate responses to external stimuli in a cell density-dependent manner 
(Hall-Stoodley et al., 2004). The microcolony then starts to expand through 
both the recruitment of additional planktonic cells and cell division (Figure 5) 
(Vlamakis et al., 2013). The bacteria then start to produce an extracellular 
matrix composed of proteins, nucleic acid and polysaccharides (Vlamakis et 
al., 2013) with the biofilm architecture maturing as a result of interactions 
between the microbial colonies and extracellular substances (Davies et al., 
1998). The 3D structure of the mature biofilm often forms pores, and in some 
cases channels to help with the distribution of nutrient and signalling 
molecules (Costerton et al., 1999, Fux et al., 2004, Hall-Stoodley et al., 2004, 
Hall-Stoodley and Stoodley, 2005). The final step in biofilm development is 
dispersion of the biofilm (Figure 5). Numerous environmental conditions 
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such as the availability and perfusion limitation of nutrients and waste, 
determine when the biofilm has reached its critical mass and when the 
dispersion of the biofilm starts (Vlamakis et al., 2008). Through the dispersion 
of motile cells from a mature biofilm the bacteria can colonise new surfaces. 
This disassembly of the biofilm causes the continuous release of single cells, 
spores, or small clusters, or even large portions of the biofilm, over an 
extended period of time and results in rapid bacterial spreading (Vlamakis et 
al., 2008). 
 
 
Figure 5: Different stages of biofilm formation by Bacillus subtilis. 
The main stages are: development, maturation and disassembly. After initial 
attachment to a surface, motile cells differentiate into either non-motile or matrix-
producing cells. During this stage the cells form chains, surrounded by self-
produced extracellular matrix. Next comes the maturation of the biofilm, here B. 
subtilis cells begin to sporulate. The final step is biofilm disassembly. In biofilms, 
genetically identical cells differentiate into a specific cell type, although this is not 
terminal and can be altered when environmental conditions change (Vlamakis et al., 
2013). Reproduced with permission from Springer Nature 
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1.4.3 Role of biofilms in infection 
Biofilms offer bacteria increased protection from their environment in a 
myriad of different ways, such as increased resistance to antibiotics, 
protection from phagocytosis, increased adherence to the epithelial tissues, 
and through the exclusion of host defence molecules like antibodies and 
anti-microbial peptides (Hall-Stoodley and Stoodley, 2009). Resistance to 
antibiotics can be up to 1000 times higher for bacteria within a biofilm 
compared to those existing planktonically (Olsen, 2015).  
 
Not only has biofilm formation been associated with several persistent tissue 
infections such as chronic otitis media, chronic rhinosinositis, recurrent 
urinary tract infections, endocarditis and cystic fibrosis-associated lung 
infection (Costerton et al., 1999), it also represents a significant problem 
when formed on artificial devices used in medicine such as: catheters, stents, 
orthopaedic implants, contact lenses and implantable electronic devices 
(Costerton et al., 1999). 
 
1.4.3 C. difficile biofilms 
Bacterial populations located within the human gastrointestinal tract exist in 
two forms: free-floating planktonic communities within the lumen, and 
sessile bacteria within mucosal-associated biofilm communities (van der 
Waaij et al., 2005). These sessile communities often contain a multitude of 
bacterial species (Edmiston et al., 1982, Zoetendal et al., 2002) and, are likely 
to play a more important role in disease pathogenesis than planktonic forms. 
However, the physical inaccessibility of the gut of healthy individuals has 
restricted the study of these mucosal communities (Crowther et al., 2014).  
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Several in vitro studies have shown an ability of C. difficile to form single 
species biofilms (Dawson et al., 2012, Dapa et al., 2013, Crowther et al., 2014, 
Semenyuk et al., 2014). In vitro biofilms are composite structured 
communities likely to be encased in extracellular DNA, proteins and 
polysaccharides (Figure 6) (Dapa et al., 2013, Crowther et al., 2014, Semenyuk 
et al., 2014). The bacterium’s ability to form sessile communities in vitro have 
been shown to alter the effectiveness of vancomycin and metronidazole 
(Dapa et al., 2013) suggesting C. difficile biofilms may have a role in recurrent 
infections. Dapa et al. additionally reported that surface protein Cwp84, 
which is required for the biogenesis of the S-layer, is required for biofilm 
formation in vitro.  Mutants in the C. difficile flagellar proteins also showed 
defective biofilms, but only in the later stages, indicating a role in biofilm 
maturation. A subsequent study by Maldarelli et al. (2016) demonstrated that 
type IV pili of C. difficile also play an important role in biofilm formation.  
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Figure 6: A hypothetical model for C. difficile biofilm formation 
The S-layer and adhesins initiate biofilm formation, with quorum sensing important 
for maturation of the biofilm. Proteins DNA and polysaccharide are the key 
components of the biofilm matrix, which offers the bacteria within increased 
resistance to vancoycin (Dapa and Unnikrishnan, 2013). Reproduced with permission 
from Landes Bioscience. 
 
More recently in vivo studies have demonstrated that C. difficile is a minority 
member of mixed species communities in a mouse model (Semenyuk et al., 
2015). Whilst a germ-free mouse model demonstrated the ability of strain 
R20291 to organise itself in a glycan-rich biofilm architecture, which 
sustainably maintains the bacteria outside the mucus layer 
(Soavelomandroso et al., 2017).  
 
  
24 
 
Studies from our lab and others have also shown a very interesting link 
between sporulation and biofilm formation. Spo0A negative mutants were 
unable to form biofilms (Dapa et al., 2013). Spo0A is known to modulate 
other cellular pathways in addition to sporulation (Molle et al., 2003) and 
likely regulates adhesins and other proteins important for adhesion. As 
mature biofilms contain microenvironments that are nutritionally deprived, it 
is plausible that the biofilm acts as a niche for spore formation during 
infection. More work is needed to identify the exact role Spo0A during 
infection. 
 
Another interesting finding of Dapa et al. (2013) was the role of the quorum 
sensing regulator LuxS. Mutants lacking a functional form of the gene were 
unable to initiate biofilm formation in vitro, with genetic complementation 
providing partial restoration of the phenotype. This suggests that a LuxS-
mediated quorum sensing system is important for biofilm formation and 
development. The precise mechanisms involved in LuxS-mediated regulation 
remain unclear (Dapa and Unnikrishnan, 2013, Dapa et al., 2013). 
 
Current knowledge of C. difficile biofilm formation and regulation is 
extremely limited compared to that of other bacterial species (Kolter, 2010). 
Therefore there is a clear need for global studies to be conducted to 
determine the requirements for C. difficile biofilm formation and regulation. 
Bacterial communities of C. difficile are likely to be crucial in recurrent CDI. 
Additionally, given that C. difficile has been isolated from various marine 
environments (Pasquale et al., 2011, Hargreaves et al., 2013), biofilm 
formation may be important for bacterial survival in such environments.  
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1.3 Quorum Sensing 
QS was first described in the regulation of bioluminescence of Vibrio fischeri 
and Vibrio harveyi (Nealson et al., 1970, Nealson and Hastings, 1979).  QS is a 
form of cell-cell communication amongst bacteria (Antunes et al., 2010). 
Through the detection of signalling molecules, autoinducers (AIs) released 
from individual bacterial cells, bacteria can get an indirect measure of their 
population density in a particular environment, and adjust gene expression 
accordingly (Antunes et al., 2010). These AIs are released during growth, 
accumulating in the environment. Once the concentration of these molecules 
reaches a threshold, or ‘quorum’, they can bind to and activate receptors on 
the cell (Antunes et al., 2010).  This generally leads to a cascade of events, 
which ultimately ends in a change to gene regulation (Bassler and Losick, 
2006). Genes regulated by QS include those involved in cell migration, 
biofilm production, virulence, sporulation and the production of toxins 
(Hammer and Bassler, 2003, Carter, 2005, Antunes et al., 2010). Three main 
QS signalling pathways have been characterised, which included the peptide 
based system in Gram-positives, the LuxSI/LuxR system in Gram-negatives 
and the LuxS/AI-2 of Vibrio spp. 
 
1.3.1 Bacterial quorum sensing systems  
Many gram-positive bacteria utilise peptide quorum sensing systems to 
control gene expression. Staphylococcus aureus has served as the model 
organism for studying bacterial peptide signalling (Novick and Geisinger, 
2008). The peptide-based QS system of S. aureus is encoded by the 
accessory gene regulator (agr) locus (Novick and Geisinger, 2008). agrD 
encodes an autoinducing peptide (AIP) which is an oligopeptide that is 
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trimmed and secreted by the membrane bound protein AgrB (Ji et al., 1995, 
Saenz et al., 2000, Zhang and Dong, 2004). The secreted AIP is 7-9 aa in 
length and contains a 5- membered thiolactone ring (Roux et al., 2009). The 
extracellular AIP binds to AgrC, a membrane-bound sensor kinase, leading to 
AgrC autophosphorylation and activation of AgrA. The agr system activates 
two promoters, P2 and P3, which produce RNAII and RNAIII respectively 
(Morfeldt et al., 1995, Novick and Geisinger, 2008).  Activation of P2 initiates 
the transcription of the agr operon from the RNAII transcript. Transcription 
from P3 produces the effector molecule of the agr system, RNAIII (Roux et 
al., 2009). It is thought that over 70 genes are regulated by the agr system in 
S. aureus (George and Muir, 2007). 
 
Gram-negative bacteria typically use LuxI/LuxR- type QS systems (Rutherford 
and Bassler, 2012). In these systems an AI synthase (homologous to LuxI in 
Vibrio fischeri) catalyses a reaction between Adenosylmethionine (SAM) and 
an acyl carrier protein (ACP) thus producing a freely diffusible acyl 
homoserine lactone (AHL) AI (Engebrecht and Silverman, 1984, More et al., 
1996, Schaefer et al., 1996, Ng and Bassler, 2009).  At high concentration, 
AHL AIs bind to cytoplasmic LuxR-like transcription factors enabling them to 
bind DNA and activate transcription of target genes (Rutherford and Bassler, 
2012). Interestingly, the AHLs produced by different bacteria possess 
different length Acyl side-chains (Fuqua et al., 2001, Ng and Bassler, 2009). 
As the interactions between the AHL AI and LuxR are highly specific, this 
chemical diversity promotes intraspecies-specific bacterial cell-cell 
communication. 
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1.3.3 luxS / Autoinducer-2  
The other main QS system is that of LuxS/AI-2 which is perhaps best studied 
in the marine bacterium Vibrio harveyi, being used to regulate the 
organism’s bioluminescence (Nealson and Hastings, 1979, Bassler and Losick, 
2006). The signalling molecule AI-2 is synthesised through reactions 
involving the enzymes Pfs and LuxS (Figure 7A). During the activated methyl 
cycle in bacteria, S-Adenosylmethionine (SAM) acts as a methyl donor, 
creating the toxic metabolite S-adenosylhomocysteine (SAH). Bacteria 
detoxify SAH in a two-step reaction, first converting it to S-
ribosylhomocysteine (SRH) through the action of the enzyme Pfs. Finally LuxS 
converts SRH into homocysteine, producing the potent QS signalling 
molecule, AI-2 as a by-product from this reaction (Schauder et al., 2001).  
 
There are currently two characterised signalling pathways for AI-2, the Lsr 
internalisation pathway exemplified by Salmonella, and the LuxPQ receptor 
pathway of Vibrio spp (Figure 7B). During the Lsr signalling pathway, AI-2 is 
internalised by Lsr ABC transport-type transporter where it is phosphorylated 
by LsrK. Phosphorylated AI-2 inhibits the lsr operon repressor LsrR and 
induces transcriptional changes to QS controlled genes.  For LuxPQ, AI-2 
binds to the LuxP membrane bound receptor, which interacts with the inner 
membrane bound protein LuxQ, causing a conformational change. This 
process removes a phosphate from LuxU, a two-component phosphorelay 
protein, which in turn dephosphorylates the response regulator, LuxO 
(Vendeville et al., 2005). 
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In recent years, BLAST (NCBI) searches have shown that LuxS homologues 
are present in most of the bacteria for which complete genome sequences 
are available (Hilgers and Ludwig, 2001, Xavier and Bassler, 2003).  This 
revelation has led to the speculation that the LuxS system could serve as a 
‘universal signal’ for interspecies cross-talk whereby the LuxS homologue of 
one species could regulate the gene expression of a different species. 
However, this is yet to be proven in species other than Vibrio.  
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A 
B 
 
Figure 7: Production and response of AI-2 
(A) The enzyme, LuxS, is responsible for the conversion of S-ribosylhomocysteine 
(SRH) to Homocysteine producing the bi-product 4,5,dihydroxy-2,3-pentanedione 
(DPD). DPD undergos spontaneous cyclisation to produces several ligands 
collectively known as AI-2. (B) Currently there are two characterised schemes for AI-
2 signalling. In one group of bacteria AI-2 binds to the periplasmic binding protein 
LsrB which forms part of the Lsr ABC transport system. After internalisation, AI-2 is 
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phosphorylated by LsrK ebalibing it to repress the action of LsrR, the lsr operon 
repressor and induced changes to gene expression. A protein complex consisting of 
LsrG, LsrE and LsrF then binds to the phospho-AI-2, forming products no longer 
capable of inducing a signalling response. In Vibrio spp. AI-2 binds to the 
membrane bound receptor LuxP which induces a conformational change to LuxQ 
that confers phosphatase activity. This process extracts a phosphate from LuxU that 
inter dephosphorylates the response regulator LuxO (Vendeville et al., 2005). 
Reproduced with permission from Springer Nature. 
 
Despite the proposed role in QS, others have speculated that LuxS is in fact a 
metabolic side product produced during the activated methyl cycle (a 
recycling pathway involved in the metabolism of methionine) (Winzer et al., 
2003). Evidence to support this comes from a study on S. aureus. Here 
Doherty et al. (2006) demonstrated that the inactivation of luxS in S. aureus 
had no effect on virulence-associated traits. Whilst it is possible that the 
phenotypic changes observed in some bacteria following inactivation of luxS, 
may be due to the absence of the AI-2 signal molecule, they could also be 
attributed to the disruption of the activated methyl cycle (Winzer et al., 
2003). 
 
1.3.2 Quorum Sensing in C. difficile  
Whole genome sequencing of C. difficile strain R20291 by Martin et al. 
(2013), revealed the presence of the C. difficile agr locus (agrACDB) which 
showed similarity to the agr genes of S. aureus. Furthermore it was shown 
that the agr locus modulates known C. difficile virulence factors (including 
flagellar biosynthesis and TcdA) in vitro and has a contributory role in 
colonisation and relapse in vivo (Martin et al., 2013). 
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1.3.4 LuxS in C. difficile 
A study by Lee and Song (2005) revealed that C. difficile possesses the 
LuxS/AI-2 homolog. The authors demonstrated that exposing early–log 
phase cells to cell free supernatants containing high levels of AI-2 obtained 
from mid-log phase culture, resulted in an increase in mRNA transcripts for 
TcdA and TcdB, suggesting a signaling role for LuxS (Lee and Song, 2005). 
Conversely, Carter et al. (2005) failed to demonstrate a role for LuxS as 
neither exogenous AI-2 nor chemically synthesized AI-2 (MHF) was found to 
have any discernible effect on toxin production. Nevertheless, it has been 
demonstrated by both groups that the AI-2, or AI-2-like molecules produced 
by C. difficile, are capable of inducing bioluminescence in a Vibrio harveyi AI-
2 reporter strain (Carter et al., 2005, Lee and Song, 2005). The specific role of 
LuxS in C. difficile remains unclear from these studies. 
 
At present, it is not known how C. difficile biofilms are regulated. During 
studies by Dapa et al. (2013) it was found that biofilms formation was 
significantly impacted in LuxS deficient mutants. Thus LuxS somehow plays a 
role in biofilm development, though the precise mechanism of action is 
unclear. As described above, LuxS may mediate quorum sensing through 
production of AI-2, and/or bacterial metabolism through S-adenosyl 
methionine synthesis (Hardie and Heurlier, 2008). Although it is likely that 
LuxS has a quorum sensing role, we cannot rule out a role in metabolism: 
clearly further work is needed to establish the exact role of LuxS.  
 
With contradictions within the literature, surrounding the role of LuxS in C. 
difficile (Lee and Song, 2005, Carter et al., 2005) combined with its apparent 
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role in C. difficile biofilm formation (Dapa and Unnikrishnan, 2013), this 
project aimed to utilise next generation sequencing technologies in order to 
characterise the role of LuxS during C. difficile biofilm formation. Since 
LuxS/AI-2 is hypothesised to be a cross-species QS signalling molecule 
(Bassler et al., 1997), we additionally set out to investigate its role in 
mediating interations with another member of the gut microbiota, 
Bacteroides fragilis. 
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Chapter 2   Materials and Methods 
 
2.1 Bacterial Strains and Culture Conditions 
Two bacterial species were primarily used in this study – C. difficile 630 and 
B1/NAP1/027 R20291 (isolated from the Stoke Mandeville outbreak in 2004 
and 2005), and Bacteroides fragilis (kindly provided by Dr Gianfranco Donelli, 
Rome). Unless otherwise stated, these were cultured under anaerobic 
conditions (80% N2, 10% CO2, 10% H2) at 37°C in an anaerobic workstation 
(Don Whitley, United Kingdom).  
 
Bacteria were streaked from glycerol stocks and grown overnight on Brain 
Heart Infusion (BHI) agar plates, supplemented with L-Cysteine [1 g/l; Sigma, 
UK] and yeast extract [5 g/l; Oxoid]. 5 ml supplemented BHI (BHIS) to which 
0.1 M glucose was added was inoculated with a streak of colonies and grown 
overnight to stationary phase. 
 
Bacterial growth curves were performed in BHIS containing 0.1 M glucose 
(BHIS-G). Overnight cultures of C. difficile R20291 were diluted to OD600 0.05 
and regrown to mid-exponential phase (0.4-0.8). Cultures were then diluted 
to a starting OD600 of 0.01 and OD600 was taken at 1 hr intervals for 12 hrs.  
 
The medium was additionally supplemented as appropriate with either 
thiamphenicol [15 µg/ml in agar or 7.5 µg/ml in broth], lincomycin [20 
µg/ml], or Clostridium difficile Selective Supplement [D-cycloserine 250 
µg/ml Cefoxitin 8 µg/ml] (Oxoid, UK).  
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For genetic manipulation, Escherichia coli strain DH5 (Invitrogen) and the 
conjugative donor strain CA434, were grown in Luria-Bertani (LB, Bacto, USA) 
at 37°C, supplemented with 20 µg/ml chloramphenicol when required.  
 
Vibrio harveyi was grown at 30°C in LB supplemented with 50 µg/ml 
kanamycin.  
 
2.2 Biofilm Assay 
Biofilms were grown as per a previously published protocol (Dapa et al., 
2013). Overnight cultures of C. difficile were diluted 1:100 in fresh BHIS-G. 1 
ml aliquots were pipetted into 24-well tissue culture treated polystyrene 
plates (Costar), and incubated under anaerobic conditions at 37°C, for 6 – 
120 hr. Tissue culture plates were pre-reduced for 48 hr in the anaerobic 
workstation prior to use. The plates were wrapped with parafilm to prevent 
liquid evaporation. Biofilm biomass was measured using crystal violet (CV) as 
previously described (Dapa et al., 2013, Varga et al., 2008). After the required 
incubation, each well of the 24-well plate was washed once with sterile 
phosphate buffer saline (PBS) and allowed to dry for a minimum of 10 min. 
The biofilm was stained using 1 ml CV. Following a 30 min incubation period 
the CV was removed, and wells were subsequently washed twice with sterile 
PBS. The dye was extracted by incubation with 1 ml methanol for 30 min at 
room temperature (RT) in aerobic conditions. The methanol-extracted dye 
was diluted 1:1, 1:10 or 1:100 and OD570 was measured with a 
spectrophotometer.  
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For bacterial cell counts from the biofilm, the planktonic phase was removed 
and wells were washed once using sterile PBS. The adherent biofilms were 
then detached by scrapping with a sterile pipette tip and re-suspended into 
1 ml PBS. Serial dilutions were prepared and plated onto BHIS plates to 
determine the CFU present in the biofilm. 
 
2.3 Co-culture Biofilm Assay 
For co-culture biofilm assays, both C. difficile and B. fragilis were diluted to a 
matching OD600 and diluted 1:100 into fresh BHIS-G. Biofilms were set up as 
before and measured by a combination of CV staining and CFU. To 
distinguish between C. difficile and B. fragilis, serial dilutions used for 
determining CFU were plated on BHIS plates additionally supplemented with 
C. difficile Selective Supplement (Oxoid, UK). 
 
2.4 Confocal Microscopy 
C. difficile strains were grown in 4-well glass chamber slides (BD Falcon, USA) 
in BHIS-G. Chamber slides were incubated at 37°C in anaerobic conditions 
for 24 hrs – 72 hrs and stained with BacLight live/dead stain mixture 
(Molecular Probes, Invitrogen), which contains the nucleic acid stains Syto 9 
and propidium iodide (staining live bacteria green and dead bacteria red 
respectively). Following incubation, wells were gently washed twice with PBS 
0.1% w/v saponin to remove unattached cells and permeabilise the biofilm. 
Biofilm samples were incubated with the dye for 15 minutes at 37°C after 
which the samples were washed twice with PBS. Cells were fixed with 4% 
paraformaldeyhyde (PFA) for 15 min. 
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All samples were visualised with a Zeiss Observer LSM 880 confocal scanning 
microscope at 60x – 100x magnification. 
 
2.5 Transmission Electron Microscopy 
For phage visualisation, C. difficile strains were grown in 24 well tissue culture 
plates (Costar, USA), 12 wells per strain, in BHIS-G.  At either 24, 48 or 72 hrs 
samples were pooled. Bacterial cells were removed by centrifugation at 6000 
x g for 30 mins. Phage were pelleted via ultra-centrifugation (Beckman 
Optima L-80 XP, Warwick) at 35,000 x g overnight.  
 
10 µl of concentrated phage was placed on an electron microscopy grid and 
incubated at RT for 2 mins. Whatman filter paper was used to draw and blot 
the suspension across the grid. Grids were air dried for 2 mins before being 
coated in 10 µl of concentrated uranyl acetate. Grids were incubated at RT 
for 2 mins before excess stain was removed by blotting. Phage were 
visualised with a transmission electron microscope (JEOL 2100 TEM/STEM, 
Warwick) and images were captured digitally at a magnification of 10,000x 
and 50,000x. 
 
2.6 AI-2 assay 
Vibrio harveyi BB170 was grown from frozen stocks on LB plates 
supplemented with 50 µg/ml kanamycin at 30°C. Single colonies were 
isolated and inoculated into 2 ml medium and grown O/N. 400 µl 50% 
glycerol, 500 µl 1M HEPES, 200 µl of 1M K2HPO4 and 200 µl 0.1 M arginine 
were added to 18.7 ml autoinducer bioassay medium [sodium chloride (17.52 
g/l), MgSO4 (12.33 g/l) and casamino acids (2.0 g/l), pH adjusted to 7.5 with 
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KOH] and inoculated with 4 µl O/N BB170 culture. 180 µl aliquots were 
placed in 96-well optical plates (Costar, USA). 20 µl of supernatant was added 
and the plate was measured on a combined luminometer/spectrometer, 
recording OD600 and light output every 30 minutes for 12 hrs. For each 
supernatant sample, the fold bioluminescence induction was calculated at 
the point that the blank samples gave the minimal relative light output (RLO).  
 
2.7 Quantitation of DNA in biofilms 
To study the presence of extracellular DNA (eDNA) within preformed C. 
difficile biofilms, biofilms were grown in a 24-well plate as described above. 
At 24 hrs the medium was removed and replaced with pre-incubated BHIS-G 
containing DNase I at either 1 U/ml or 2 U/ml. Biofilms were incubated for an 
additional 24 hrs before being stained with 0.2% CV as described above. 
  
2.8 Exogenous addition of DPD 
Biofilm assays were setup as described above in BHIS-G containing 1 nM, 10 
nM, 100 nM, or 1 µM of chemically synthesised, exogenous DPD (OMM 
scientific, USA).  BHIS-G was used as a control. Samples were washed and 
stained with 0.2% CV at either 24 or 72 hrs. 
 
2.9 Liquid Chromatography Mass Spectrometry  
To analyse the biological molecules produced and utilised by both C. difficile 
and B. fragilis, biofilm supernatants were filter-sterilised (0.2 µm) to remove 
bacterial cells. Biological molecules were extracted by combining the cell-free 
supernatants with an equal volume of ethyl acetate. Ethyl acetate 
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supernatant mix was centrifuged at 15,000 g for 5 minutes and the ethyl 
acetate phase containing the biological molecules was removed.  
 
2.10 DNA Extraction 
DNA was extracted using phenol:chloroform:isoamyl alcohol (25:24:1) (pH 8) 
(Sigma-Aldrich, UK). 1- 10 ml of bacterial cultures were centrifuged at 5000 g 
for 10 min and the cell pellet was re-suspended in 180 µl lysis buffer (PBS 
with 10 mg/ml lysozyme). Samples were incubated at 37°C for 30 min. 4 µl 
RNase was added and samples were incubated for 15 min. After incubation 
25 µl proteinase K solution (Qiagen, Germany), 85 µl ddH2O and 110 µl 10% 
w/v SDS solution were added and samples were incubated at 65°C for 30 
min. An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) (pH 8) 
(Sigma-Aldrich, UK) was added and samples were mixed thoroughly by 
inversion. Samples were centrifuged at 15,000 x g for 3 min. The top layer 
was transferred into a fresh phase-lock tube and phenol/chloroform 
extraction was repeated a further 2 times. DNA was precipitated through the 
addition of 40 µl 3M sodium acetate and 800 µl ice-cold 100% ethanol. 
Samples were mixed and incubated at -80°C for 30 min. DNA was pelleted by 
centrifugation at 15,000 x g  for 15 min. Supernatants were removed and 
samples were washed with 1 ml 70% ethanol followed by centrifugation at 
15,000 x g for 3 min. Supernatants were removed and samples were allowed 
to air dry for 45 min at RT. Finally the DNA pellets were re-dissolved in 50 µl 
ddH2O. DNA concentrations were determined by use of Nano-drop or Qubit 
2.0 Fluorometer (Life Technologies, UK) following the manufacturers 
protocol. 
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2.11 RNA Extraction 
RNA was extracted from both planktonic cells and adherent biofilms. For 
planktonic RNA extraction, 1-2 ml of bacterial culture was centrifuged at 
5000 x g for 10 min. The supernatant was removed and the cells were re-
suspended in 1 ml Trizol (Ambion, USA). 
 
For biofilm extractions, the biofilms were grown in 24-well tissue culture 
plates. At the desired time-point, wells were washed once with PBS before 
adherent cells were disrupted and re-suspended in 1 ml Trizol (Ambion, 
USA). 
 
For both conditions, the re-suspended bacteria were transferred to lysing 
matrix tubes (MP Biomedicals, USA) containing 0.1 mm silica beads. Tubes 
were processed in a FastPrep-24 instrument (MP biosciences) for 6 x 20 
second cycles at 6.5 m/s.  Following disruption, samples were centrifuged at 
16,000 x g for 5 min at 4°C. Approximately 700 µl of liquid was transferred to 
fresh RNase-free tubes and incubated at RT for 5 min, before 300 µl 
chloroform was added. Samples were vortexed for 10 sec and centrifuged at 
16,000 x g for 15 min at 4°C.  The aqueous phase was transferred to a fresh 
RNase-free tube containing 200 µl 95% ice-cold ethanol and incubated on 
ice for 10 min. 
 
The mixture was transferred to a spin column assembly (SV Total RNA 
isolation system; Promega, USA) and centrifuged at 16,000 x g for 1 min. 
Columns were washed twice with 600 µl and 250 µl RNA washing solution. 
RNA was eluted in 45 µl RNase free water. DNase treatment was carried out 
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using Turbo DNase kit (Ambion, USA) according to the manufacturer’s 
instruction for rigorous clean-up.  
 
RNA was cleaned up using RNeasy mini kit (Qiagen, Germany). The volume 
of each sample was adjusted to 100 µl with RNase free water and 350 µl of 
RLT buffer was added. RNA was diluted with 250 µl 100% ethanol. Samples 
were transferred to RNeasy Mini Spin column and centrifuged at 8000 x g for 
15 sec. The flow-through was discarded. Samples were washed twice with 
500 µl RPE buffer at 8000 x g for 15 seconds and 2 minutes respectively. 
Samples were eluted in 45 µl RNase-free water. 
 
RNA integrity was confirmed on a RNA 6000 pico lab-chip using a 
bioanalyzer 2100 instrument (Agilent, UK) following the manufacturer’s 
instruction. Samples were stored at -80°C until further analysis. 
 
2.12 Qubit® 2.0 Fluorometer assay 
The Qubit® 2.0 fluorometer assay kit (Life Technologies, UK) was routinely 
used for the quantification of both DNA and RNA in studies samples, as per 
the manufacturer’s instructions. The Qubit® reagent was diluted 1:200 in 
Qubit® buffer and mixed briefly by vortexing. 1-10 µl of DNA or RNA sample 
was combined with 190-199 µl of the prepared reagent, mixed briefly and 
incubated for 2 minutes. Samples were measured using the Qubit® 
fluorometer. The DNA BR (broad range; 1-1000 ng/µl) assay kit was used for 
measuring DNA concentration. For sequencing experiments the DNA HS 
(high sensitivity; 0.02-100 ng/µl) assay kit was used. The RNA BR (1-1000 
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ng/µl) assay kit was used to quantify all RNA samples. The fluorometer was 
calibrated using the appropriate standards. 
 
2.13 Genomic DNA Sequencing 
Extracted genomic DNA was diluted to 0.2 ng/µl and 5 µl (1 ng) was used to 
prepare DNA sequencing libraries as per the manufacturer’s instruction 
(Nexteria® XT DNA Library Preparation Kit, illumina). Each sample was 
uniquely indexed using 2 index primers, index 1 (i7/N7XX) and index 2 
(i5/S5XX), as described by the manufacturer. The Agilent 2100 Bioanalyzer 
(Agilent, UK) was used to determine both the quality and size of the DNA 
fragments following the manufacturer’s instruction (DNA High Sensitivity kit, 
Agilent).   
 
The molar concentration for the DNA libraries was calculated using the 
formula: 
 
Molar concentration = concentration (g/l) / (DNA fragment size (bp) x 650) 
 
The DNA libraries were diluted to a concentration of 4 nM, combined and 
denatured using 0.2 M sodium hydroxide. The final DNA library was prepared 
to a concentration of 10 -12 pM and sequenced using paired end technology 
using a version-2 500-cycle kit on an illumina MiSeqTM (illumina, UK). 
 
2.14 RNA sequencing 
Following RNA extraction and clean-up, rRNA was depleted from a total of 5 
µg of extracted RNA using RiboZEROTM (illumina, UK) according to the 
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manufacturer’s protocol, purifying the RNA with ethanol precipitation for 
optimal RNA recovery. RiboZERO rRNA depletion resulted in 7 µl rRNA-
depleted RNA. The Agilent 2100 Bioanalyzer (Agilent, UK) was used to assess 
both the quality and to confirm rRNA depletion as described above. cDNA 
libraries were prepared using 5 µl rRNA depleted RNA following the 
manufacturer’s instruction (TruSEQ LT, illumina), Unique RNA adapter indices 
were used to identify individual samples (Table 1). The DNA High Sensitivity 
kit (Agilent, UK) was used to determine both the fragment sizes and quality 
of the cDNA libraries using the 2100 Bioanalyzer (Agilent, UK) instrument, 
with the cDNA concentration determined by a fluorometer assay (as 
described previously). Each sample was diluted to a concentration of 4 nM, 
before being combined and denatured using 0.2 M sodium hydroxide. The 
final cDNA library was prepared to a concentration of 10 -12 pM and 
sequenced using paired end technology using a version-3 150-cycle kit on 
an illumina MiSeqTM (illumina, UK). 
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Table 1: Indices used for RNA sequencing 
Sample Replicates Indices 
WT (Planktonic) Planktonic: 1/2/3 
 
 
 
Biofilm: 1/2/3 
 
 
 
Co-culture: 1/2/3 
 
1.AR002 
2:AR004 
3:AR005 
 
1.AR013 
2:AR008 
3:AR006 
 
1.AR018 
2:AR004 
3:AR015 
LuxS (Planktonic) Planktonic: 1/2/3 
 
 
 
Biofilm: 1/2/3 
 
 
 
Co-culture: 1/2/3 
 
 
 
DPD: 1/2/3 
1.AR013 
2:AR016 
3:AR012 
 
1.AR008 
2:AR002 
3:AR005 
 
1.AR015 
2:AR013 
3:AR016 
 
1.AR002 
2:AR003 
3:AR005 
B. fragilis Biofilm: 1/2/3 1.AR006 
2:AR007 
3:AR008 
 
2.15 Quantitative-PCR 
To confirm phage differences between C. difficile WT and LuxS, PCR primers 
were designed for each phage gene identified by RNA-sequencing (Table 2). 
Blast searches were conducted on each primer to confirm specificity within 
the C. difficile genome.  
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Table 2: PCR primers for Phage genes identified by RNA-seq 
Gene Name Sequence 
CDR20291_1212 CDR20291_1212_FW atatatTCAGCAGGACAGGATGAACC 
CDR20291_1212_REV cgcgcgGCTGTAAACTCTTTTCCTCCTGC 
CDR20291_1208 CDR20291_1208_FW atatatAGGCTCCAACACCAAAAGAA 
CDR20291_1208_REV cgcgcgACCATAACCCATAACATCTTGAAGT 
CDR20291_1215 CDR20291_1215_FW atatatTGGGCTTTGGAAGTAGATGGAG 
CDR20291_1215_REV cgcgcgGACCTTAACTGTTCCTGGACCA 
CDR20291_1436 CDR20291_1436_FW atatatACAAAAGTTTCCAGAGATGGATGC 
CDR20291_1436_REV cgcgcgTGCTGTGTTACCTAATGCGGT 
CDR20291_1444 CDR20291_1444_FW atatatTCATCTGAAGAAGACGAAGCACT 
CDR20291_1444_REV cgcgcgTGTCCAGTATGCTTACCATTGT 
CDR20291_1449 CDR20291_1449_FW atatatGAGGGGTTTTGCTAGCGACT 
CDR20291_1449_REV cgcgcgTGAAGAGGAAGCAGCGTGAG 
 
 
Supernatants were collected from biofilm samples at 24 or 72 hrs. Bacterial 
cells were removed by centrifugation at 5000 g for 10 min and the resulting 
supernatant was treated with Turbo DNase (Invitrogen) following the 
manufacturer’s protocol to removed biofilm extracellular DNA. Phage DNA 
was extracted by combining samples with an equal volume of 
phenol/chloroform as described previously (section 2.10). 
 
Phage DNA was quantified using a fluorometer assay (section 2.12). 16S PCR 
was used to confirm the removal of bacterial genomic DNA. A standard 
qualitative PCR with prophage primers (Table 2) was used to determine the 
presence of the prophage. 
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2.16 Generation of chemically competent E. coli 
Chemically competent E. coli cells were created using Mix and Go E. coli 
Transformation kit (Zymo Research, USA) following the manufacturer’s 
instruction. E. coli strain DH5α or CA434 was plated on LB agar and single 
colonies were picked for overnight growth in 5 ml LB broth at 37°C. 0.5 ml of 
fresh overnight culture was inoculated into 50 ml ZymoBrothTM and bacteria 
were incubated at 26°C shaking at 150-250 rpm, until OD600 0.4-0.6. Cultures 
were incubated on ice for 10 min before being pelleted by centrifugation 
(1,600-2500 x g) at 4°C for 10 min. The supernatant was removed and the 
cells were re-suspended in 5 ml of ice-cold 1x Wash buffer before a second 
centrifuge at 1,600-2,500 x g for 10 min at 4°C. The supernatant was 
completely removed and the cells were gently re-suspended in 5 ml ice-cold 
competent buffer. 200 µl aliquots were prepared on ice and stored at -80°C 
until needed.  
 
2.17 Sanger Sequencing 
Plasmids and amplicons were Sanger sequenced by GATC- Biotech. The 
single primer reaction required a 2.5 pmol final primer concentration. 20-80 
ng DNA was required with a final volume 10 µl. A combination of A Plasmid 
Editor (ApE) and SnapGene Viewer software was used to analyse the 
sequence data.   
 
2.18 Generation of a SNAPCD tag fluorescent luxS promotor fusion 
The luxS promoter sequence was cloned into the pFT47 vector (Figure 8). 
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Figure 8: Schematic for pFT47 
 
The 281 bp promoter region, immediately upstream of the luxS gene was 
amplified by PCR from R20291 genomic DNA (isolated using 2.10). The 
amplification reaction was carried out using Phusion High-Fidelity DNA 
polymerase (New England Biolabs, USA) (Table 3) with primers 
F1_luxSpromoter and R1_luxSpromoter, both of which contained the 
appropriate restriction site (Table 4): 
 
 
 
 
 
 
 
pFT47 
pMTL84121+SNAP 
(6652 bp) 
NotI (81) 
NdeI (95) 
EcoRI (112) 
BglII (166) 
XhoI (170) 
HindIII (740) 
PvuII (746) 
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Table 3: PCR conditions for Phusion High-Fidelity DNA polymerase 
Reaction volume PCR Program 
10 µl         5X Phusion HF 
1 µl           10 mM dNTPs 
2.5 µl        10 µM Forward Primer 
2.5 µl        10 µM Reverse Primer 
2 µl           Genomic DNA < 250 ng 
0.5 µl        Phusion DNA Polymerase 
31.5 µl      H2O 
50 µl        Total Volume 
95°C for 5 minutes 
Then 35 cycles of: 
             95°C for 30 seconds 
             60°C for 30 seconds 
             72°C for 30 seconds 
72°C for 10 minutes 
4°C hold 
  
 
Table 4: Sequences for primers used for cloning the luxS promotor region into 
pFT47. Restriction sites shown in blue. 
Name Sequence 
F1_luxSpromoter atatatatGCGGCCGCACAACTGCCAATAATACAATCAGC 
 
R1_luxSpromoter cgcgcgCTCGAGCTTTTTCCATTATTTAATCCTCCA 
 
 
The PCR fragment was checked using agarose gel electrophoresis, and 
cleaned up using Wizard® SV Gel and PCR Clean-Up System (Promega, USA), 
following the manufacturer’s instruction. 
 
Two double restriction enzyme digestion reactions were carried out for the 
vector and PCR product respectively using restriction enzymes NotI-HF (New 
England Biolabs, USA) and XhoI (New England Biolabs, USA). 1 µg of DNA 
was combined with 5 µl 10X CutSmart® NEB Buffer, 1 µl NotI-HF restriction 
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enzyme, and 1 µl XhoI restriction enzyme. The final volume was adjusted to 
50 µl with Nuclease-free water and incubated at 37°C for 15 min.  
 
Following a second clean-up with wizard® SV Total Gel and PCR Clean-Up 
System (Promega, USA) the luxS promoter region was cloned into the pFT47 
vector by one-step ligation with T4 DNA ligase (New England Biolabs). 2 µl 
T4 DNA Ligase Buffer was combined with 50 ng vector DNA, 10 ng PCR 
product, 5 µl H2O and 1 µl T4 DNA Ligase. The reaction was incubated at RT 
for 10 min and then transformed into chemically competent E. coli DH5α 
(Section 2.16). LB agar supplemented with 25 µg/ml chloramphenicol was 
used to select for transformants. Several colonies were picked and inoculated 
into LB liquid broth supplemented with 12.5 µg/ml chloramphenicol. Plasmid 
was purified from overnight cultures using a MiniPrep kit (Qiagen, Germany) 
following the manufacturer’s protocol. The DNA sequence was checked by 
Sanger sequencing using primers F1_luxSPromotor and R1_luxSpromotor. 
 
The reporter SNAP-tag was transferred into the C. difficile recipient by 
conjugation. A sequence verified plasmid, was re-transformed into 
chemically competent E. coli conjugative donor strain CA434, using LB plates 
supplemented with 25 µg/ml chloramphenicol to select for transformants. C. 
difficile R20291 and E.coli CA434/pFT47-luxSpromoter were inoculated for 
overnight culture in BHIS and LB supplemented with 12.5 µg/ml 
Chloramphenicol respectively. 1 ml stationary overnight culture of E. coli was 
pelleted by centrifugation at 5000 x g for 10 min and washed with 0.5 ml 
PBS. The E. coli donor pellet was then re-suspended in 200 µl stationary 
overnight culture of C. difficile R20291 and the conjugation mixture was 
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pipetted onto a BHIS non-selective plate in discrete drops and incubated for 
24 hrs under anaerobic conditions to allow conjugal transfer of the SNAP-tag 
promotor fusion from the E. coli donor to the C. difficile recipient. Following 
incubation, all cells were harvested and re-streaked on C. difficile selective 
BHIS plates (supplemented with D-cycloserine 250 µg/ml, Cefoxitin 8 µg/ml 
and thiamphenicol 15 µg/ml. The plates were incubated under anaerobic 
conditions at 37°C for 24 - 72 hrs. Single colonies were isolated and re-
streaked and cultured for storage in 30% glycerol at -80°C. The plasmid was 
extracted and checked by Sanger sequencing as described above, to confirm 
uptake of pFT-47 containing the luxS promotor fusion. 
  
2.19 SNAPCD tag promotor fusion assay 
Overnight cultures of C. difficile R20291 WT, R20291::luxS, 
R20291::luxS/pFT47, and R20291::luxS/pFT47-luxSpromoter were inoculated 
1-100 into fresh BHIS with 0.1 M glucose. 1 ml aliquots were taken when 
culture had reached OD600 0.5, 1, 1.5, and 2. Samples were stained with 250 
nM SNAP-cell TMR-Star (New England Biolabs, USA) and incubated for 30 
min at RT. Cells were collected by centrifugation at 4000 x g for 5 min and 
washed with 1 ml PBS. Washing was repeated a further 3 times before the 
cells were re-suspended in 1 ml PBS and 50 µl of sample was transferred into 
a 96 well plate (Costar, USA) in triplicate.  Plates were measure on a plate 
reader measuring florescence. 
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2.20 Bioinformatics methods 
2.20.1 Genomes used for analysis 
Whole-genome reference sequences of C. difficile R20291 and 630, and B. 
fragilis NCTC 9343 were downloaded from the online archive of the National 
Centre for Biotechnology Information (NCBI). The accession numbers were 
NC_013316 (R20291), NC_009089 (630) and CR626927 (NCTC 9343).  
 
2.20.2 Whole genome assembly and annotation 
RNA SPAdes3.6 was employed for the de novo assembly of B. fragilis 
(Bankevich et al., 2012).  The recommended “careful” mode was selected to 
minimise mismatches. The contigs generated were then reordered using the 
Mauve Contig Mover (Rissman et al., 2009) based on the CR626927 reference 
genome. Finally Prokka (version 1.11) (Seemann, 2014) was used to annotate 
the draft genome ready for use in subsequent RNA-seq analysis. Whole 
genome and RNA-seq data were visualised in Artimus (Rutherford et al., 
2000)  
 
2.20.4 Genome variant calling 
To confirm C. difficile mutant integrity and ensure that there were no 
second-site mutations, the computational pipeline breseq (Deatherage and 
Barrick, 2014) was used with default parameters, to compare both R20291 
WT and R20291::luxS to the reference genome (2.20.1) identifying single 
nucleotide polymorphisms (SNP).  
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2.20.5 RNA-seq analysis 
The paired-end sequencing reads from RNA-seq experiments were mapped 
against the appropriate reference genome (NC_013316 for R20291 and the 
de novo assembled sequenced [2.20.2] for B. fragilis). To account for the first 
and second read being in the opposite orientation (an artefact from the 
cDNA stranded preparation), the first read was flipped into the correct 
orientation using the seqtk command-line tool. The reference genome was 
indexed using BWA index (Li and Durbin, 2009) after which BWA mem was 
used to map the sequencing reads. The outputted “SAM” file containing the 
aligned reads was converted to a binary “BAM” file before being sorted and 
indexed using SAMtools (Li et al., 2009). 
 
2.20.6 Differential gene expression analysis 
Sorted BAM (2.20.5) and GFF (general feature format) files were input into 
the coverageBed tool (Quinlan and Hall, 2010), producing a text file (one for 
each biological replicate), with the number of reads mapping to each feature 
of the genome. These text files were input into the R package DESeq2 which 
calculated the differential gene expression using a negative binomial 
distribution model (Love et al., 2014). The data was filtered by applying a cut-
off of 1.6 for the fold change and 0.05 for the adjusted P-value.    
 
2.21 Statistical Analysis and figure generation 
Microsoft Excel was used to create bar graphs and line graphs from numeric 
data. Paired student’s t-test was used to determine if differences between 
two groups were significant. Fishers exact t-test was used to confirm RNA-
seq data. Heat maps were generated using the “heatmap.2” function of the 
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“gplots” package in R or microscope bioinformatics 
(http://microscopebioinformatics.org/). Both figures and tables were 
generated using Microsoft PowerPoint. Image analysis was performed with 
the Fiji image processing package (Schindelin et al., 2012). 
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Chapter 3 
 The role of LuxS in C. difficile – C. difficile interactions within 
biofilms 
 
3.1 Introduction 
With the discovery of the cross-species signalling role for the LuxS/AI-2 QS 
system (Bassler et al., 1997), it was quickly assumed that many species of 
bacteria possessing a functional LuxS homolog, utilise AI-2 QS. However, 
given the absence of a clear receptor for AI-2, and conflicting studies for the 
role of LuxS during toxin production (Carter, 2005, Lee and Song, 2005), the 
precise function of LuxS in C. difficile remains shrouded.  
 
Currently bacteria are known to respond to AI-2 through two major 
pathways. One mechanism is triggered by the interaction of AI-2 with LuxPQ, 
a two-component signal regulator found in Vibrio species. The other 
mechanism uses an ATP-binding-cassette transporter to import AI-2. The 
lack of genomic evidence of these AI-2 receptors in many bacteria, coupled 
with the potentially important role of LuxS in central metabolism, has led 
some to suggest a non-QS role of LuxS in many bacteria (Rezzonico and 
Duffy, 2008). However, as a number of these species are capable of 
responding to AI-2, it is possible that there are other uncharacterised AI-2 
receptors/ pathways (Yoshida et al., 2005, Huang et al., 2009, Sztajer et al., 
2008, Shao et al., 2007, Li et al., 2015). 
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Quorum sensing plays an important role in the biofilm formation, 
development and dispersal of many species (Davies et al., 1998, Hammer and 
Bassler, 2003, Solano et al., 2014, Abee et al., 2011, De Araujo et al., 2010, 
Hardie and Heurlier, 2008, Sakuragi and Kolter, 2007). The LuxS/AI-2 QS 
system in particular has been implicated for a role in biofilm formation, 
development and dispersal in a number of different species (Huang et al., 
2009, Karim et al., 2013, Li et al., 2015, Sztajer et al., 2008, Wilson et al., 2012, 
Yoshida et al., 2005, Auger et al., 2006, De Araujo et al., 2010, Hardie and 
Heurlier, 2008).  
 
Recently mutants of luxS  were reported to be defective for biofilm formation 
of C. difficile (Dapa et al., 2013), but the mechanisms responsible have yet to 
be elucidated.  Utilising a number of molecular biology techniques, this study 
aimed to determine the function of LuxS during C. difficile – C. difficile 
interactions and in biofilm formation.   
 
3.2 Results 
3.2.1 Genomic Sequencing for mutant confirmation 
To confirm the identity of both WT and luxS mutant (LuxS) strains, and to 
ensure that no additional SNPs were introduced during the handling of 
either strain, single colonies of both strains were sequenced in triplicate as 
described in chapter 2.  Whole genome sequences for each replicate were 
compared to the published reference genome of C. difficile R20291 
(accession number: NC_013316). 
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As genomic sequencing confirmed that with the exception of luxS, both WT 
and LuxS possessed the same SNPs, the observed defect in biofilm formation 
for LuxS was caused by the insertional mutation to this gene (Table 5).  
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Table 5: Observed mutations present in both WT and LuxS compared to published 
genome (NC_013316) 
Position Mutation Annotation Gene 
9,694 G→T G82V (GGA→GTA)  rsbW 
32,998 +AAT noncoding (75/76 nt) CDR20291_t27 
132,959 T→C noncoding (25/77 nt) CDR20291_t40 
206,398 +A intergenic (+957/-214) CDR20291_0157  / CDR20291_0158 
358,260 Δ1 bp coding (165/891 nt) rbsK → 
581,480 +A intergenic (+314/-264) CDR20291_0482 / glsA 
581,487 +A intergenic (+321/-257) CDR20291_0482 / glsA 
581,494 +A intergenic (+328/-250) CDR20291_0482 / glsA 
593,845 68 bp x 2 duplication CDR20291_0492 / CDR20291_0493 
1,564,432 Δ1 bp intergenic (-190/-104) CDR20291_1320 / CDR20291_1321 
1,568,676 C→A Q138K (CAA→AAA)  CDR20291_1323  
1,578,167 Δ1 bp intergenic (-88/-158) CDR20291_1334 / CDR20291_1335 
1,578,202 +A intergenic (-123/-123) CDR20291_1334 / CDR20291_1335 
1,592,813 A→T intergenic (-173/-67) CDR20291_1346 / CDR20291_1347 
1,864,416 +T intergenic (-357/+171) CDR20291_1575 / CDR20291_1577 
1,899,596 Δ1 bp intergenic (+263/-537) CDR20291_1614 / CDR20291_1615 
2,077,305 Δ1 bp intergenic (+47/-70) CDR20291_1777 / CDR20291_1778 
2,120,669 A→G D202G (GAC→GGC)  vncR 
2,235,738 Δ1 bp coding (246/270 nt) CDR20291_1913  
2,262,059 +A intergenic (-203/-163) CDR20291_1935 / CDR20291_1936 
2,264,190 Δ1 bp intergenic (+96/-398) CDR20291_1938 / CDR20291_1939 
2,298,110 +T intergenic (-120/+216) CDR20291_1968 / CDR20291_1969 
2,361,948 C→A intergenic (+54/+234) CDR20291_2018 / CDR20291_2019 
2,361,956 +A intergenic (+62/+226) CDR20291_2018 / CDR20291_2019 
2,367,941 +T intergenic (-547/-536) CDR20291_2022 / bipA 
2,578,157 Δ1 bp intergenic (-716/-91) CDR20291_2190 / CDR20291_2191 
2,674,744 Δ1 bp intergenic (-96/+547) CDR20291_2280 / CDR20291_2281 
2,680,786 +T intergenic (-267/+103) CDR20291_2286 / CDR20291_2287 
2,772,179 Δ1 bp intergenic (-803/+619) CDR20291_2367 / CDR20291_2369 
2,881,464 Δ1 bp coding (1308/2337 nt) CDR20291_2456  
3,077,986 Δ1 bp intergenic (-232/-97) glyA / CDR20291_2616 
3,162,098 Δ1 bp intergenic (-163/+74) secA2 / slpA 
3,361,915 Δ1 bp intergenic (-151/-432) CDR20291_2840 / CDR20291_2841 
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3.2.3 LuxS is required for biofilm formation  
The WT and LuxS strains were studied for biofilm formation at different times 
using a previously described biofilm formation assay (in 24 well dishes). 
Biofilms were quantitated by crystal violet and colony counting as described 
in Chapter 2. As observed by Dapa et al. (2013), the C. difficile LuxS produces 
a dramatic defect during biofilm formation, observed with both crystal violet 
staining (Figure 9A) and by fluorescent microscopy (Figure 9B & C) at both 
24 and 72 hrs in BHIS supplemented with 0.1 M glucose (BHIS-G). 
Interestingly, the CFU/ml for both WT and LuxS remained at similar levels 
during both timepoints, despite the observed defect in biofilm formation 
(Figure 9D). Since both strains display similar planktonic growth (Figure 10), 
these data suggest that the biofilm defect is caused by differences in the 
amount of extracellular matrix produced by WT and LuxS, rather than a 
growth defect.  
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Figure 9: Analysis of LuxS biofilm formation in vitro  
(A) WT and LuxS biofilms were grown for 24 and 72 hrs and stained with 
0.2% CV. (B + C) Biofilms were visualised by microscopy at 48 hrs using 
live/dead staining, WT (B) and LuxS (C). Live bacteria stained green whilst 
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dead bacteria stained red using syto 9 and propidium iodide dye 
respectively. (D) CFU was calculated from biofilms. N=7, error bars = 
standard deviation.  
 
3.2.5 AI-2 production by C. difficile 
To investigate luxS expression and to confirm production of the signalling 
molecule, AI-2, cell-free supernatants were collects at various timepoints and 
assayed with the AI-2 reporter, Vibrio harveyi. The amount of fluorescents 
induced by C. difficile produced AI-2 was compared to stationary-phase V. 
harveyi cell-free supernatants which were assumed to be inducing 100% 
fluorescents. As BHIS-G had an inhibitory effect on the growth of V. harveyi 
(data not shown), C. difficile was grown in BHI, in stationary planktonic 
conditions. At each time point the OD600 was measured and 1 ml of culture 
was filter-sterilised and the cell-free supernatants were frozen at -20°C 
before being assayed with V. harveyi. We found that AI-2 is maximally 
produced at the transition to stationary phase (Figure 10). As expected the 
LuxS did not produce AI-2 (Figure 10). 
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Figure 10: Growth and AI-2 production by WT and LuxS. 
Strains were grown anaerobically in BHI medium. Aliquots were removed for 
OD 600 readings (line) and cell-free supernatants from each time point were tested 
for AI-2 activity using V. harveyi BB170 reporter assay (bars). Bioluminescence is 
shown as a percentage of wildtype V. harveyi BB120 bioluminescence, which was 
assumed to be 100 % 
 
 
3.2.4 Visualisation of luxS expression (SNAP) 
In order to study the expression profile of luxS during biofilm formation, and 
to visualise the localisation of luxS expression within a biofilm, a florescent 
promoter fusion was generated. Since Green fluorescent protein (GFP) 
chromophores strictly require molecular oxygen for maturation of 
fluorescence (Cubitt et al., 1995, Perez-Arellano and Perez-Martinez, 2003, 
Landete et al., 2015) we utilised O-6-methylguanine-DNA methyltransferase 
based tags (SNAP-tags) which can function in anaerobic environments. As 
luxS is expressed as part of an operon, we cloned the 281 bp region directly 
upstream of luxS as described in Chapter 2 (2.18). While the PCR and Sanger 
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sequencing showed fusion was generated successfully (data not shown) we 
were unable to detect fluorescence at multiple timepoints during growth in 
BHIS-G and BHI.  
 
3.2.6 Exogenous addition of AI-2 (MHF and DPD) 
As LuxS has roles in the activated methyl cycle and in the LuxS/AI-2 QS 
system, it is unclear whether species that contain LuxS, but do not possess a 
clear AI-2 receptor use AI-2 for QS, or if  AI-2 production is simply a 
metabolic by-product of the reaction of SRH to homocysteine catalysed by 
LuxS (Rezzonico and Duffy, 2008).  
 
To determine whether LuxS possesses a QS role in C. difficile, we tested if the 
exogenous addition of two forms of AI-2, 5-methyl-4-hydroxy-3(2H)-
furanone (MHF) and 4,5-dihydroxy-2,3-pentanedione (DPD), could restore 
biofilm formation in LuxS.  No clear effect was observed with the addition of 
different concentrations of MHF (Figure 11a). We were able to partially 
complement LuxS with 100 nM DPD (Figure 11B&C). Whilst we were unable 
to observe full complementation with the selected concentrations of DPD, we 
observe that increased concentrations had an inhibitory effect. Such 
inhibitory effects of AI-2 /DPD have been reported previously (Rickard et al., 
2006). 
 
 
 
 
 
  
62 
 
A 
 
B 
 
C 
 
 (A) No response was observed with various concentrations of 5-methyl-4-hydroxy-
3(2H)-furanone (MHF) n=9 error bars show standard deviation. (B) Dosage response 
observed for LuxS with the addition of exogenous 4,5-dihydroxy-2,3-pentanedione 
(DPD), with high concentrations having an inhibitory effect. N=3 error bars show 
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Figure 11: LuxS response to Exogenous AI-2 
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standard deviation. (C) 100 nM DPD can partially compensate the biofilm defect of 
LuxS. N= 21 error bars show the standard deviation. 
 
3.2.7 Planktonic RNA-sequencing (RNA-seq) analysis 
 
AI-2 has been shown to affect expression of several virulence related genes 
in many bacteria (Cao et al., 2011, Stroeher et al., 2003, Sircili et al., 2004, 
Coulthurst et al., 2004). To probe the precise role of LuxS/AI-2 in C. difficile 
further, we analysed the global transcriptome of LuxS with the view that 
transcriptional pathways altered in LuxS would provide clues to LuxS/AI-2 
function.  We employed RNA-seq to take a “snap-shot” of the gene 
expression during planktonic growth. Logarithmic phase growth, where AI-2 
was produced at a reasonable level (Figure 10) was selected to ensure 
reproducibility for replicates. Both strains were cultured in 50 ml falcon tubes 
in 25 ml BHI and incubated at 37°C in anaerobic conditions. Total RNA was 
extracted when the OD600 for each sample reached 0.8 (6 hrs). RNA replicates 
were prepared from cultures on different days to ensure reproducibility. 
 
Following RNA isolation, samples were tested by PCR to ensure no 
contamination with genomic DNA. As bacterial RNA consists mainly of 
ribosomal RNA (most notably 16S and 23S), RiboZero (Illumina) was used for 
the depletion of rRNA substantially increasing the number of reads available 
for sequencing from mRNA. The Illumina TruSeq Stranded total RNA kit was 
used to generate cDNA libraries which were then sequenced on the Illumina 
MiSeq at 12 pM. 
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The sequencing reads for each replicate of both WT and LuxS were 
processed (2.14) and both strains were mapped to the published genome for 
R20291 (GenBank accession no. NC_013316). CoverageBed was used to 
count the reads that mapped to each gene of the reference sequence 
(Quinlan, 2014). The mapped reads were then normalised and analysed using 
DESeq2, to calculate the differential expression of genes and the log2-fold 
change between conditions (Love et al., 2014). To account for false positives, 
DESeq2 uses P and Q-values to determine whether changes in gene 
expression are statistically significant, whereby the Q-value is a false 
discovery rate adjustment to the P-value i.e. a Q-value (P-adjusted value) of 
0.05 indicates 5% of the statistically significant tests (by P-value) were false 
positives. The variation between samples was analysed using heat maps and 
principle component analysis (PCA) plots generated from the DESeq2 
dataset. Significant changes to gene expression were based upon a P-
adjusted value of ≤ 0.05 and log-fold change of ≥ 1.6.  
 
Surprisingly, no differentially expressed genes passed these cut off values, 
with the log-2 fold change for a majority of genes being between 1 and -1 
(Figure 12A). As the replicates for each condition do not cluster amongst 
themselves (Figure 12B & C), we hypothesise that LuxS is not influencing C. 
difficile at this timepoint.  
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A      B 
    
C 
 
Figure 12: Planktonic RNA-seq quality control. 
Mean normalised counts plotted against log2 fold change (A), a heat map (B) of 
Euclidian distances between samples and a PCA plot (C) showing sample-sample 
distances for replicates of WT and LuxS. These were calculated using R and DESeq2 
 
 
3.2.8 Biofilm RNA-seq analysis  
As we failed to detect changes in gene expression during planktonic growth, 
we focused our attention to analysing the gene expression of WT and LuxS 
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within biofilms. Given the clear phenotype for LuxS during biofilm formation 
and development, we would expect differences in the gene expression 
profiles between the two strains. Additionally, with the ability for DPD to 
partially complement LuxS, we also sought to analyse the gene expression 
for LuxS complimented with exogenous DPD. 
 
RNA was extracted from 24 and 48h biofilms, however the quality of RNA 
obtained was poor, and contamination with genomic DNA was a major 
problem (data not shown). Good quality RNA was extracted from early 
biofilms (18 hrs) (Figure 13a and b). The cells were washed and lysed (as 
described in Chapter 2), the RNA was processed and sequenced as described 
above, and the DeSeq2 variance analysis package (Love et al., 2014) was used 
to identify genes that were differentially expressed by ≥ 1.6-fold with a p-
adjusted value ≤ 0.05, (N=3), in both LuxS and LuxS with DPD relative to the 
wildtype. 
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(A) WT    LuxS 
 
(B) 
 
Figure 13: Bioanalyser and 16S PCR of RNA isolated form biofilms at 18 hrs. 
(A) shows the RNA isolated from biofilms 18 hrs post inoculation for the first 
biological replicate for WT and LuxS. (B) A 16S PCR was performed on all replicates 
to ensure all replicates were free of genomic DNA contamination. 
 
Although statistical analysis using DESeq2 showed individual replicates for 
each condition did not cluster (Figure 14a), 21 genes were found to be 
consistently differentially expressed across all replicates of LuxS (Table 6) 
with 26 genes identified in LuxS supplemented with DPD (Table 7). We 
therefore hypothesise that similarities between both WT, LuxS, and LuxS with 
DPD were responsible for the lack in clustering, rather than variance between 
replicates.  
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A       
   
B 
 
Figure 14: PCA plots and heat map of WT, LuxS and LuxS + DPD biofilm 
samples. 
The heat map (A) shows the Euclidian distance between samples whilst the PCA plot 
(B) shows the sample-to-sample distances for replicates of WT, LuxS and LuxS + 
DPD. Both the heat map and PCA plot were calculated using R and DESeq2. 
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Transcriptional analysis of LuxS during biofilm formation 
Interestingly, all 18 down-regulated genes correspond to two prophage 
regions (CDR20291_1197 - CDR20291_1226 and CDR20291_1415 – 
CDR20291_1464) located within the C. difficile R20291 genome (Figure. 15A, 
B & C), as identified using the online phage search tool: Phaster (Arndt et al., 
2016, Zhou et al., 2011). Fishers exact T-test was used to validate the RNA-
seq data with a calculated p-value < 0.001 for both prophage regions.  
 
It is interesting to note that both trehalose-6-phosphate hydrolase (TreA, 
CDR20291_2930) and a PTS system transporter (CDR20291_2554) are up-
regulated in LuxS. Trehalose is an osmoprotectant that can be hydrolysed to 
glucose and glucose 6-phosphate by the enzyme trehalose-6-phosphate 
hydrolase, where it can be utilised as a carbon source (Rimmele and Boos, 
1994). Recent studies have demonstrated the ability for upregulation of the 
trehalose operon to enhance C. difficile growth in the presence of trehalose 
(Collins et al., 2018a). 
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A 
B
 
C 
 
Figure 15: Phage genes present in C. difficile. 
(A) Three Prophage regions are identified in C. difficile using Phaster. Regions 2 and 
3 were detected as down regulated in LuxS. (B) shows locus of region 2. (C) shows 
locus of region 3. 
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Table 6: Genes up- and down-regulated in the LuxS relative to the WT C. difficile. 
Genes specific to LuxS (red), genes differentially expressed in both LuxS and LuxS 
DPD (black). 
 
Note: P-adjusted value ≤ 0.05 
 
Transcriptional analysis of LuxS + DPD during biofilm formation 
A total of 26 genes were found to be differentially expressed in LuxS + DPD 
compared to wildtype. Of these, 22 were down-regulated with only 4 up-
regulated genes detected. 20 of the differently expressed genes were found 
to match the differential expression of LuxS. 1 additional gene was found to 
be up-regulated (CDR20291_1523, encoding a two-component sensor 
No. Gene ID log2FoldChange Gene annotation 
1 CDR20291_1206 -0.994213972 hypothetical protein 
2 CDR20291_1207 -1.059645046 hypothetical protein 
3 CDR20291_1208 -1.227114763 hypothetical protein 
4 CDR20291_1210 -1.08584066 hypothetical protein 
5 CDR20291_1211 -1.0763802 hypothetical protein 
6 CDR20291_1212 -1.009946545 phage cell wall hydrolase 
7 CDR20291_1214 -1.09972952 phage protein 
8 CDR20291_1215 -1.038498251 phage protein 
9 CDR20291_1216 -1.047731727 phage protein 
10 CDR20291_1217 -0.999294901 phage tail fiber protein 
11 CDR20291_1218 -0.898724949 hypothetical protein 
 
 
12 CDR20291_1425 -0.928686375 virulence-associated protein e 
13 CDR20291_1432 -1.243533992 phage terminase large subunit 
14 CDR20291_1433 -1.154529376 phage portal protein 
15 CDR20291_1436 -1.156306053 phage major capsid protein 
16 CDR20291_1442 -1.085573967 phage protein 
17 CDR20291_1444 -1.257181603 phage protein 
18 CDR20291_1449 -1.008627768 phage tail tape measure protein 
 
 
19 CDR20291_2554 0.895993497 PTS system glucose-specific transporter subunit IIA 
 
20 CDR20291_2927 1.587075038 cellobiose-phosphate degrading protein 
21 CDR20291_2930 1.444846424 trehalose-6-phosphate hydrolase 
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histidine kinase), whilst 5 additional genes were found to be down-regulated 
(CDR20291_0782, CDR20291_1219, CDR20291_1220, CDR20291_1450 and 
CDR20291_3144). The other two down-regulated genes correspond to a 
MarR family transcriptional regulator (CDR20291_0782) and pyruvate 
formate-lyase 3 activating enzyme (CDR20291_3144).  
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Table 7: Genes up- and down-regulated in the LuxS DPD relative to the WT C. 
difficile. Genes specific to LuxS DPD (red), genes differentially expressed in both 
LuxS and LuxS DPD (black) 
No. Gene ID log2FoldChange Gene annotation 
1  CDR20291_0782 -1.1341491 MarR family transcriptional regulator 
  
2 CDR20291_1206 -1.0880825 hypothetical protein 
3 CDR20291_1207 -1.247361 hypothetical protein 
4 CDR20291_1208 -1.171661 hypothetical protein 
5 CDR20291_1210 -1.0380968 hypothetical protein 
6 CDR20291_1211 -0.9248567 hypothetical protein 
7 CDR20291_1212 -0.9178215 phage cell wall hydrolase 
8 CDR20291_1215 -1.0082721 phage protein 
9 CDR20291_1216 -0.9809553 phage protein 
10 CDR20291_1217 -0.9891455 phage tail fiber protein 
11 CDR20291_1218 -0.8462165 hypothetical protein 
12  CDR20291_1219 -1.0438119 hypothetical protein 
13  CDR20291_1220 -1.112373 hypothetical protein 
  
14 CDR20291_1425 -1.0024545 virulence-associated protein e 
15 CDR20291_1432 -1.3464056 phage terminase large subunit 
16 CDR20291_1433 -1.1120734 phage portal protein 
17 CDR20291_1436 -1.1073332 phage major capsid protein 
18 CDR20291_1442 -1.1314477 phage protein 
19 CDR20291_1444 -1.3252432 phage protein 
20 CDR20291_1449 -1.0659773 phage tail tape measure protein 
21  CDR20291_1450 -1.0110874 phage cell wall hydrolase 
  
22  CDR20291_3144 -0.8819971 pyruvate formate-lyase 3 activating enzyme 
  
23  CDR20291_1523 0.95295327 two-component sensor histidine kinase 
  
24 
CDR20291_2554 0.90467383 
PTS system glucose-specific transporter subunit 
IIA 
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25 CDR20291_2927 1.81490679 cellobiose-phosphate degrading protein 
26 CDR20291_2930 1.59849263 trehalose-6-phosphate hydrolase 
 
Note: P-adjusted value ≤ 0.05 
 
Transmission electron microscopy (JEOL 2100 TEM/STEM, Warwick) was 
utilised to visualise any phage particles produced within C. difficile biofilms 
or biofilm supernatants. Samples were taken from both disrupted biofilms 
and the supernatant at 48 hrs and phages were isolated via 
ultracentrifugation (Beckman Optima L-80 XP, Warwick) at 35,000 rpm for 12 
hrs. Whilst phage-like particles could be observed in WT biofilm supernatants 
(Figure 16 A&B), these were very few in number, and not consistently 
detected. 
A                                                               B 
   
Figure 16: Transmission electron microscopy (TEM) image of phage like 
particles present in WT biofilm supernatants.  
Samples prepared from biofilms at 24 hrs and were stained with concentrated 
uranyl acetate 
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To demonstrate the presence of phage within the biofilm we instead 
disrupted biofilms at 24 hrs and 48 hrs. Cells were removed via centrifugation 
at 10,000 x g for 10 minutes. Samples were then treated with DNase to 
remove extracellular DNA, a key component of biofilms. With the cells 
removed, and eDNA degraded, the only DNA present in each sample would 
be DNA that was protected from the DNase treatment i.e. within a phage. 
This DNA was isolated by phenol chloroform extraction as described in 
chapter 2 and PCR was performed with primers for the RNA-seq identified 
phage genes (Figure 17). 16S primers, which would detect any DNA from 
whole bacteria were used as a control. As no DNA band was present for the 
16S control, we can conclude that bands present in phage primer samples, 
were as a result of the presence of intact phage within the C. difficile 
biofilms.   
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Figure 17: Phage present in C. difficile biofilms. 
(a) 16S PCR of DNA isolated from biofilms of WT and LuxS post DNase treatment. 
(b) PCR of phage CDR20291_1436 (1436) and CDR20291_1208 (1208).  
 
Discussion 
Biofilms are an important mode of growth offering increased resistance to 
environmental stresses, resistance to antibiotics, and a means for persistence 
for pathogenic bacteria (Costerton et al., 1999, Mah and O'Toole, 2001, Keren 
et al., 2004b, Keren et al., 2004a, Hall-Stoodley et al., 2004, Lewis, 2005, 
Ahmed et al., 2009). Many bacteria utilise QS to regulate the genes required 
for biofilm formation (Zhu and Mekalanos, 2003, Hammer and Bassler, 2003, 
Yoshida et al., 2005, Sakuragi and Kolter, 2007, Hardie and Heurlier, 2008, 
Huang et al., 2009, Ahmed et al., 2009, De Araujo et al., 2010, Li and Tian, 
2012, Karim et al., 2013, Li et al., 2015, Dixit et al., 2017). Interestingly many of 
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these studies have implicated AI-2 as being involved in biofilm formation and 
development (Gonzalez Barrios et al., 2006, Shao et al., 2007, Ahmed et al., 
2009, Li et al., 2015).  
 
Given the ability of C. difficile to produce in vitro biofilms (Dawson et al., 
2012, Ðapa et al., 2013, Crowther et al., 2014, Walter et al., 2015, Pantaleon et 
al., 2015, Maldarelli et al., 2016) and a notable defect in biofilm formation for 
mutants of luxS (Dapa et al., 2013), we sought to investigate the mechanisms 
responsible for this defect.  
 
Although luxS is responsible for the production of AI-2, the lack of a 
characterised receptor in many species (including C. difficile), has led some to 
question whether phenotypes associated with the inactivation of this enzyme 
are due to QS or due to its metabolic role in the activated methyl cycle 
(Rezzonico and Duffy, 2008, Wilson et al., 2012). However, since we were able 
to achieve partial restoration of the biofilm within LuxS through the addition 
of exogenous DPD, our data suggests that C. difficile is not only capable of 
producing AI-2, but could also be responding via a currently uncharacterised 
receptor pathway. As specific concentrations of DPD are required to 
complement the biofilm defects in other bacteria (Rickard et al., 2006), it is 
possible that a narrower range of concentrations would need to be tested in 
order to achieve complete restoration of the biofilm in C. difficile. 
Additionally the commercial DPD is known to be unstable, and this could 
also explain the reduced activity (Chen et al., 2002, Federle and Bassler, 
2003). 
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RNA-seq was used to identify genes responsible for the observed phenotype 
in LuxS. During the early stages of biofilm formation we identified 18 genes 
down-regulated in the LuxS. Interestingly all 18 of these genes correspond to 
two prophage regions present within the C. difficile genome. Upon further 
investigation, we were able to detect the presence on intact prophage within 
C. difficile biofilm samples. Bacteriophage have been associated with both 
biofilm formation (Secor, 2016) and biofilm dispersal (Rossmann et al., 2015) 
in other bacteria. In Pseudomonas aeruginosa a filamentous phage has been 
shown to help bind bacteria, providing structure to the biofilm (Secor, 2016). 
Whereas in Enterococcus faecalis, an AI-2 induced phage release has been 
demonstrated to be playing an active role in biofilm dispersal (Rossmann et 
al., 2015). Since the phage are down-regulated in LuxS we hypothesise that 
the prophage found in C. difficile are facilitating biofilm formation under the 
control of AI-2 which likely happens through cell lysis and the release of e-
DNA, DNA has previously been shown to be a key component of the C. 
difficile biofilm with DNase activity impacting biofilm formation and 
preformed biofilms (Dapa et al., 2013). Furthermore, our observation that 
LuxS biofilms relatively have more live bacteria than the WT supports the 
idea that bacterial lysis occurs in the presence of LuxS/AI-2.  
 
With the gene expression profile for LuxS and LuxS with DPD being largely 
the same, with three additional prophage genes being down-regulated in 
LuxS with DPD, we can surmise that the DPD is having little affect at 18 hrs or 
100 nM. Since previous studies have demonstrated a role for cysteine in the 
down regulation of pyruvate formate-lyase 3 activating enzyme 
(CDR20291_3144) (Dubois et al., 2016). It is likely that the other differentially 
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expressed genes specific to this condition, are artefacts from the loss of 
metabolic function for LuxS in the activated methyl cycle.  
 
During infection we suspect that as C. difficile cell numbers increase, so too 
does the extracellular concentration of AI-2. Once a critical concentration is 
detected, biofilm formation is induced together with the transcription of 
prophage genes within a subset of the population. Cells expressing these 
genes then lyse, releasing e-DNA and increasing the overall biomass of the 
biofilm. With the ability of biofilms to provide increased resistance to 
antibiotics (Lewis, 2008, Dapa et al., 2013), we hypothesise that the 
production of biofilms during infection, could offer a reservoir for recurrent 
disease (Figure 18). 
 
 
Extracellular concentration of AI-2 increases as cells grow. When a threshold 
concentration is reached, phage expression is induced in a subset of the population. 
These cells lyse releasing eDNA, a key component of the biofilm.  
 
Figure 18: A hypothetical model for the role of phage in C. difficile biofilm 
formation. 
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Chapter 4   
C. difficile interactions with B. fragilis  
4.1 Introduction 
It has long been proposed that a healthy gut microbiota offers colonisation 
resistance against C. difficile, and that only when the gut microbiota is in a 
state of dysbiosis, can the disease take hold (Vollaard and Clasener, 1994, 
Seekatz and Young, 2014). Whilst the precise mechanisms responsible for 
this innate resistance to C. difficile colonisation are yet to be understood, a 
number of factors have been proposed. These include competition for 
nutrients, ecological competition, niche exclusion, and more recently, the 
production of inhibitory secondary bile salts (Theriot and Young, 2015, 
Winston and Theriot, 2016, Theriot et al., 2016, Robinson et al., 2014, Britton 
and Young, 2012). The recent expansion in the use of FMT for the most 
severe cases of CDI, highlights the urgency in understanding how the 
different members of the microbiota interact with C. difficile (Adamu and 
Lawley, 2013). In the past decade, a number of studies have aimed at 
identifying the microbial taxa associated with either: disease development or 
C. difficile inhibition. However, due to the limited number of co-culture 
studies in this field, the exact microbes within these taxa and mechanisms of 
their interactions with C. difficile remain elusive (Seekatz and Young, 2014).   
 
Multiple studies investigating the elderly, adults and FMT patients, have 
consistently identified Bacteroides spp. amongst others, as being negatively 
correlated to C. difficile colonisation (Weingarden et al., 2014, Hopkins and 
Macfarlane, 2002, Manges et al., 2010, Schubert et al., 2014, Tvede and Rask-
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Madsen, 1989, Khoruts et al., 2010, van Nood et al., 2013, Hamilton et al., 
2013, Fuentes et al., 2014, Petrof et al., 2013, Khanna et al., 2016). As many of 
these studies have not resolved species level, the mechanisms of action 
remain unclear. Bacteroides have been shown to be nutritionally diverse, 
capable of utilising a wide variety of carbon sources. As such these bacteria 
are thought to be responsible for the majority of polysaccharide digestion 
that occurs in the large intestine (Franks et al., 1998, Salyers, 1984). 
Additionally B. fragilis has been shown to influence the development of the 
immune response (Hopkins and Macfarlane, 2003).    
 
The high microbial density within the gut means that C. difficile likely needs 
to interact with other members of the gut microbiota, to establish itself 
within this niche. Previously, a role for the LuxS/AI-2 QS system in inter-
species signalling has been proposed (Bassler et al., 1997, Hammer and 
Bassler, 2003). Given the potential signalling role for the LuxS/AI-2 within the 
C. difficile population we hypothesised that C. difficile LuxS/AI-2 QS may 
influence interactions of C. difficile with the other bacteria present in the gut. 
With the ability of several members of Bacteroides to produce AI-2, it would 
be interesting to investigate the mechanisms involved in C. difficile – 
Bacteroides interactions.  
 
4.2 Results 
4.2.1 Development of a mixed biofilm assay 
In order to investigate the role of LuxS in influencing inter-species 
interactions of C. difficile, we first examined the interactions between the gut 
associated Bacteroides spp. Bacteroides fragilis and C. difficile.  
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To ensure that B. fragilis and C. difficile grow well in a common medium, 
growth curves were performed in BHIS-G (Figure 19), a medium previously 
shown to promote maximal C. difficile biofilm production (Dapa et al. 2013). 
Although growth dynamics were different, both C. difficile and B. fragilis 
grew to comparable OD600 (2.216 and 1.704 respectively). BHIS-G was used 
throughout the co-culture experimentation.   
 
 
 
Figure 19: Growth curve of B. fragilis and C. difficile in BHIS-G  
The growth of B. fragilis and C. difficile was evaluated in BHIS-G. C. difficile grew 
faster with a logarithmic rate of 0.380 per hour and a maximal OD600 of 2.216. 
Compared to B. fragilis which had a logarithmic rate of 0.208 OD600 per hour and a 
maximal OD600 of 1.704.  
 
For co-culture biofilms, O/N cultures for both species were set up in BHIS-G 
and the OD600 was adjusted to 1 after 12-16 hrs of growth. Both species were 
diluted 1:100 into 24 well dishes, and incubated for different times. During 
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initial investigation using CV biofilm assay, it was noted that B. fragilis mono-
culture formed limited levels of biofilm, compared with C. difficile. When C. 
difficile was co-cultured with B. fragilis, significantly less total biofilm was 
produced (by CV staining), compared to the C. difficile monoculture biofilms 
(Figure 20A).   
 
The number of CFUs within mixed biofilms was determined as described in 
Chapter 2.  A distinct colony morphology was observed for both species 
when plated on BHIS plates selective for C. difficile; C. difficile produced large 
opaque colonies appearing slightly yellow/green in colour with irregular 
edges, while B. fragilis produced pin prick transparent colonies. When 
incubated for a longer time point (48 – 72 hrs) these colonies became white 
opaque in colour with smooth edges. CFU counts obtained from the mono 
and co-culture biofilms, confirmed that B. fragilis was a poor biofilm 
producer during mono-culture. Interestingly, when both species were 
cultured together the CFU/ml for C. difficile was significantly reduced (Figure 
20B), while the CFU/ml for B. fragilis were significantly increased. The 
reduction in colony counts of C. difficile was observed at both 24 and 72 hrs 
(data not shown).  
 
To observe biofilms by confocal microscopy, strains were inoculated into 4-
well glass chamber slides and stained with live/dead (Syto 9 and propidium 
iodide dye, respectively) after 48 hrs. Monoculture biofilms (Figure 21A) 
contained more live bacteria, denoted by the greener colour, with co-culture 
biofilms (Figure 21B) containing more dead cells. 
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These data suggest that the presence of B. fragilis in co-culture results in 
inhibition of C. difficile growth within biofilms.  
 
A. 
 
B. 
 
Figure 20: B. fragilis mediated inhibition of C. difficile in mixed biofilms. 
(A) Biofilm formation of C. difficile, B. fragilis and both species co-cultured (mixed) 
as measured by crystal violet. (B) CFU / ml for both C. difficile and B. fragilis from 
mono and co-culture biofilms. A logarithmic scale is used on the Y-axis. The error 
bars represent standard deviations (P<0.05), N=3. 
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A               B 
       
Figure 21: Confocal microscopy of C. difficile and co-culture biofilms. 
Live/dead staining shows dead (red) and live (green) bacteria (Syto 9 and propidium 
iodide dye, respectively) in monoculture C. difficile WT (A), and co-culture with B. 
fragilis (B). 
 
To investigate this B. fragilis-mediated inhibition further, C. difficile and B. 
fragilis were co-cultured under planktonic conditions, at both 6 and 10 hrs. 
This was performed in BHIS-G liquid culture, in falcon tubes. Interestingly, at 
both of these timepoints the colony counts for C. difficile remained at 
comparable levels, in both mono and co-culture conditions (Figure 22).  
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Figure 22:  No inhibition of C. difficile during planktonic growth. 
CFU / ml for both C. difficile and B. fragilis from mono and co-culture during 
planktonic growth. A logarithmic scale is used on the Y-axis. The error bars 
represent standard deviations. 
 
4.2.2 LuxS in co-culture 
To investigate potential signalling functions of LuxS in C. difficile interactions 
with other bacterial species, we then investigated the role of LuxS in C. 
difficile – B. fragilis interactions. To do this, both C. difficile WT and luxS 
mutant were individually co-cultured with B. fragilis as biofilms at a 1:1 ratio 
(by OD600) in 24 well tissue culture dishes.  
 
A reduction in biofilm biomass as measured by CV was observed for both C. 
difficile WT and LuxS in co-culture with B. fragilis (Figure 23A). Colony counts 
of C. difficile in monoculture were similar for both WT and LuxS, with 
maximal numbers observed at 24h for both strains. As described earlier, 
when both strains were co-cultured with B. fragilis the colony counts for C. 
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difficile were significantly reduced. Interestingly, this reduction is more 
pronounced for the WT than the luxS mutant (Figure 23B) with a ten-fold 
reduction in mean CFU/ml being observed for the luxS mutant compared to 
a 2 log reduction for the WT.  
C. difficile 
A 
B.  
 
Figure 23: B. fragilis inhibition of C. difficile is more prominent for WT than 
LuxS 
(A) CV assay for mono- and co-cultures of C. difficile WT and LuxS with B. fragilis. 
The error bars represent standard deviations (P<0.05), N=9. (B) CFU / ml for C. 
difficile WT, C. difficile LuxS during co-culture with B. fragilis. A logarithmic scale is 
used on the Y-axis. The error bars represent standard deviations (P<0.05), N=3. 
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Confocal imaging (Figure 24) showed that C. difficile LuxS had reduced 
biofilms compared to WT, although clearly the mixed biofilm of LuxS was 
distinct both in structure and composition compared to the WT C. difficile/ B. 
fragilis biofilms. 
A               B 
    
Figure 24: Confocal microscopy of LuxS and co-culture biofilms. 
(A)Live/dead staining shows dead (red) and live (green) bacteria (Syto 9 and 
propidium iodide dye, respectively) in monoculture C. difficile LuxS.(B) Co-culture 
with B. fragilis. 
 
LuxS may serve a metabolic function in addition to a potential role in 
signalling via AI-2. Hence we sought to determine the likelihood of QS being 
responsible for the observed C. difficile inhibition. As only selected members 
of the Bacteroidetes are capable of producing AI-2 (Antunes et al., 2005) with 
this ability varying within the B. fragilis species (Peixoto et al., 2014). We first 
set up an AI-2 assay to assess the ability of both monocultures and co-
cultures to produce AI-2. Cell free supernatants were obtained from 
  
89 
 
monoculture biofilms of C. difficile WT, C. difficile LuxS and B. fragilis, 
together with co-cultures of both C. difficile strains with B. fragilis. Samples 
were taken at 36 hrs to account for differences in growth dynamics. We did 
not observe any AI-2 production by the B. fragilis strain. Whilst this strain is 
unable to produce AI-2 (Figure 25), some species have been shown to be QS 
“cheaters” capable of responding to AI-2 but lacking the ability to produce 
the signalling molecule. This can be evolutionarily advantageous as 
production of signalling molecules can be metabolically demanding for the 
cell (Fiegna and Velicer, 2003, Sandoz et al., 2007, Jiricny et al., 2010, Popat et 
al., 2012).  
 
 
Figure 25: AI-2 production during biofilm growth in BHI.  
Late log-phase C. difficile WT is displayed as a comparison. Cell-free supernatants 
were taken from each condition and assayed for AI-2 activity using V. harveyi. 
Bioluminescence is shown as a percentage of wild-type V. harveyi BB120 
bioluminescence, which was assumed to be 100%.  
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As the B. fragilis strain is a clinical isolate, we sequenced the genome using a 
Nexteria XT kit on an illumina miseq to identify whether LuxS was present. 
We repeated this sequencing twice at different times, however, after denovo 
assembly both sequences retained >1000 contigs suggesting that regions of 
the genome sequence were missing. Therefore we were unable to verify the 
presence of a LuxS homologue, as it is possible that this gene resides on a 
region of the genome that failed to get sequence. However, analysis of the 
sequences revealed a putative two-component histone kinase which shared 
36% identities and 54% similarities with the AI-2 sensor kinase/phosphatase, 
LuxQ of Vibrio fischeri (Figure 26), suggesting that B. fragilis may be able to 
detect AI-2 produced by other species. 
 
 
  
91 
 
 
 
Figure 26: Alignment of the putatitive two-component histone kinase with the 
LuxQ sequence from V. fischeri.  
The sequences were aligned using the CLUSTAL w algorithm. ‘*’ indicates positions 
which have a single, fully conserved residue. ‘:’ indicates conservation between 
groups of strongly similar properties with a score > 0.5 in the Gonnet PAM 
250 matrix.. ‘.’ indicates conservation between groups of weakly similar 
properties with a score =< 0.5 in the Gonnet PAM 250 matrix.. 
 
4.2.3 Secreted inhibitors 
To investigate whether any inhibitory molecules were being secreted by B. 
fragilis, we first tested cell-free supernatants from a planktonically grown 
O/N culture of B. fragilis, incubated for 48 hrs. C. difficile cells were 
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resuspended in 80% B. fragilis cell free supernatant and incubated for 24 hrs 
for biofilm formation. Whilst no inhibition was observed for C. difficile under 
these conditions (Figure 27), it is possible that any inhibitory molecule 
responsible for the inhibition of C. difficile observed in co-culture conditions, 
are only produced in the presence of C. difficile.  
 
To test this, cell-free supernatants were prepared from monoculture biofilms 
of B. fragilis and co-culture biofilms of C. difficile and B. fragilis grown for 24 
hrs. These supernatants were added to preformed biofilms at 24 hrs and 
incubated for a further 24 hrs. However, the biofilm B. fragilis supernatants 
also failed to inhibit the growth of C. difficile (Figure 28:), with enhanced 
growth detected with co-culture supernatants.  
 
 
Figure 27: Cell free supernatants from planktonically cultured B. fragilis fail to 
inhibit C. difficile. 
CFU / ml for C. difficile and C. difficile resuspended in cell-free B. fragilis supernatant 
obtained from planktonic bacteria. The error bars represent standard deviations. 
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Figure 28: Cell free supernatants from B. fragilis biofilms fail to inhibit C. 
difficile.  
CFU / ml for C. difficile and C. difficile resuspended in either cell-free B. fragilis 
biofilm supernatant or cell-free co-culture biofilm supernatant The error bars 
represent standard deviations (P<0.05).  
 
In order to isolate any molecules that may be responsible for the observed 
inhibition, we used Liquid Chromatography Mass Spectrometry (Agilent 6300 
Ion Trap LC/MS) in collaboration with Dr Christopher Corre and Dr Fabrizio 
Alterti (University of Warwick), We observed the presence of a molecule with 
a mass of 136 present in B. fragilis monocultures and the mixed samples 
containing B. fragilis. (Figure 29). Further analysis by liquid chromatography 
high resolution mass spectrometry yielded a predicted formula of C4H9NO4 
which corresponds to 4 known natural products: L-γ-hydroxythreonine, α-
(hydroxymethyl)serine, D-erythro-2-amino-3,4-dihydroxybutanoic acid, 2-
amino-2-deoxy-L-erythronic acid.    
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A            B 
 
C            D 
 
E            F 
 
Figure 29: LCMS spectra for biofilm supernatant for C. difficile and B. fragilis. 
(A) C. difficile WT. (B) C. difficile WT co-cultured with B. fragilis. (C) C. difficile LuxS. 
(D) C. difficile LuxS co-cultured with B. fragilis. (E) B. fragilis. (F) Media blank. 
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4.3 Discussion 
 
With the vast number of bacterial species present within the gut (Gerritsen et 
al., 2011), it is likely that the bacteria occupying this niche are forced to 
interact with one another. Some of these interactions will be mutualistic, as is 
seen in the oral cavity (Kuramitsu et al., 2007), with bacteria forming multi-
species bacterial communities allowing for bacterial cross-feeding, where the 
enzymes produced by one species make metabolites available for another 
species (Ng et al., 2013). Other interactions however will be antagonistic, with 
bacteria directly inhibiting competing species. One method of inhibition is 
through the production of microbial products such as bacteriocins, microbial 
peptides with bactericidal activity (Majeed et al., 2013, Wang and Kuramitsu, 
2005). Alternatively these antagonisms can be nutrients based where specific 
members of the microbiota are better adapted to sequestering certain 
nutrients, thus exhausting the supply for others. An example being the ability 
for E. coli Nissle 1917 to out compete S. typhimurium through its increased 
ability to sequester iron (Deriu et al., 2013).  
 
Here we sought to study interactions of C. difficile with other gut bacteria in 
adherent communities, and examine the role of luxS in inter-bacterial 
interactions. We showed that B. fragilis has an inhibitory effect on C. difficile 
when within adherent biofilms and that LuxS may mediate the inhibition 
observed. Whilst the production of an inhibitory molecule by B. fragilis 
cannot be completely ruled out, our data suggests that other mechanisms 
such as nutritional competition are more likely candidates for the observed 
inhibition. 
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The data presented here, demonstrate the first example of B. fragilis 
inhibition of C. difficile. Whilst a number of studies have highlighted a 
negative correlation between the presence of Bacteroides spp. and disease 
instances of C. difficile (Seekatz and Young, 2014), few studies have been 
conducted to ascertain the underlying mechanisms. Studies have largely 
focused on the ability of Bacteroides spp. to metabolise bile acids, due to the 
evidence that secondary bile acids such as deoxycholic acid inhibit C. difficile 
growth (Sorg and Sonenshein, 2008, Buffie et al., 2014).  
 
In a very recent study it was shown that production of the enzyme bile salt 
hydrolase, is responsible for the inhibitory effect of Bacteroides ovatus on C. 
difficile (Yoon et al., 2017). They reported that in the presence of bile acids, 
cell free supernatants for B. ovatus were capable of inhibiting the growth of 
C. difficile (Yoon et al., 2017). Interestingly however, it was found that in the 
absence of bile acids, the Bacteroides culture instead promoted C. difficile 
growth (Yoon et al., 2017). Since we do not supplement bile acids in our 
system, we can conclude that an alternate mechanism is responsible for B. 
fragilis mediated inhibition of C. difficile. 
 
Culturing the two species together in mixed biofilms, we observed a clear 
defect in biofilm formation and clear decrease in CFU counts for C. difficile. 
As this inhibition was not seen during planktonic growth, we hypothesise 
three potential modus operandi for the observed inhibition: 
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Firstly, B. fragilis could need to detect the presence of C. difficile. Sequencing 
of the B. fragilis strain revealed that despite the lack of a luxS homolog, this 
B. fragilis strain does possess a putative two-component histidine kinase with 
shared homology to the AI-2 sensor kinase/phosphatase, LuxQ, suggesting 
that whilst B. fragilis is not able to produce AI-2 itself, it may be capable of 
responding to AI-2. There are several examples of QS cheaters or bacteria 
capable of detecting and responding to QS signals while lacking the ability 
to produce the signalling molecule themselves (Rainey and Rainey, 2003, 
Fiegna and Velicer, 2003, Griffin et al., 2004, Diggle et al., 2007, Sandoz et al., 
2007, Ross-Gillespie et al., 2007, Jiricny et al., 2010, Popat et al., 2012). If true, 
B. fragilis may be altering its gene expression upon detection of C. difficile 
AI-2, thus creating an environment less favourable for C. difficile. As a large 
number of antimicrobial compounds produced by bacteria are secondary 
metabolites, which are metabolically costly to produce, bacteria often tightly 
regulate their expression (Nett et al., 2009). If such a molecule were 
responsible for the observed inhibition then it is likely that it would only be 
expressed in the co-culture conditions and not when in monoculture.  
 
Alternatively the mechanisms responsible for the observed inhibition could 
require the bacteria to be in close proximity. Strains of B. fragilis have been 
shown to possess the type VI secretion system (T6SS) (Russell et al., 2014, 
Coyne et al., 2016) a multiprotein complex shown to inhibit or kill other 
members of the Bacteroidales (Chatzidaki-Livanis et al., 2016). Although such 
inhibition has not previously been shown between Gram-positives and 
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Gram-negatives, the inability of cell-free supernatants to inhibit C. difficile, 
leaves this possibility open. 
 
Finally the inhibition observed here could simply be the result of a nutritional 
limitation at a later time point. It could be that B. fragilis gains a competitive 
advantage over C. difficile between 10 and 24 hrs post inoculation. This could 
be the result of the production of metabolic by products, or complex 
components that are broken down may be utilised by B. fragilis.  
 
We detected a small molecule with an m/z of 136 and predicted molecular 
formula, C4H9NO4, by LC/MS in B. fragilis biofilm supernatants. No known 
inhibitory molecule shares this formula. As it is produced by B. fragilis in all 
tested conditions and given the failure of cell free supernatants for both B. 
fragilis mono and co-cultures to inhibit C. difficile, this molecule seems an 
unlikely candidate for the observed inhibition. In addition to this, this 
molecule was produced in the LuxS co-cultures suggesting that this is not 
responsible for a LuxS-mediated inhibition of C. difficile in B. fragilis co-
cultures. 
 
Although our data demonstrates that LuxS is involved in B. fragilis-mediated 
inhibition of C. difficile, the role of LuxS or AI-2 in this inhibition remains 
unclear. Whilst we cannot rule out a role for signalling, the LuxPQ receptor 
complex has previously only been discovered in Vibrionale (Rezzonico and 
Duffy, 2008). Although our data suggests possible homology to LuxQ is 
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present in B. fragilis, further research is required to determine whether this 
species is capable of detecting and responding to AI-2.  
 
As LuxS plays an important role in the detoxification of SAH (Schauder et al., 
2001), the metabolic implications for its inactivation cannot be ignored. 
During analysis of LuxS inactivation in Lactobacillus reuteri it was found that 
the subsequent transcriptional and metabolic changes were not found to be 
cell-density dependant, suggesting that this was likely a metabolic 
consequence to the inactivation of LuxS (Wilson et al., 2012).  
 
This will be explored further utilising co-culture RNA-sequencing in chapter 
5. 
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Chapter 5 Understanding inter-species interactions within 
biofilms 
 
5.1 Introduction 
RNA-seq, a relatively new sequencing-based technology, can provide a 
snapshot of the entire transcriptome of a bacterial population at a given 
point in time. Transcriptomic studies can provide insight into the regulation 
of bacterial genes involved in metabolism and other cellular functions. RNA-
seq has recently become the de facto method for transcriptome studies 
(Nicolas et al., 2012, Choi, 2016) due to its many advantages over previous 
methods, such as not requiring previous knowledge of the reference 
sequence or coding sequence, low background noise, identification of short 
or poorly expressed transcripts, single nucleotide resolution, identification of 
transcriptional start sites, and identification of RNA processing.  
 
As bacteria seldom exist in isolation, interspecies interactions influence the 
bacterial physiology and pathogenicity. During such interactions, both 
partners respond in a multitude of ways, often adjusting their gene 
expression (Wolf et al., 2018). Dual species RNA-seq has enabled researchers 
to gain a deeper insight into such changes during a number of interspecies 
conditions, including host-pathogen, mutualistic and commensal interactions 
(Dutton et al., 2016, Sugimura and Saito, 2017, Wolf et al., 2018). Such 
studies have unveiled the importance of the carbon storage regulator system 
for the virulence of Yersinia pseudotuberculosis (Nuss et al., 2017), and the 
ability for Streptococcus gordonii to promote Candida albicans yeast-to-
hyphae transition (Dutton et al., 2016).     
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Having established the ability for B. fragilis to inhibit C. difficile growth 
during biofilm conditions, with notable differences between C. difficile WT 
and luxS mutant (LuxS), we sought to identify the pathways that mediate this 
effect. Utilising RNA-seq, we aimed to compare the transcriptional 
landscapes of both C. difficile strains and B. fragilis, in mono and co-culture.  
 
Results 
Dual and mono species RNA seq from biofilms 
C. difficile WT and LuxS, together with B. fragilis were grown in both mono 
and co-culture, in BHIS-G at 37°C in anaerobic conditions, in 24-well tissue 
culture plates (Figure 30). To avoid RNA degradation, RNA was extracted 
from bacterial biofilms after 18 hrs, post inoculation. 3 wells per sample were 
combined and the RNA was extracted and cDNA libraries were prepared 
using TruSeq stranded total RNA kit (Illumina) as described in Chapter 2. 3 
biological replicates were used per condition.   
 
 
Figure 30: Mono and Co-culture condition for C. difficile WT and LuxS (Purple) 
and B. fragilis (Red).  
RNA was isolated at 18 hrs from three wells per samples.   
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Analysis by BLAST (NCBI) demonstrated species specificity for mapping, co-
culture samples were mapped to each species reference separately. Initial 
mapping of the B. fragilis strain to a published reference proved 
unsuccessful, offering a poor rate of alignment of 60%. As the B. fragilis 
strain has not been previously sequenced, and because we were not 
successful in generating high quality genome sequence, a reference was 
generated from RNA library of B. fragilis using the software rnaSPAdes 
(Bankevich et al., 2012) and annotated using Prokka (Seemann, 2014). The 
reads from each condition were mapped to their respective reference 
sequence using BWA (Li and Durbin, 2009, Li and Durbin, 2010) and counted 
using coverageBed (Quinlan, 2014).  
 
Metabolic pathways in C. difficile were identified using the KEGG mapper 
(Kanehisa and Goto, 2000), a tool that identifies the function of genes in a 
published genome. As the B. fragilis strain used in this study does not have a 
published reference genome, blastKOALA (Kanehisa et al., 2016) was used to 
search for gene homology within metabolic pathways. 
 
5.1.4 Transcriptional responses of C. difficile WT and luxS mutant strains during co-
culture with B. fragilis. 
A total of 45 genes were differentially expressed in WT C. difficile, during co-
culture with B. fragilis. Of these 21 were down-regulated and 24 were up-
regulated. 69 genes were differentially expressed in C. difficile LuxS during 
co-culture with B. fragilis, 34 of with were down-regulated and 35 up-
regulated (Figure 31). A total of 26 genes were up or down-regulated in both 
WT and LuxS (Table 7). These include 6 up-regulated genes (accB, abfH, abfT, 
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abfD, sucD and cat1) involved in carbon and butanoate metabolism (Figures 
32 and 33 respectively), with cat1 encoding succinyl-CoA:coenzyme A 
transferase being the most highly up-regulated gene for both WT and LuxS 
(Table 7). nanE, which encodes a putative N-acetylmannosamine-6-
phosphate 2-epimerase was also up-regulated while gene bcd2, which 
encodes butyryl-CoA dehydrogenase, an enzyme involved in butanoate 
metabolism was down-regulated in both strains. 
     
 
Figure 31: Heat map comparing differentially expressed genes of C. difficile. 
A total of 88 genes were differentially expressed between WT and LuxS. 
 
8 genes of the up-regulated genes were specific to WT during co-culture. Of 
these, 4 genes involved in fatty acid biosynthesis and metabolism are noted 
to be up-regulated: fabH encoding 3-oxoacyl-[acyl-carrier protein] synthase 
III, fabK encoding trans-2-enoyl-ACP reductase, accC biotin carboxylase 
(acetyl-CoA carboxylase subunit A), and accB biotin carboxyl carrier protein 
of acetyl-CoA carboxylase (Figure 34). Additionally plsX encoding fatty acid / 
phospholipid synthesis protein, was also up-regulated.   
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18 up-regulated genes were specific to LuxS in co culture. These include a 
putative homocysteine S-methyltransferase, a putative osmoprotectant ABC 
transporter, substrate binding/ permease protein, ribonucleoside-
diphosphate reductase alpha chain (nrdE) and two genes from the trehalose 
operon: a PTS system II ABC transporter, and trehalose-6-phosphate 
hydrolase (treA). 
 
11 genes were found to be down-regulated exclusively in WT (Table 8). 
These include idhA, hisH, eutB and a putative radical SAM superfamily 
protein.  
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Figure 32: Metabolic pathway for Carbon metabolism.  
Carbon metabolism genes present in C. difficile (green). 6 genes are found to 
be up-regulated in both WT and LuxS (accB, abfH, abfT, abfD, sucD and cat1) 
(blue).  
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Figure 33: Metabolic pathway for Butanoate metabolism.  
Butanoate metabolism genes present in C. difficile (green). 6 genes found to 
be up-regulated in both WT and LuxS (accB, abfH, abfT, abfD, sucD and cat1) 
(blue).  
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Figure 34: Metabolic pathway for Fatty Acid Biosynthesis.  
Fatty acid biosynthesis genes present in C. difficile (green). 4 genes, fabH, 
fabK, accC and accB, are found to be up-regulated in C. difficile WT only 
(blue). 
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24 genes are found to be down-regulated only in LuxS (Table 9). These 
include 3 genes involved in thiamine metabolism thiD, thiK and thiE1, 
(CDR20291_1497, CDR20291_1498 and CDR20291_1499 respectively) which 
encode a putative phosphomethylpyrimidine kinase, 4-methyl-5-beta-
hydroxyethylthiazole kinase and thiamine-phosphate pyrophosphorylase 
respectively (Figure 35). Other genes also down-regulated include: pflD; 
putative formate acetyltransferase and proC2 pyroline-5-carboxylate 
reductase. 
  
 
Figure 35: Metabolic pathway for Thiamine metabolism.  
Thiamine metabolism genes presents in C. difficile (green). 3 thiD, thiK and, thiE1  
genes were found to be down-regulated in LuxS (pink). 
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Table 8: Genes up- and down-regulated in both C. difficile WT and LuxS, in C. 
difficile-Bacteroides fragilis co-cultures relative to WT C. difficile. 
Gene ID Log2foldchange Gene Annotation 
CDR20291_0196 1.242760946 hypothetical protein 
CDR20291_0197 1.024719474 hypothetical protein  
CDR20291_0511 -1.947939847 hypothetical protein 
CDR20291_0512 -1.790659218 hypothetical protein  
CDR20291_0910 -1.118039675 butyryl-CoA dehydrogenase  
CDR20291_1015 1.855396639 fatty acid biosynthesis transcriptional regulator  
CDR20291_1799 -1.559955287 hypothetical protein  
CDR20291_1862 1.571375262 biotin carboxyl carrier protein of acetyl-CoA 
carboxylase  
CDR20291_1878 -1.084562908 ABC transporter ATP-binding protein  
CDR20291_1931 1.501260024 AraC family transcriptional regulator 
CDR20291_1935 1.754871647 hypothetical protein  
CDR20291_2077 1.310107407 Sodium:dicarboxylate symporter  
CDR20291_2140 2.555234046 N-acetylmannosamine-6-phosphate 2-epimerase 
 
CDR20291_2227 3.630122723 NAD-dependent 4-hydroxybutyrate 
dehydrogenase 
CDR20291_2228 3.789825947 4-hydroxybutyrate CoA transferase 
CDR20291_2229 3.695347944 hypothetical protein 
CDR20291_2230 3.544168193 gamma-aminobutyrate metabolism 
dehydratase/isomerase 
CDR20291_2231 3.864728796 succinate-semialdehyde dehydrogenase 
[NAD(P)+] 
CDR20291_2232 4.2239099 succinyl-CoA:coenzyme A transferase 
CDR20291_2233 4.339535053 hypothetical protein  
CDR20291_2418 -1.624152909 hypothetical protein 
CDR20291_2419 -1.384788131 aminotransferase  
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CDR20291_2611 -1.45763049 two-component response regulator 
CDR20291_2612 -1.940640211 hypothetical protein 
CDR20291_2613 -1.569696353 polysaccharide deacetylase  
CDR20291_3110 1.176093028 hypothetical protein 
 
Note: P adjusted value< 0.05. Green text denotes up-regulated genes, blue 
text denotes down-regulated genes. 
 
Table 9: Genes up- and down-regulated in C. difficile WT, in C. difficile-
Bacteroides fragilis co-cultures relative to WT C. difficile 
 
Gene ID log2FoldChange Gene Annotation 
CDR20291_0194 1.38220809 10 kDa chaperonin  
CDR20291_0363 -1.377088342 radical SAM protein 
CDR20291_0364 -1.003594522 hypothetical protein 
CDR20291_0365 -1.461206801 (R)-2-hydroxyisocaproate dehydrogenase  
CDR20291_0659 -1.24853552 radical SAM protein  
CDR20291_1016 1.708784707 glycerol-3-phosphate acyltransferase PlsX 
CDR20291_1017 1.701199239 3-oxoacyl-ACP synthase III 
CDR20291_1018 1.246932597 trans-2-enoyl-ACP reductase  
CDR20291_1271 -1.156719781 hypothetical protein  
CDR20291_1309 -1.208810668 phosphohydrolase  
CDR20291_1337 1.329049949 transcriptional regulator  
CDR20291_1400 -1.833327377 imidazole glycerol phosphate synthase subunit 
HisH  
CDR20291_1834 -1.411634275 ethanolamine/propanediol ammonia-lyase heavy 
chain  
CDR20291_1861 1.412304008 biotin carboxylase acetyl-CoA carboxylase subunit 
A  
CDR20291_2027 1.63094576 2-nitropropane dioxygenase 
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CDR20291_2416 -1.231650825 hypothetical protein 
CDR20291_2417 -1.574982111 hypothetical protein  
CDR20291_2610 -1.046806871 two-component sensor histidine kinase  
CDR20291_3225 1.022902487 formate/nitrite transporter 
 
Note: P adjusted value< 0.05. Green text denotes up-regulated genes, blue 
text denotes down-regulated genes. 
 
Table 10: Genes up and down-regulated in C. difficile LuxS in in C. difficile-
Bacteroides fragilis co-cultures relative to WT C. difficile. 
 
LuxSmix log2FoldChange Gene Annotation 
CDR20291_0025 -1.320529858 acetoin:2%2C6-dichlorophenolindophenol 
oxidoreductase subunit alpha  
CDR20291_0491 1.096435454 RNA methylase 
CDR20291_0492 1.180203419 hypothetical protein 
CDR20291_0493 1.007610513 outer membrane lipoprotein  
CDR20291_0615 -0.869149983 nucleotide phosphodiesterase  
CDR20291_0715 1.624572548 N-acetylmuramoyl-L-alanine amidase  
CDR20291_0802 -2.260047134 ABC transporter substrate-binding protein  
CDR20291_0911 -1.241809993 electron transfer flavoprotein subunit beta  
CDR20291_1359 -0.850952233 hypothetical protein  
CDR20291_1366 0.92740269 ferrous ion transport protein  
CDR20291_1370 -1.124726418 tyrosyl-tRNA synthetase  
CDR20291_1374 1.165117564 iron-sulfur protein  
CDR20291_1497 -1.456295839 phosphomethylpyrimidine kinase 
CDR20291_1498 -1.727285435 hydroxyethylthiazole kinase 
CDR20291_1499 -1.276386794 thiamine-phosphate pyrophosphorylase 
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CDR20291_1591 -1.517990203 dinitrogenase iron-molybdenum cofactor  
CDR20291_1691 1.418730417 nitrite and sulfite reductase subunit  
CDR20291_1716 1.314365385 thiol peroxidase 
CDR20291_1717 1.110872045 hypothetical protein  
CDR20291_1901 -1.832663158 ABC transporter ATP-binding protein 
CDR20291_1902 -1.875507101 ABC transporter substrate-binding protein 
CDR20291_1903 -1.659329494 ABC transporter permease 
CDR20291_1904 -1.638608704 hypothetical protein  
CDR20291_1925 -1.548059893 flavodoxin  
CDR20291_1934 1.545622858 hypothetical protein 
CDR20291_1936 1.336887442 GntR family transcriptional regulator 
CDR20291_1937 1.373694549 ABC transporter ATP-binding protein  
CDR20291_2389 1.261970927 competence protein  
CDR20291_2474 -1.434272008 DNA-directed RNA polymerase subunit omega  
CDR20291_2515 -1.6039508 amino acid permease family protein 
CDR20291_2516 -1.176482249 cobalt dependent x-pro dipeptidase  
CDR20291_2660 -0.958813531 teichuronic acid biosynthesis glycosyl transferase  
CDR20291_2830 1.113329954 ribonucleoside-diphosphate reductase subunit alpha  
CDR20291_2870 -2.33551794 hypothetical protein  
CDR20291_2928 1.753815574 PTS system transporter subunit IIABC 
CDR20291_2930 1.571316791 trehalose-6-phosphate hydrolase  
CDR20291_3075 1.364968728 osmoprotectant ABC transporter substrate-
binding/permease  
CDR20291_3104 0.809909777 sigma-54-dependent transcriptional activator  
CDR20291_3142 -1.665916251 pyrroline-5-carboxylate reductase 
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CDR20291_3143 -1.830480704 formate acetyltransferase 
CDR20291_3144 -1.643573257 pyruvate formate-lyase 3 activating enzyme 
CDR20291_3434 1.44024185 homocysteine S-methyltransferase 
 
Note: P adjusted value< 0.05. Green text denotes up-regulated genes, blue 
text denotes down-regulated genes. 
 
 
 
As C. difficile WT is more susceptible to B. fragilis mediated inhibition 
compared to LuxS, we sought to identify transcriptional differences between 
the two strains. With the ability for C. difficile to gain a competitive 
advantage against other members of the gut microbiota through its ability to 
utilise trehalose (Collins et al., 2018a), it is interesting to note an upregulation 
of two genes from the trehalose operon: treA (CDR20291_2930) and a PTS 
system transporter (CDR20291_2928) in LuxS. To investigate if the 
upregulation of the trehalose operon in C. difficile LuxS provided the mutant 
with a competitive advantage over the WT, we first tested the ability of both 
WT to produce a biofilm in the presence of 1 µM, 10 µM, 100 µM and 1000 
µM trehalose (Figure 36A). Since supplementing the medium with additional 
levels of glucose, equivalent to trehalose, also had an inhibitory effect (Figure 
36A), we switched the medium to BHIS, removing the glucose entirely (Figure 
36B). In the absence of glucose, the levels of trehalose tested had no effect 
on the biofilm formation of WT, with slight inhibition seen at higher 
concentration in LuxS.   
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A 
B  
 
 
Figure 36: Biofilm formation of C. difficile WT and LuxS with and without 
trehalose as measured by crystal violet. 
(A) WT was tested with 1 µM, 10 µM, 100 µM and 1000 µM trehalose together with 
2000 µM Glucose in BHIS-G. (B) Both WT and LuxS were tested with lower 
concentrations of 1 µM, 10 µM trehalose. WT grown in BHIS-G was used as for 
comparison. N=3 with error bars representing standard deviation. 
 
 
4.2.5 Transcriptional profiles of B. fragilis during co-culture with C. difficile WT and 
LuxS 
When co-cultured with C. difficile WT, 335 genes were differentially 
expressed in B. fragilis compared to monoculture biofilms, with 139 genes 
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being up-regulated and 196 down-regulated. 324 genes were differentially 
expressed during B. fragilis co-culture with LuxS compared to B. fragilis 
monoculture. Of these 150 were up-regulated and 174 down-regulated. In 
total, 266 shared genes were found to be up and down-regulated in both co-
culture conditions. Of these the 28 highest up- and down- regulated genes 
are shown in Table 11 & 12 respectively. Whilst the highest up-regulated 
gene in both conditions encodes a virus attachment protein, no other viral 
genes were shown to be up-regulated. The next highest up-regulated genes 
in both conditions encoding desulfoferrodoxin and rubrerythrin.  With both 
of these proteins containing iron, it is curious that multiple copies of fecR, a 
key regulator for the ferric citrate transport system (Andrews et al., 2003), 
and ferrous iron transport protein B were also up-regulated. It should be 
noted that many of the other up-regulated genes corresponded to 
hypothetical proteins of unknown function.  
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Figure 37: Heat map comparing differentially expressed genes of B. fragilis. 
Differentially expressed genes in B. fragilis were compared between all culture 
conditions.  
 
Table 11: Genes up-regulated in B. fragilis, in both C. difficile WT and LuxS-
Bacteroides fragilis co-cultures relative to B. fragilis mono-culture. 
 
log2FoldChange Gene Annotation 
9.287946 Virus attachment protein p12 family protein 
7.634947 Desulfoferrodoxin 
6.03326 Rubrerythrin 
4.659762 hypothetical protein 
2.93005 hypothetical protein 
2.652998 hypothetical protein 
2.266419 DNA-binding transcriptional repressor MngR 
2.231958 hypothetical protein 
1.932819 L-fucose isomerase 
1.759508 NADP-dependent 7-alpha-hydroxysteroid dehydrogenase 
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1.698321 Alkyl hydroperoxide reductase subunit F 
1.623389 2-isopropylmalate synthase 
1.569406 Sensor histidine kinase RcsC 
1.56776 Galactokinase 
1.546709 Carbamoyl-phosphate synthase large chain 
1.519255 fec operon regulator FecR 
1.495672 UDP-glucose 4-epimerase 
1.491419 3-isopropylmalate dehydratase small subunit 
1.462756 indolepyruvate oxidoreductase subunit beta 
1.452842 3-isopropylmalate dehydrogenase 
1.431211 fec operon regulator FecR 
1.412666 fec operon regulator FecR 
1.38758 fec operon regulator FecR 
1.372355 hypothetical protein 
1.355325 hypothetical protein 
1.312292 integration host factor subunit alpha 
1.304238 hypothetical protein 
1.295602 3-isopropylmalate dehydratase large subunit 
 
Note: P adjusted value< 0.05. 
Table 12: Genes down-regulated in B. fragilis, in C. difficile WT and LuxS-
Bacteroides fragilis co-cultures relative to B. fragilis mono-culture. 
 
log2FoldChange Gene Annotation 
-2.98798 hypothetical protein 
-2.80775 Biopolymer transport protein ExbD/TolR 
-2.75952 Biopolymer transport protein ExbD/TolR 
-2.45804 hypothetical protein 
-2.45438 ECF RNA polymerase sigma factor SigW 
-2.36995 Efflux pump periplasmic linker BepF 
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-2.28626 Inner membrane protein YhiM 
-2.27704 Gram-negative bacterial tonB protein 
-2.24283 colicin uptake protein TolQ 
-2.21503 Histidine decarboxylase proenzyme precursor 
-2.17528 hypothetical protein 
-2.12616 hypothetical protein 
-2.12196 putative TonB-dependent receptor precursor 
-2.11095 hypothetical protein 
-2.0886 hypothetical protein 
-2.0541 hypothetical protein 
-2.02612 Acetylxylan esterase precursor 
-2.02381 Porin subfamily protein 
-2.02379 tetratricopeptide repeat protein 
-2.0236 hypothetical protein 
-1.95909 Outer membrane protein OprM precursor 
-1.94728 TonB-dependent Receptor Plug Domain protein 
-1.89613 hypothetical protein 
-1.88633 Choloylglycine hydrolase 
-1.8758 Putative NAD(P)H-dependent FMN-containing oxidoreductase 
YwqN 
-1.86516 ISXO2-like transposase domain protein 
 
Note: P adjusted value< 0.05. 
 
Additionally there are a number of metabolic pathways up-regulated in both, 
these include 4 genes (encoding 3-isopropylmalate dehydratase small 
subunit, 3-isopropylmalate dehydrogenase, Galactokinase and 3-
isopropylmalate dehydratase large subunit) involved in valine, leucine and 
isoleucine biosynthesis and C5-Branched dibasic acid metabolism (Figure 38 
and 39 respectively). 
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Similarly, several metabolic pathways are down-regulated in both co-culture 
conditions. These include 6 genes involved in carbon metabolism (Figure 40), 
4 genes involved in alanine, aspartate and glutamate metabolism, and 4 
genes involved in the biosynthesis of amino acids, however these appear to 
be single genes rather than specific pathways (Figure 41).  
 
Despite both co-culture conditions only sharing 82% of differentially 
expressed genes compared to the monoculture, analysis by blastKOALA 
(Kanehisa et al., 2016) did not clearly highlight any metabolic pathways as 
being differentially expressed between the co-culture conditions, with many 
of the genes being annotated as hypothetical genes.  
 
A total of 67 genes were found to be specific to C. difficile WT co-culture, 
with 29 of these up-regulated (Table 12) and 38 down-regulated (Table 13). 
Similarly 58 genes were found to be specific to C. difficile LuxS co-culture, 
with 38 of these up-regulated (Table 14) and 20 down-regulated (Tables 15). 
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Figure 38: Metabolic pathway for valine, leucine and isoleucine biosynthesis.  
4 genes were found to be differentially expressed in B. fragilis during co-culture with 
C. difficile WT and LuxS (green). 
 
  
121 
 
 
Figure 39: Metabolic pathway for C5-branched diabasic acid metabolism.  
4 genes were found to be differentially expressed in B. fragilis during co-culture with 
C. difficile WT and LuxS (green). 
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Figure 40: Metabolic pathway for carbon metabolism.  
4 genes involved in carbon metabolism are down-regulated in B. fragilis co-cultured 
with C. difficile WT and LuxS (green).  
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Figure 41: Metabolic pathway for Alanine, Aspartate and Glutamate 
metabolism.  
4 genes involved in Alanine, Aspartate and Glutamate metabolism are down-
regulated in B. fragilis co-cultured with C. difficile WT and LuxS (green).  
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Table 13: Genes up-regulated in B. fragilis, in C. difficile WT-Bacteroides fragilis 
co-cultures relative to B. fragilis mono-culture 
 
log2FoldChange Gene Annotation 
1.311516 RNA polymerase sigma factor 
1.30583 N-acetylmuramoyl-L-alanine amidase 
1.296892 tRNA-Arg(ccg) 
1.287475 Phytochrome-like protein cph1 
1.273862 L-fucose-proton symporter 
1.192976 SusD family protein 
1.125756 putative N-acetyltransferase YvbK 
1.046014 hypothetical protein 
0.929316 hypothetical protein 
0.918517 7-cyano-7-deazaguanine synthase 
0.895506 3-deoxy-D-manno-octulosonic acid transferase 
0.894201 hypothetical protein 
0.892291 Putative multidrug export ATP-binding/permease 
protein 
0.880993 hypothetical protein 
0.880608 NADPH-dependent 7-cyano-7-deazaguanine 
reductase 
0.876389 Nicotinamide-nucleotide amidohydrolase PncC 
0.862807 hypothetical protein 
0.845284 50S ribosomal protein L35 
0.844678 Peptide-N-glycosidase F%2C N terminal 
0.843493 Abhydrolase family protein 
0.839781 Phospho-N-acetylmuramoyl-pentapeptide-
transferase 
0.829317 hypothetical protein 
0.825833 Beta-1%2C4-mannooligosaccharide phosphorylase 
0.811321 lipid-A-disaccharide synthase 
0.811099 hypothetical protein 
0.81081 Aspartate/alanine antiporter 
0.807753 Arylsulfatase 
0.802685 DNA-invertase hin 
0.801621 D-3-phosphoglycerate dehydrogenase 
 
Note: P adjusted value< 0.05. 
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Table 14:  Genes down-regulated in B. fragilis, in C. difficile WT-Bacteroides fragilis 
co-cultures relative to B. fragilis mono-culture. 
 
log2FoldChange Gene Annotation 
-1.40341 hypothetical protein 
-1.37746 hypothetical protein 
-1.37108 hypothetical protein 
-1.36255 hypothetical protein 
-1.28886 Fimbrillin-A associated anchor proteins Mfa1 and 
Mfa2 
-1.22553 hypothetical protein 
-1.19669 hypothetical protein 
-1.19434 hypothetical protein 
-1.19075 Nitroreductase family protein 
-1.15186 hypothetical protein 
-1.12987 hypothetical protein 
-1.1191 hypothetical protein 
-1.11384 hypothetical protein 
-1.09063 hypothetical protein 
-1.0769 Quercetin 2%2C3-dioxygenase 
-1.07478 Hydroxylamine reductase 
-1.07286 ECF RNA polymerase sigma factor SigH 
-1.07215 Multidrug resistance protein MdtA precursor 
-1.05139 Chagasin family peptidase inhibitor I42 
-1.01228 Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex 
-1.00722 hypothetical protein 
-0.99411 Putative pyridoxal phosphate-dependent 
aminotransferase EpsN 
-0.9932 Alpha-amylase precursor 
-0.9877 hypothetical protein 
-0.98757 putative deferrochelatase/peroxidase YfeX 
-0.98646 hypothetical protein 
-0.97934 Hexokinase 
-0.95502 Flavodoxin 
-0.93045 Succinyl-CoA ligase [ADP-forming] subunit beta 
-0.92318 Carboxymuconolactone decarboxylase family protein 
-0.89637 tRNA 2'-O-methylase 
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-0.88426 Putative SOS response-associated peptidase YedK 
-0.86662 Helix-turn-helix 
-0.86218 hypothetical protein 
-0.86014 Tyrocidine synthase 1 
-0.85888 GDP-mannose 4%2C6-dehydratase 
-0.83579 hypothetical protein 
-0.82748 Putative zinc ribbon domain protein 
 
Note: P adjusted value< 0.05. 
 
Table 15: Genes up-regulated in B. fragilis, in C. difficile LuxS-Bacteroides fragilis 
co-cultures relative to B. fragilis mono-culture 
 
log2FoldChange Gene Annotation 
1.50249 hypothetical protein 
1.48934 Tyrosine recombinase XerD 
1.295481 fec operon regulator FecR 
1.280656 tRNA-Leu(caa) 
1.235375 Reverse rubrerythrin-1 
1.220847 hypothetical protein 
1.200963 ATP-dependent Clp protease ATP-binding subunit 
ClpC 
1.188287 hypothetical protein 
1.176729 tRNA-Thr(cgt) 
1.133713 hypothetical protein 
1.109684 60 kDa chaperonin 
1.09403 10 kDa chaperonin 
1.08306 Tyrosine recombinase XerC 
1.066955 NAD-specific glutamate dehydrogenase 
1.063195 fec operon regulator FecR 
1.03149 fec operon regulator FecR 
1.021451 hypothetical protein 
1.015769 tRNA-Phe(gaa) 
0.990297 hypothetical protein 
0.98787 tRNA-Arg(gcg) 
0.980119 MarR family protein 
0.956639 hypothetical protein 
0.951389 hypothetical protein 
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0.938171 Septum formation protein Maf 
0.932255 ATP synthase subunit beta 
0.92593 hypothetical protein 
0.921887 hypothetical protein 
0.905375 30S ribosomal protein S20 
0.89716 hypothetical protein 
0.885735 hypothetical protein 
0.871156 hypothetical protein 
0.865619 50S ribosomal protein L34 
0.843942 tRNA-Asp(gtc) 
0.843727 Cellobiose 2-epimerase 
0.835563 50S ribosomal protein L36 
0.817012 30S ribosomal protein S21 
0.802377 tRNA-Lys(ttt) 
0.800503 50S ribosomal protein L31 type B 
 
Note: P adjusted value< 0.05. 
 
 
Table 16: Genes down-regulated in B. fragilis, in C. difficile LuxS-Bacteroides 
fragilis co-cultures relative to B. fragilis mono-culture. 
 
log2FoldChange Gene Annotation 
-1.4039 hypothetical protein 
-1.33473 hypothetical protein 
-1.33023 hypothetical protein 
-1.19678 hypothetical protein 
-1.11145 Lactate utilization protein C 
-1.06955 Molecular chaperone Hsp31 and glyoxalase 3 
-1.03246 hypothetical protein 
-1.01929 putative metallo-hydrolase 
-1.01713 Colicin I receptor precursor 
-0.98589 Cadmium%2C zinc and cobalt-transporting ATPase 
-0.9256 Bifunctional transcriptional activator/DNA repair 
enzyme Ada 
-0.91437 Pyruvate formate-lyase 1-activating enzyme 
-0.9142 hypothetical protein 
-0.87106 putative A/G-specific adenine glycosylase YfhQ 
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-0.86216 Lipoprotein-releasing system transmembrane protein 
LolE 
-0.8445 FMN reductase [NAD(P)H] 
-0.83554 putative oxidoreductase 
-0.81525 Transaldolase 
-0.8053 Aminopeptidase YwaD precursor 
-0.80259 dTDP-4-dehydrorhamnose reductase 
 
Note: P adjusted value< 0.05. 
 
Discussion 
 
In this Chapter we have described RNA-seq of co-cultures of C. difficile and 
B. fragilis. The purpose of this study was to determine the mechanisms 
responsible for the observed B. fragilis mediated inhibition of C. difficile. 
Although our data does not predict a single mechanism responsible for the 
B. fragilis mediated inhibition of C. difficile, we identified a number of 
potentially important metabolic pathways differentially expressed in both 
organisms in the conditions tested.   
 
Although upregulation was observed for 6 genes involved in carbon and 
butanoate metabolism for both C. difficile WT and LuxS, these genes (accB, 
abfH, abfT, abfD, sucD and cat1) are all involved in the utilisation of succinate 
as a carbon source. As B. fragilis is known to produce succinate (Macy et al., 
1978), it is likely that the upregulation in these pathways results from the 
increased levels of succinate in the culture medium. However, since gut 
microbiota-produced succinate promotes C. difficile growth in vivo (Ferreyra 
et al., 2014), it is unlikely that these changes are directly responsible for the 
observed inhibition of C. difficile. However, bacteria utilise carbohydrates in a 
sequential manner (Bruckner and Titgemeyer, 2002). Consistent with this, we 
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observed a down regulation of genes important for the utilisation of 
pyruvate such as bcd2 and idhA encoding for butyryl-CoA dehydrogenase 
and (r)-2-hydroxyisocaproate dehydrogenase respectively. Such a shift in 
metabolism could allow B. fragilis to fully consume other metabolites, and 
thus enabling it to outcompete C. difficile.   
 
Interestingly, the ability of C. difficile to utilise trehalose as a carbon source 
through the expression of the trehalose operon, has been shown to provide 
a growth advantage to C. difficile against other bacteria (Collins et al., 2018a). 
As such, the LuxS upregulation of a phosphotransferase system component 
and treA (both in the trehalose operon), likely enables increased utilisation of 
trehalose, providing an additional carbon source. Like glucose, trehalose acts 
as an osmoprotectant (Tanghe et al., 2003). As such its presence within the 
cell likely helps to maintain the conformation of proteins during cellular 
dehydration (Pareek et al., 2010). Therefore its increased utilisation could 
negatively impact biofilm formation (as seen in chapter 3). Although 
exogenous trehalose levels similar to those used by Collins et al. (2018) had 
an inhibitory effect on biofilm formation of both WT and LuxS, this trehalose 
induced inhibition appears to be concentration dependent. Therefore it is 
possible that the ideal concentration of trehalose would have a differential 
effect on LuxS and WT. It would also be useful to assess the impact of 
trehalose on the CFU of WT and LuxS. 
 
Fatty acids are an essential component of bacterial cell membranes (Fujita et 
al., 2007) and thus important for bacterial growth. During co-culture we 
observed upregulation of 5 genes responsible for fatty acid synthesis (plsX, 
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fabH, fabK, accB and accC) in C. difficile WT. In Bacillus subtilis the 
upregulation of fatty acid synthesis genes have been associated with the 
response to environmental stresses due to the changes offered to membrane 
fluidity and diffusion rate (Ter Beek et al., 2008). The upregulation of these 
genes in C. difficile could be indicative of a response to a B. fragilis produced 
inhibitory molecule. 
 
Interestingly, C. difficile LuxS demonstrates a down regulation of genes 
involved in the salvage of thiamine thiD, thiK and thiE1 (Melnick et al., 2004). 
As the active form of thiamine, thiamin diphosphate (ThDP), is indispensable 
for the carbohydrate and branched-chain amino acid metabolic enzymes 
(Melnick et al., 2004), a defect in its production could prove fatal to the 
bacteria concerned.  However, as C. difficile LuxS survives better than the WT 
during co-culture conditions, further work would be necessary to assess the 
role of thiamine during C. difficile co-cultures.  
 
Since many bacteria require branched-chain amino acids (isoleucine, leucine 
and, valine) for protein synthesis, branched-chain fatty acid synthesis, and 
environmental adaptation (Kaiser et al., 2018). The observed upregulation of 
genes involved in valine, leucine and isoleucine biosynthesis during co-
culture with C. difficile is likely due to changes in the abundance of these 
amino acids in the growth medium. 
 
Iron is essential for virtually all organisms and bacterial elaborate a number 
of mechanisms to sequester iron.  It is interesting to note that a number of 
copies of the ferric citrate transport system regulator, fecR, are found to be 
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up-regulated in B. fragilis during both culture conditions. The ferric citrate 
transport system is an iron uptake system that responds to the presence of 
citrate (Wagegg and Braun, 1981, Staudenmaier et al., 1989, Andrews et al., 
2003). Interestingly, analysis of the C. difficile genome using BLAST (NCBI) 
found that C. difficile does not possess this iron uptake system. Additionally 
there is some evidence of ferric citrate being an iron source in the gut 
(Andrews et al., 2003). Hence B. fragilis may have a possible advantage in 
sequestering iron, and outcompeting C. difficile and preventing it from 
colonising the gut 
 
Finally, with a large number of hypothetical genes being differentially 
expressed in B. fragilis, homology analysis would need to be performed in 
order to rule out the possibility of these genes producing an inhibitory 
molecule. 
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Chapter 6  Discussion 
 
Recurrent infections caused by many pathogens, have been associated with 
the ability to form biofilms (Romling and Balsalobre, 2012). Biofilms offer the 
bacteria within increased resistance to a range of environmental stresses, 
including, antibiotic and oxygen stress and protection from phagocytosis 
(Davey and O'Toole G, 2000, Hall-Stoodley and Stoodley, 2009). In recent 
years it has become clear that the causative agent of CDI, C. difficile, is not 
only capable of forming biofilms in vitro (Dawson et al., 2012, Ðapa et al., 
2013, Crowther et al., 2014, Walter et al., 2015, Pantaleon et al., 2015, 
Maldarelli et al., 2016) but that some clinical relevant strains, are also capable 
of forming biofilm like structures in vivo (Soavelomandroso et al., 2017). With 
20-36% of instances of CDI resulting in recurrent infections (Barbut et al., 
2000, Rupnik et al., 2009, Smits et al., 2016) the mechanisms responsible 
need to be understood.  
 
Quorum sensing is thought to regulate biofilm formation, development and 
dispersal of many bacterial species by enabling the bacteria to coordinate 
gene expression (Zhu and Mekalanos, 2003, Hammer and Bassler, 2003, 
Sakuragi and Kolter, 2007, Hardie and Heurlier, 2008, De Araujo et al., 2010, 
Li and Tian, 2012, Solano et al., 2014). The LuxS/AI-2 QS system has been of 
particular interest to researchers (Hardie and Heurlier, 2008). LuxS, an 
enzyme in the activated methyl cycle, is responsible for the production of the 
potent, cross-species QS signalling molecule, AI-2 (Bassler et al., 1997, 
Schauder et al., 2001, Federle and Bassler, 2003). Given the role for LuxS 
during the biofilm formation, development or dispersal of many species 
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(Chen et al., 2002, Yoshida et al., 2005, De Keersmaecker et al., 2005, Auger et 
al., 2006, Rickard et al., 2006, Gonzalez Barrios et al., 2006, Shao et al., 2007, 
Sztajer et al., 2008, Huang et al., 2009, Ahmed et al., 2009, De Araujo et al., 
2010, Cao et al., 2011, Karim et al., 2013, Li et al., 2015), it has been proposed 
that AI-2 is the “universal language” of bacteria (Federle and Bassler, 2003, 
Hardie and Heurlier, 2008). However, with many species lacking the two 
characterised AI-2 receptors, others have hypothesised that the metabolic 
function of LuxS is responsible for the observed phenotypes in many of these 
species (Rezzonico and Duffy, 2008, Wilson et al., 2012). 
 
The role for LuxS in C. difficile has remained clouded, with conflicting studies 
for its role in toxin production (Carter et al., 2005, Lee and Song, 2005). More 
recently it has been demonstrated that a C. difficile luxS mutant (LuxS) 
exhibits a severe defect during biofilm formation (Ðapa et al., 2013). This 
study aimed to utilise a number of molecular biology techniques in order to 
characterise the role of LuxS during in vitro biofilm formation. With the 
implicated cross-species signalling role for LuxS/AI-2 (Federle and Bassler, 
2003), coupled with the ability for other members of the gut microbiota 
(including Bacteroidies) to provide colonisation resistance to C. difficile 
(Lawley et al., 2012), we also sought to investigate how luxS influences the 
interactions between C. difficile and a gut commensal and pathogen, B. 
fragilis.  
 
During C. difficile mono-culture, we observed a defect in biofilm formation at 
both 24 and 72 hrs which was consistent with the findings of Dapa et al. 
(2013). Similarly to Carter et al. (2005), the addition of MHF, a chemical form 
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of AI-2, had no effect on LuxS. However, through the exogenous addition of 
DPD, the precursor to AI-2, we were able to partially restore the biofilm 
formation of LuxS in a dose-dependent manner. These results suggest a role 
of LuxS/AI-2 QS in C. difficile biofilm formation.  
 
Utilising RNA-sequencing, we identified two prophage regions down-
regulated during the early stages of biofilm formation (18 hrs). In other 
bacteria, prophage have been associated with both the development of 
Pseudomonas aeruginosa biofilms and dispersal of Enterococcus faecalis 
(Secor, 2016, Rossmann et al., 2015). Furthermore, the phage mediated 
biofilm dispersal of E. faecalis is regulated by AI-2 (Rossmann et al., 2015). 
Through PCR analysis we were able to confirm the presence of these 
prophage within C. difficile biofilms. Since the expression of prophage results 
in the lysis of the host cell (Young, 1992), coupled with the observation by 
Ðapa et al. (2013) that e-DNA is a key component of C. difficile biofilm, we 
hypothesise C. difficile is utilising prophage induction for the purpose of 
releasing the cell contents and e-DNA from a subset of the bacterial 
population. With the ability for clinically relevant C. difficile strains to 
produce biofilm-like structures in vivo (Soavelomandroso et al., 2017) 
combined with the increased antibiotic resistance biofilms offer C. difficile in 
vitro (Ðapa et al., 2013), we believe that this mode of growth could offer a 
reservoir for recurrent infections.  
 
Since microbial dysbiosis in the gut is the major risk factor for developing 
CDI, the replenishment of “normal” members of the gut microbiota by means 
of faecal microbiota transplantation has proved to be an effective treatment 
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for the most severe cases of CDI (Smits et al., 2016). However, due to the 
complex nature of the gut microbiota, the mechanisms responsible for 
colonisation resistance are poorly understood.  With a number of sequencing 
studies indicating the ability for members of the Bacteroidetes to resist C. 
difficile colonisation (Seekatz and Young, 2014) and evidence that selected 
strains of B. fragilis have the ability to produce AI-2 (Antunes et al., 2005). 
Coupled with the evidence that C. difficile is capable of forming mixed 
species communities in mice (Semenyuk et al., 2015), we sought to 
investigate how C. difficile luxS influences interaction with B. fragilis during 
biofilm formation.     
 
First we studied the interactions of WT C. difficile and B. fragilis when co-
cultured in biofilms. Interestingly we found that B. fragilis had an inhibitory 
effect on C. difficile during biofilm growth (as measured by CFU) that was not 
observed during planktonic co-culture conditions. Furthermore cell free 
supernatants of B. fragilis failed to inhibit C. difficile growth. A very recent 
study demonstrated that production of the enzyme: bile salt hydrolase, is 
responsible for the inhibitory effect of B. ovatus on C. difficile (Yoon et al., 
2017). They reported that in the presence of bile acids, cell free supernatants 
for B. ovatus were capable of inhibiting the growth of C. difficile whereas, in 
the absence of bile acids C. difficile growth was promoted (Yoon et al. 2017). 
Since bile acids are not supplemented into our media, a different mechanism 
is likely responsible for B. fragilis mediated inhibition of C. difficile. 
 
In comparison, we found that whilst LuxS was inhibited during co-culture 
with B. fragilis, the levels of inhibition were far greater for WT. Although we 
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cannot rule out the possibility of an inhibitory molecule being produced by 
B. fragilis upon detection of C. difficile, the dual species RNA-seq data hints 
at involvement of metabolic pathways or nutritional inhibition in the 
inhibition of C. difficile.   
 
The incorporation of iron into proteins is key for survival of all organisms. It is 
therefore interesting to note a clear upregulation of multiple copies of the 
ferric citrate transport system in B. fragilis, during co-culture with C. difficile. 
Ferric citrate is actively transported across the outer membrane by FecA, and 
across the inner membrane by FecBCDE proteins (Wagegg and Braun, 1981, 
Pressler et al., 1988, Staudenmaier et al., 1989). As C. difficile does not 
possess the ferric citrate transport system, we suspect that B. fragilis is better 
adapted at sequestering iron. With the presence of ferric citrate in the gut 
(Kortman et al., 2014), iron starvation could play an important role in 
colonisation resistance. 
 
The differences in B. fragilis mediated inhibition of C. difficile between WT 
and LuxS could also be attributed to the observed upregulation in LuxS, of 
two genes on the trehalose operon (a PTS system component and TreA). 
Although the effect on CFU and an increased range of Trehalose 
concentrations would need to be further investigated. Recent studies have 
suggested that upregulation of these genes afford the bacteria a fitness 
advantage in vivo (Robinson et al., 2014, Collins et al., 2018a).  Additional, 
with the role of trehalose as an osmoprotectant, the increased utilisation in 
LuxS could be having a negative effect on the biofilm formation of this strain. 
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In conclusion, we demonstrated strong evidence to suggest a signalling role 
for LuxS/AI-2 in C. difficile that likely induces the release of prophage. We 
speculate that this in turn increases lyses a subset of the bacterial population, 
releasing eDNA and increasing the levels of biofilm formation.  Additionally 
we demonstrated the ability for B. fragilis to inhibit C. difficile during the 
biofilm mode of growth. Co-culture RNA-seq analysis has demonstrated a 
possible metabolic effect causing the observed inhibition. However, with the 
large number of hypothetical genes differentially expressed in B. fragilis, the 
possibility of the synthesis of an inhibitory molecule cannot be ruled out. 
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Future work 
This work has given insight into the role of prophage during in vitro C. 
difficile biofilm formation. Several key steps forward would include the 
quantification of biofilm eDNA to confirm that the observed differential 
regulation of prophage genes between WT and LuxS, results in changes to 
the level of eDNA. As C. difficile has been shown to produce biofilm like 
structures in vivo (Semenyuk et al., 2015, Soavelomandroso et al., 2017). It 
would also be important to determine whether LuxS affects adherence to 
tissue culture cells with an aim of characterising its effect in vivo. The final 
step for this work would also be to establish the role of this enzyme in 
virulence.  
 
For the observed B. fragilis mediated inhibition of C. difficile, further analysis 
is required to fully characterise the mechanisms responsible. With inhibition 
only observed during biofilm growth, metabolomics studies including 
proteomic and RNA-seq analysis could be used to track metabolic changes 
at multiple timepoints, rather than the “snapshot” approach used. 
Additionally it would be useful to expand these studies to other members of 
the Bacteroidetes to identify whether the mechanism utilised by B. fragilis to 
inhibit C. difficile is species specific, or whether this is conserved amongst 
other species. 
 
As the key risk factor for the development of CDI is disruption to the gut 
microbiota, it would be interesting to further these studies with a number of 
species representative of both a healthy and diseased gut. Such studies in a 
physiologically relevant model, such as the vertical diffusion chamber model 
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developed in our laboratory, could help to shed light on the complex inter-
microbial interactions that are responsible for the colonisation resistance of 
the healthy microbiota.  
 
As a number of differentially expressed genes in B. fragilis, are annotated as 
hypothetical proteins with unknown function. Further analysis is needed to 
assess their impact during co-culture. Such work could yield the production 
of an inhibitory molecule against C. difficile.    
 
Finally, given the consistent up-regulation of the trehalose operon in LuxS.  It 
would be interesting to fully assess its role during co-culture. This could be 
done by testing a wider range of concentrations and assessing its impact on 
the CFU of both WT and LuxS.   
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Appendix  
 
Table S1: All Genes up- and down-regulated in B. fragilis, in C. difficile WT-
Bacteroides fragilis co-cultures relative to B. fragilis mono-culture. 
 Gene identifier log2FoldChange Product 
bf_rs_03152 1.31151618 RNA polymerase sigma factor 
bf_rs_01567 1.30582995 N-acetylmuramoyl-L-alanine amidase 
bf_rs_02264 1.29689246 tRNA-Arg(ccg) 
bf_rs_01254 1.28747467 Phytochrome-like protein cph1 
bf_rs_01030 1.27386249 L-fucose-proton symporter 
bf_rs_01257 1.19297587 SusD family protein 
bf_rs_01509 1.12575629 putative N-acetyltransferase YvbK 
bf_rs_01907 1.04601422 hypothetical protein 
bf_rs_02466 0.9293162 hypothetical protein 
bf_rs_00894 0.91851713 7-cyano-7-deazaguanine synthase 
bf_rs_02556 0.895506 3-deoxy-D-manno-octulosonic acid transferase 
bf_rs_00770 0.89420097 hypothetical protein 
bf_rs_01245 0.89229059 Putative multidrug export ATP-binding/permease protein 
bf_rs_01085 0.88099287 hypothetical protein 
bf_rs_00895 0.88060769 NADPH-dependent 7-cyano-7-deazaguanine reductase 
bf_rs_01448 0.87638903 Nicotinamide-nucleotide amidohydrolase PncC 
bf_rs_01836 0.86280653 hypothetical protein 
bf_rs_01057 0.84528417 50S ribosomal protein L35 
bf_rs_00537 0.84467834 Peptide-N-glycosidase F%2C N terminal 
bf_rs_01075 0.84349289 Abhydrolase family protein 
bf_rs_00189 0.83978061 Phospho-N-acetylmuramoyl-pentapeptide-transferase 
bf_rs_03080 0.82931744 hypothetical protein 
bf_rs_00834 0.82583297 Beta-1%2C4-mannooligosaccharide phosphorylase 
bf_rs_02026 0.81132105 lipid-A-disaccharide synthase 
bf_rs_01653 0.81109879 hypothetical protein 
bf_rs_02254 0.81081041 Aspartate/alanine antiporter 
bf_rs_02339 0.80775334 Arylsulfatase 
bf_rs_03030 0.80268521 DNA-invertase hin 
bf_rs_01201 0.80162109 D-3-phosphoglycerate dehydrogenase 
bf_rs_01736 -0.8274754 Putative zinc ribbon domain protein 
bf_rs_01302 -0.8357887 hypothetical protein 
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bf_rs_01112 -0.8588795 GDP-mannose 4%2C6-dehydratase 
bf_rs_01884 -0.8601448 Tyrocidine synthase 1 
bf_rs_02192 -0.8621834 hypothetical protein 
bf_rs_01418 -0.8666213 Helix-turn-helix 
bf_rs_01339 -0.8842581 Putative SOS response-associated peptidase YedK 
bf_rs_02268 -0.8963737 tRNA 2'-O-methylase 
bf_rs_02955 -0.9231776 Carboxymuconolactone decarboxylase family protein 
bf_rs_01351 -0.9304549 Succinyl-CoA ligase [ADP-forming] subunit beta 
bf_rs_01007 -0.955022 Flavodoxin 
bf_rs_01605 -0.979336 Hexokinase 
bf_rs_00279 -0.9864582 hypothetical protein 
bf_rs_01321 -0.9875694 putative deferrochelatase/peroxidase YfeX 
bf_rs_02874 -0.9876972 hypothetical protein 
bf_rs_01816 -0.9932022 Alpha-amylase precursor 
bf_rs_00505 -0.9941066 Putative pyridoxal phosphate-dependent aminotransferase 
EpsN 
bf_rs_02297 -1.0072175 hypothetical protein 
bf_rs_01005 -1.0122806 Dihydrolipoyllysine-residue acetyltransferase component of 
pyruvate dehydrogenase complex 
bf_rs_00888 -1.0513925 Chagasin family peptidase inhibitor I42 
bf_rs_00419 -1.0721486 Multidrug resistance protein MdtA precursor 
bf_rs_01154 -1.0728616 ECF RNA polymerase sigma factor SigH 
bf_rs_01264 -1.0747784 Hydroxylamine reductase 
bf_rs_00886 -1.0769047 Quercetin 2%2C3-dioxygenase 
bf_rs_01818 -1.090627 hypothetical protein 
bf_rs_00666 -1.1138356 hypothetical protein 
bf_rs_01014 -1.1191019 hypothetical protein 
bf_rs_00957 -1.1298746 hypothetical protein 
bf_rs_02248 -1.151859 hypothetical protein 
bf_rs_00131 -1.1907486 Nitroreductase family protein 
bf_rs_03151 -1.1943367 hypothetical protein 
bf_rs_00525 -1.1966945 hypothetical protein 
bf_rs_02975 -1.2255261 hypothetical protein 
bf_rs_01315 -1.2888614 Fimbrillin-A associated anchor proteins Mfa1 and Mfa2 
bf_rs_02081 -1.3625527 hypothetical protein 
bf_rs_01958 -1.3710842 hypothetical protein 
bf_rs_03077 -1.377462 hypothetical protein 
bf_rs_03003 -1.4034069 hypothetical protein 
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bf_rs_03155 9.28794563 Virus attachment protein p12 family protein 
bf_rs_03086 7.6349471 Desulfoferrodoxin 
bf_rs_03072 6.03325998 Rubrerythrin 
bf_rs_03166 4.65976216 hypothetical protein 
bf_rs_00677 2.93004973 hypothetical protein 
bf_rs_00222 2.65299814 hypothetical protein 
bf_rs_00221 2.26641901 DNA-binding transcriptional repressor MngR 
bf_rs_01618 2.23195774 hypothetical protein 
bf_rs_00148 1.93281884 L-fucose isomerase 
bf_rs_02052 1.75950799 NADP-dependent 7-alpha-hydroxysteroid dehydrogenase 
bf_rs_01338 1.72164992 tRNA-Arg(tct) 
bf_rs_00791 1.69832127 Alkyl hydroperoxide reductase subunit F 
bf_rs_02029 1.62338926 2-isopropylmalate synthase 
bf_rs_00043 1.58578594 tRNA-Gln(ttg) 
bf_rs_01305 1.56940593 Sensor histidine kinase RcsC 
bf_rs_01029 1.56776049 Galactokinase 
bf_rs_02411 1.54670918 Carbamoyl-phosphate synthase large chain 
bf_rs_02599 1.51925504 fec operon regulator FecR 
bf_rs_01253 1.49567239 UDP-glucose 4-epimerase 
bf_rs_02030 1.49141904 3-isopropylmalate dehydratase small subunit 
bf_rs_01061 1.46275613 indolepyruvate oxidoreductase subunit beta 
bf_rs_02028 1.45284187 3-isopropylmalate dehydrogenase 
bf_rs_02940 1.43121061 fec operon regulator FecR 
bf_rs_02241 1.41266608 fec operon regulator FecR 
bf_rs_02743 1.41160764 RNA polymerase sigma factor SigV 
bf_rs_00674 1.38757997 fec operon regulator FecR 
bf_rs_01987 1.37235468 hypothetical protein 
bf_rs_01783 1.35532527 hypothetical protein 
bf_rs_01568 1.31229239 integration host factor subunit alpha 
bf_rs_01699 1.30423791 hypothetical protein 
bf_rs_02031 1.295602 3-isopropylmalate dehydratase large subunit 
bf_rs_02841 1.28810105 hypothetical protein 
bf_rs_02675 1.24759394 Autoinducer 2 sensor kinase/phosphatase LuxQ 
bf_rs_00577 1.2413622 HTH-type transcriptional activator Btr 
bf_rs_01202 1.23666221 hypothetical protein 
bf_rs_01668 1.22879006 ACT domain protein 
bf_rs_03031 1.21730538 hypothetical protein 
bf_rs_02926 1.21276045 hypothetical protein 
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bf_rs_01426 1.19936263 Chaperone protein HtpG 
bf_rs_00627 1.18162145 Glycosyl hydrolase family 57 
bf_rs_03008 1.17199863 mRNA interferase YafQ 
bf_rs_02150 1.15409411 hypothetical protein 
bf_rs_00864 1.14407471 hypothetical protein 
bf_rs_00365 1.13961018 fec operon regulator FecR 
bf_rs_02832 1.13922453 23S ribosomal RNA 
bf_rs_01838 1.13912045 hypothetical protein 
bf_rs_00811 1.13837215 Outer membrane protein 41 precursor 
bf_rs_03132 1.13002777 hypothetical protein 
bf_rs_01239 1.10929565 Leucine Rich repeats (2 copies) 
bf_rs_03037 1.10816435 hypothetical protein 
bf_rs_02408 1.10660339 Fimbrillin-A associated anchor proteins Mfa1 and Mfa2 
bf_rs_02230 1.09961947 Acetolactate synthase isozyme 2 large subunit 
bf_rs_02399 1.08407984 hypothetical protein 
bf_rs_01086 1.08407605 hypothetical protein 
bf_rs_02433 1.07391745 Transcriptional regulatory protein DegU 
bf_rs_03138 1.07014526 hypothetical protein 
bf_rs_01784 1.06893257 hypothetical protein 
bf_rs_01566 1.06865561 transcriptional repressor DicA 
bf_rs_02590 1.06407662 site-specific tyrosine recombinase XerC 
bf_rs_00865 1.06398909 tRNA-Cys(gca) 
bf_rs_01565 1.04563885 hypothetical protein 
bf_rs_01379 1.03485885 tRNA-Lys(ctt) 
bf_rs_02389 1.02328388 30S ribosomal protein S2 
bf_rs_01277 1.02164857 Undecaprenol kinase 
bf_rs_00371 1.02120257 tRNA-Met(cat) 
bf_rs_02946 1.01803948 Tyrosine recombinase XerC 
bf_rs_01794 0.9987764 Inner membrane protein YhaI 
bf_rs_02390 0.99872926 30S ribosomal protein S9 
bf_rs_02252 0.99613625 Methylmalonyl-CoA mutase large subunit 
bf_rs_00843 0.98987401 Alpha-xylosidase 
bf_rs_00756 0.98619346 50S ribosomal protein L25 
bf_rs_03100 0.9843561 hypothetical protein 
bf_rs_00150 0.97580954 Lactaldehyde reductase 
bf_rs_01445 0.96350482 hypothetical protein 
bf_rs_00793 0.95952031 Alkyl hydroperoxide reductase subunit C 
bf_rs_01284 0.93733378 hypothetical protein 
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bf_rs_00846 0.93382112 hypothetical protein 
bf_rs_03009 0.93278166 hypothetical protein 
bf_rs_00863 0.92145531 Ferrous iron transport protein B 
bf_rs_02388 0.91253771 Elongation factor Ts 
bf_rs_03154 0.90735125 tRNA-Leu(taa) 
bf_rs_01704 0.90636011 Oxygen regulatory protein NreC 
bf_rs_03094 0.90350551 hypothetical protein 
bf_rs_00831 0.90337948 fec operon regulator FecR 
bf_rs_01062 0.90075564 2-oxoacid ferredoxin oxidoreductase 
bf_rs_03176 0.89918261 tRNA-Cys(gca) 
bf_rs_01586 0.89872304 Enamine/imine deaminase 
bf_rs_02895 0.89735416 hypothetical protein 
bf_rs_02533 0.89694346 30S ribosomal protein S7 
bf_rs_02973 0.88439951 hypothetical protein 
bf_rs_01705 0.88331711 hypothetical protein 
bf_rs_01329 0.8832437 7%2C8-dihydro-6-hydroxymethylpterin-pyrophosphokinase 
(HPPK) 
bf_rs_00113 0.8811749 Transcriptional regulatory protein CssR 
bf_rs_01126 0.87811703 hypothetical protein 
bf_rs_02779 0.87476747 tRNA-Ser(tga) 
bf_rs_01283 0.85878664 ATP synthase epsilon chain 
bf_rs_01904 0.84923802 putative multidrug resistance protein EmrK 
bf_rs_00893 0.84761778 hypothetical protein 
bf_rs_00753 0.84507226 hypothetical protein 
bf_rs_01440 0.83817494 LysM domain/BON superfamily protein 
bf_rs_02364 0.83783458 Outer membrane protein TolC precursor 
bf_rs_01900 0.83597516 Glutaconyl-CoA decarboxylase subunit beta 
bf_rs_02145 0.82745043 multifunctional tRNA nucleotidyl transferase/2'3'-cyclic 
phosphodiesterase/2'nucleotidase/phosphatase 
bf_rs_02960 0.82700303 Initiator Replication protein 
bf_rs_00591 0.82217009 tRNA-Tyr(gta) 
bf_rs_02781 0.81197346 Type-1 restriction enzyme R protein 
bf_rs_02908 0.81175107 putative type I restriction enzymeP M protein 
bf_rs_00021 0.80858197 hypothetical protein 
bf_rs_02534 0.80579627 30S ribosomal protein S12 
bf_rs_02532 0.80016137 Elongation factor G 
bf_rs_02086 -0.8081468 Membrane-bound lytic murein transglycosylase D precursor 
bf_rs_02659 -0.8224957 Rhomboid family protein 
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bf_rs_00696 -0.8475926 4-hydroxythreonine-4-phosphate dehydrogenase 
bf_rs_01143 -0.8547906 Glycerate dehydrogenase 
bf_rs_01631 -0.8768321 hypothetical protein 
bf_rs_01737 -0.8771644 hypothetical protein 
bf_rs_02111 -0.8832072 Pyridoxine kinase 
bf_rs_00381 -0.8951966 Pesticin receptor precursor 
bf_rs_01629 -0.9149566 hypothetical protein 
bf_rs_01477 -0.9190529 Sirohydrochlorin cobaltochelatase 
bf_rs_02293 -0.9222049 Alkaline phosphatase synthesis sensor protein PhoR 
bf_rs_01006 -0.9272701 2-oxoisovalerate dehydrogenase subunit beta 
bf_rs_00094 -0.9354762 putative oxidoreductase UxuB 
bf_rs_00655 -0.9413947 hypothetical protein 
bf_rs_01240 -0.9417596 hypothetical protein 
bf_rs_02707 -0.9484609 FKBP-type 22 kDa peptidyl-prolyl cis-trans isomerase 
bf_rs_01610 -0.9545397 Superoxide dismutase [Mn/Fe] 
bf_rs_02976 -0.9691988 hypothetical protein 
bf_rs_00859 -0.9742635 hypothetical protein 
bf_rs_02536 -0.9883208 hypothetical protein 
bf_rs_01771 -0.9915956 ECF RNA polymerase sigma factor SigG 
bf_rs_01273 -0.993827 Dihydroorotate dehydrogenase (quinone) 
bf_rs_01465 -1.0026354 Outer membrane efflux protein 
bf_rs_01800 -1.0056264 Quercetin 2%2C3-dioxygenase 
bf_rs_01153 -1.0121551 LemA family protein 
bf_rs_00804 -1.030075 5-amino-6-(5-phosphoribosylamino)uracil reductase 
bf_rs_02914 -1.0365247 hypothetical protein 
bf_rs_01094 -1.0393486 site-specific tyrosine recombinase XerD 
bf_rs_00858 -1.0467807 VIT family protein 
bf_rs_01920 -1.0537024 Toluene efflux pump periplasmic linker protein TtgD precursor 
bf_rs_00656 -1.0622069 Thioredoxin reductase 
bf_rs_00273 -1.0721348 Glutaminase 1 
bf_rs_02058 -1.0737126 2-oxoglutarate carboxylase small subunit 
bf_rs_02803 -1.0996581 NADP-dependent alcohol dehydrogenase C 2 
bf_rs_01486 -1.1164628 Multidrug export protein EmrB 
bf_rs_00695 -1.1196561 hypothetical protein 
bf_rs_00878 -1.1219033 Sodium-dependent dicarboxylate transporter SdcS 
bf_rs_02120 -1.1290797 hypothetical protein 
bf_rs_01709 -1.1314864 Thioredoxin-1 
bf_rs_03013 -1.13866 Iron-binding zinc finger CDGSH type 
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bf_rs_00996 -1.1438901 metal-dependent hydrolase 
bf_rs_00797 -1.1473893 hypothetical protein 
bf_rs_01168 -1.1700034 Outer membrane porin F precursor 
bf_rs_02276 -1.1734706 Ribonucleoside-diphosphate reductase NrdZ 
bf_rs_00311 -1.1769065 Chaperone protein Skp precursor 
bf_rs_02308 -1.1872936 Glutathione peroxidase homolog BsaA 
bf_rs_00779 -1.187941 H(+)/Cl(-) exchange transporter ClcA 
bf_rs_01503 -1.1915586 Ribonucleoside-diphosphate reductase subunit beta 
bf_rs_00721 -1.1956832 hypothetical protein 
bf_rs_00418 -1.2101859 Efflux pump membrane transporter BepE 
bf_rs_01487 -1.2124012 putative multidrug resistance protein EmrK 
bf_rs_00557 -1.2310067 Alpha/beta hydrolase family protein 
bf_rs_02334 -1.2444157 P-protein 
bf_rs_00796 -1.2459206 hypothetical protein 
bf_rs_02082 -1.2529842 hypothetical protein 
bf_rs_02077 -1.2532428 Beta-lactamase type II precursor 
bf_rs_00254 -1.2612446 hypothetical protein 
bf_rs_02722 -1.2625819 hypothetical protein 
bf_rs_00417 -1.271637 Outer membrane protein TolC precursor 
bf_rs_00844 -1.2830586 lipoprotein involved with copper homeostasis and adhesion 
bf_rs_00667 -1.2847118 hypothetical protein 
bf_rs_02045 -1.2950846 Cupin domain protein 
bf_rs_01396 -1.2964615 hypothetical protein 
bf_rs_02050 -1.2975506 hypothetical protein 
bf_rs_02095 -1.303823 Peptide methionine sulfoxide reductase MsrA/MsrB 
bf_rs_02059 -1.3089473 Methylmalonyl-CoA carboxyltransferase 1.3S subunit 
bf_rs_02034 -1.3091907 bacterioferritin 
bf_rs_02166 -1.314465 Anaerobic ribonucleoside-triphosphate reductase 
bf_rs_00198 -1.3231242 ECF RNA polymerase sigma factor SigH 
bf_rs_00556 -1.3269467 LemA family protein 
bf_rs_01960 -1.3378983 Oxygen-insensitive NAD(P)H nitroreductase 
bf_rs_00253 -1.3431219 Cytochrome c-type protein NrfH 
bf_rs_02567 -1.3476378 Anaerobic C4-dicarboxylate transporter DcuA 
bf_rs_02993 -1.3515175 LexA repressor 
bf_rs_00619 -1.3574769 RNA polymerase sigma factor SigM 
bf_rs_00356 -1.3640885 hypothetical protein 
bf_rs_01397 -1.3712617 hypothetical protein 
bf_rs_01989 -1.3715409 Pyruvate dehydrogenase [ubiquinone] 
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bf_rs_00272 -1.3728099 Glutamate decarboxylase 
bf_rs_01395 -1.3775276 hypothetical protein 
bf_rs_00238 -1.3800271 hypothetical protein 
bf_rs_02219 -1.3809837 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 
bf_rs_01684 -1.3927229 Diaminopimelate epimerase 
bf_rs_01325 -1.3940762 hypothetical protein 
bf_rs_01562 -1.3966586 acid-resistance membrane protein 
bf_rs_00355 -1.4124654 hypothetical protein 
bf_rs_01357 -1.4179478 putative peroxiredoxin 
bf_rs_00930 -1.4186478 Bifunctional aspartate aminotransferase and L-aspartate beta-
decarboxylase 
bf_rs_00233 -1.4294595 hypothetical protein 
bf_rs_00989 -1.4295437 DUF based on B. Theta Gene description 
bf_rs_00331 -1.4317878 hypothetical protein 
bf_rs_01957 -1.4418027 putative oxidoreductase/MSMEI_2347 
bf_rs_00990 -1.4525212 hypothetical protein 
bf_rs_00956 -1.4549231 hypothetical protein 
bf_rs_02113 -1.4572691 Lactate utilization protein B 
bf_rs_02538 -1.4592502 hypothetical protein 
bf_rs_00665 -1.460306 ECF RNA polymerase sigma factor SigW 
bf_rs_02537 -1.4639961 hypothetical protein 
bf_rs_00980 -1.4769224 putative inner membrane protein 
bf_rs_00133 -1.4941466 hypothetical protein 
bf_rs_01690 -1.5060874 Guanosine-5'-triphosphate%2C3'-diphosphate 
pyrophosphatase 
bf_rs_00332 -1.5129506 Malate dehydrogenase 
bf_rs_01266 -1.5325706 Transcriptional activator protein Anr 
bf_rs_01167 -1.5501012 Collagen triple helix repeat (20 copies) 
bf_rs_02083 -1.5580982 Phosphotransferase RcsD 
bf_rs_00452 -1.5665639 hypothetical protein 
bf_rs_02114 -1.5826976 Lactate utilization protein A 
bf_rs_01711 -1.6312913 5-methyltetrahydropteroyltriglutamate--homocysteine 
methyltransferase 
bf_rs_00234 -1.638754 hypothetical protein 
bf_rs_02080 -1.6469501 hypothetical protein 
bf_rs_02568 -1.655064 L-asparaginase 2 precursor 
bf_rs_02470 -1.6590086 PBP superfamily domain protein 
bf_rs_02051 -1.6643223 hypothetical protein 
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bf_rs_00931 -1.6680404 Aspartate/alanine antiporter 
bf_rs_01414 -1.6840453 Efflux pump membrane transporter BepE 
bf_rs_00235 -1.6996337 Periplasmic beta-glucosidase precursor 
bf_rs_00236 -1.700038 SusD family protein 
bf_rs_02197 -1.7017285 Outer membrane efflux protein 
bf_rs_00958 -1.7175992 hypothetical protein 
bf_rs_01544 -1.7186707 hypothetical protein 
bf_rs_01757 -1.7208456 hypothetical protein 
bf_rs_01295 -1.7226524 inner membrane protein 
bf_rs_00960 -1.7394796 hypothetical protein 
bf_rs_00854 -1.7404828 hypothetical protein 
bf_rs_02414 -1.7415846 Outer membrane protein 40 precursor 
bf_rs_01543 -1.7540328 hypothetical protein 
bf_rs_02930 -1.7691478 fermentation/respiration switch protein 
bf_rs_02569 -1.790518 hypothetical protein 
bf_rs_00329 -1.8197717 Glutamate/gamma-aminobutyrate antiporter 
bf_rs_02075 -1.8377218 hypothetical protein 
bf_rs_00330 -1.8482564 hypothetical protein 
bf_rs_00999 -1.8611781 hypothetical protein 
bf_rs_02905 -1.8651553 ISXO2-like transposase domain protein 
bf_rs_02802 -1.8757986 Putative NAD(P)H-dependent FMN-containing oxidoreductase 
YwqN 
bf_rs_02244 -1.8863317 Choloylglycine hydrolase 
bf_rs_00998 -1.8961329 hypothetical protein 
bf_rs_00237 -1.9472779 TonB-dependent Receptor Plug Domain protein 
bf_rs_01412 -1.9590933 Outer membrane protein OprM precursor 
bf_rs_02906 -2.0236036 hypothetical protein 
bf_rs_02469 -2.0237868 tetratricopeptide repeat protein 
bf_rs_00891 -2.0238123 Porin subfamily protein 
bf_rs_01274 -2.0261186 Acetylxylan esterase precursor 
bf_rs_01000 -2.0540976 hypothetical protein 
bf_rs_01307 -2.0886013 hypothetical protein 
bf_rs_00199 -2.1109472 hypothetical protein 
bf_rs_00200 -2.121964 putative TonB-dependent receptor precursor 
bf_rs_01092 -2.1261581 hypothetical protein 
bf_rs_00961 -2.1752793 hypothetical protein 
bf_rs_00908 -2.2150308 Histidine decarboxylase proenzyme precursor 
bf_rs_02474 -2.2428322 colicin uptake protein TolQ 
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bf_rs_02471 -2.2770435 Gram-negative bacterial tonB protein 
bf_rs_01363 -2.2862609 Inner membrane protein YhiM 
bf_rs_01413 -2.3699461 Efflux pump periplasmic linker BepF 
bf_rs_01090 -2.4543795 ECF RNA polymerase sigma factor SigW 
bf_rs_01091 -2.4580421 hypothetical protein 
bf_rs_02472 -2.7595166 Biopolymer transport protein ExbD/TolR 
bf_rs_02473 -2.8077479 Biopolymer transport protein ExbD/TolR 
bf_rs_00201 -2.9879808 hypothetical protein 
 
 
 
Table S2: All Genes up- and down-regulated in B. fragilis, in C. difficile LuxS-
Bacteroides fragilis co-cultures relative to B. fragilis mono-culture. 
 
 Gene identifier log2FoldChange Product 
bf_rs_03116 1.50249038 hypothetical protein 
bf_rs_00412 1.48934005 Tyrosine recombinase XerD 
bf_rs_02127 1.29548052 fec operon regulator FecR 
bf_rs_02593 1.2806558 tRNA-Leu(caa) 
bf_rs_01792 1.2353753 Reverse rubrerythrin-1 
bf_rs_02909 1.22084668 hypothetical protein 
bf_rs_01427 1.20096345 ATP-dependent Clp protease ATP-binding subunit ClpC 
bf_rs_02997 1.18828678 hypothetical protein 
bf_rs_01065 1.17672925 tRNA-Thr(cgt) 
bf_rs_00574 1.13371334 hypothetical protein 
bf_rs_01993 1.1096845 60 kDa chaperonin 
bf_rs_01994 1.0940297 10 kDa chaperonin 
bf_rs_02911 1.08305958 Tyrosine recombinase XerC 
bf_rs_02143 1.06695477 NAD-specific glutamate dehydrogenase 
bf_rs_02972 1.06319546 fec operon regulator FecR 
bf_rs_00620 1.03149045 fec operon regulator FecR 
bf_rs_01491 1.02145126 hypothetical protein 
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bf_rs_02039 1.01576918 tRNA-Phe(gaa) 
bf_rs_03113 0.99029687 hypothetical protein 
bf_rs_03172 0.98787019 tRNA-Arg(gcg) 
bf_rs_00358 0.98011931 MarR family protein 
bf_rs_00832 0.95663866 hypothetical protein 
bf_rs_00767 0.95138856 hypothetical protein 
bf_rs_01889 0.93817056 Septum formation protein Maf 
bf_rs_01282 0.93225515 ATP synthase subunit beta 
bf_rs_03056 0.92592987 hypothetical protein 
bf_rs_02999 0.92188748 hypothetical protein 
bf_rs_00178 0.90537518 30S ribosomal protein S20 
bf_rs_02814 0.89716045 hypothetical protein 
bf_rs_02866 0.8857347 hypothetical protein 
bf_rs_02896 0.8711559 hypothetical protein 
bf_rs_00295 0.86561938 50S ribosomal protein L34 
bf_rs_03169 0.84394207 tRNA-Asp(gtc) 
bf_rs_01072 0.84372681 Cellobiose 2-epimerase 
bf_rs_02507 0.83556286 50S ribosomal protein L36 
bf_rs_02553 0.81701194 30S ribosomal protein S21 
bf_rs_03177 0.80237688 tRNA-Lys(ttt) 
bf_rs_01910 0.80050296 50S ribosomal protein L31 type B 
bf_rs_01301 -0.8025912 dTDP-4-dehydrorhamnose reductase 
bf_rs_02606 -0.8052951 Aminopeptidase YwaD precursor 
bf_rs_01852 -0.8152527 Transaldolase 
bf_rs_01735 -0.8355356 putative oxidoreductase 
bf_rs_02275 -0.8444998 FMN reductase [NAD(P)H] 
bf_rs_02683 -0.8621557 Lipoprotein-releasing system transmembrane protein LolE 
bf_rs_00953 -0.8710608 putative A/G-specific adenine glycosylase YfhQ 
bf_rs_00810 -0.9141991 hypothetical protein 
bf_rs_02167 -0.9143676 Pyruvate formate-lyase 1-activating enzyme 
bf_rs_02588 -0.9255988 Bifunctional transcriptional activator/DNA repair enzyme Ada 
bf_rs_00809 -0.9858948 Cadmium%2C zinc and cobalt-transporting ATPase 
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bf_rs_01476 -1.017128 Colicin I receptor precursor 
bf_rs_01210 -1.0192883 putative metallo-hydrolase 
bf_rs_00766 -1.0324571 hypothetical protein 
bf_rs_01961 -1.0695528 Molecular chaperone Hsp31 and glyoxalase 3 
bf_rs_02112 -1.1114543 Lactate utilization protein C 
bf_rs_00727 -1.19678 hypothetical protein 
bf_rs_03146 -1.3302347 hypothetical protein 
bf_rs_01478 -1.3347272 hypothetical protein 
bf_rs_02716 -1.4038976 hypothetical protein 
bf_rs_03155 9.49727508 Virus attachment protein p12 family protein 
bf_rs_03086 7.42483668 Desulfoferrodoxin 
bf_rs_03072 5.99041778 Rubrerythrin 
bf_rs_03166 5.22671344 hypothetical protein 
bf_rs_00677 2.94941467 hypothetical protein 
bf_rs_00222 2.55126285 hypothetical protein 
bf_rs_00221 2.16886211 DNA-binding transcriptional repressor MngR 
bf_rs_01618 2.07361235 hypothetical protein 
bf_rs_02052 1.77272895 NADP-dependent 7-alpha-hydroxysteroid dehydrogenase 
bf_rs_02940 1.7284758 fec operon regulator FecR 
bf_rs_02743 1.69887539 RNA polymerase sigma factor SigV 
bf_rs_00043 1.67587978 tRNA-Gln(ttg) 
bf_rs_01338 1.66917587 tRNA-Arg(tct) 
bf_rs_03094 1.64631852 hypothetical protein 
bf_rs_01987 1.62881003 hypothetical protein 
bf_rs_02241 1.6208994 fec operon regulator FecR 
bf_rs_01305 1.61776139 Sensor histidine kinase RcsC 
bf_rs_02399 1.54668945 hypothetical protein 
bf_rs_01379 1.51680269 tRNA-Lys(ctt) 
bf_rs_00148 1.47897635 L-fucose isomerase 
bf_rs_03031 1.47570767 hypothetical protein 
bf_rs_00791 1.4591713 Alkyl hydroperoxide reductase subunit F 
bf_rs_03008 1.4538937 mRNA interferase YafQ 
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bf_rs_01565 1.45036582 hypothetical protein 
bf_rs_02411 1.4347406 Carbamoyl-phosphate synthase large chain 
bf_rs_02029 1.43244153 2-isopropylmalate synthase 
bf_rs_00365 1.42773623 fec operon regulator FecR 
bf_rs_01426 1.40284414 Chaperone protein HtpG 
bf_rs_01566 1.36719931 transcriptional repressor DicA 
bf_rs_02926 1.35419467 hypothetical protein 
bf_rs_01061 1.35058075 indolepyruvate oxidoreductase subunit beta 
bf_rs_00674 1.31952666 fec operon regulator FecR 
bf_rs_00846 1.31111918 hypothetical protein 
bf_rs_02028 1.28560337 3-isopropylmalate dehydrogenase 
bf_rs_02841 1.2694133 hypothetical protein 
bf_rs_03132 1.26257754 hypothetical protein 
bf_rs_01568 1.24792281 integration host factor subunit alpha 
bf_rs_00591 1.24630888 tRNA-Tyr(gta) 
bf_rs_02150 1.24574493 hypothetical protein 
bf_rs_00371 1.2423177 tRNA-Met(cat) 
bf_rs_02030 1.22383423 3-isopropylmalate dehydratase small subunit 
bf_rs_02031 1.22255565 3-isopropylmalate dehydratase large subunit 
bf_rs_00864 1.21646959 hypothetical protein 
bf_rs_03138 1.21442784 hypothetical protein 
bf_rs_02408 1.20626989 Fimbrillin-A associated anchor proteins Mfa1 and Mfa2 
bf_rs_03037 1.20593408 hypothetical protein 
bf_rs_01253 1.20349607 UDP-glucose 4-epimerase 
bf_rs_01783 1.19659048 hypothetical protein 
bf_rs_03176 1.19636334 tRNA-Cys(gca) 
bf_rs_02433 1.18260592 Transcriptional regulatory protein DegU 
bf_rs_02895 1.17406524 hypothetical protein 
bf_rs_03009 1.16616354 hypothetical protein 
bf_rs_01086 1.16540725 hypothetical protein 
bf_rs_01202 1.16407331 hypothetical protein 
bf_rs_01284 1.16107249 hypothetical protein 
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bf_rs_02599 1.13133631 fec operon regulator FecR 
bf_rs_01126 1.12127525 hypothetical protein 
bf_rs_01705 1.1114447 hypothetical protein 
bf_rs_03154 1.106627 tRNA-Leu(taa) 
bf_rs_02590 1.09676216 site-specific tyrosine recombinase XerC 
bf_rs_02675 1.09630555 Autoinducer 2 sensor kinase/phosphatase LuxQ 
bf_rs_01668 1.09579608 ACT domain protein 
bf_rs_00577 1.07939668 HTH-type transcriptional activator Btr 
bf_rs_01239 1.06702287 Leucine Rich repeats (2 copies) 
bf_rs_01784 1.0640091 hypothetical protein 
bf_rs_02946 1.0584182 Tyrosine recombinase XerC 
bf_rs_02832 1.0498986 23S ribosomal RNA 
bf_rs_02252 1.04906334 Methylmalonyl-CoA mutase large subunit 
bf_rs_02657 1.03765279 DNA-binding protein HU 
bf_rs_00865 1.0352581 tRNA-Cys(gca) 
bf_rs_01794 1.0333348 Inner membrane protein YhaI 
bf_rs_00863 1.01842316 Ferrous iron transport protein B 
bf_rs_02533 1.01465797 30S ribosomal protein S7 
bf_rs_01699 1.01265797 hypothetical protein 
bf_rs_01283 1.00391663 ATP synthase epsilon chain 
bf_rs_02779 1.0020912 tRNA-Ser(tga) 
bf_rs_02389 1.00101624 30S ribosomal protein S2 
bf_rs_02364 0.99687963 Outer membrane protein TolC precursor 
bf_rs_00831 0.99546516 fec operon regulator FecR 
bf_rs_00753 0.99535172 hypothetical protein 
bf_rs_01277 0.98879852 Undecaprenol kinase 
bf_rs_01445 0.98821021 hypothetical protein 
bf_rs_00627 0.9850084 Glycosyl hydrolase family 57 
bf_rs_01586 0.97286913 Enamine/imine deaminase 
bf_rs_00114 0.96362387 Signal-transduction histidine kinase senX3 
bf_rs_00811 0.95941118 Outer membrane protein 41 precursor 
bf_rs_02959 0.95457172 hypothetical protein 
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bf_rs_00113 0.95250686 Transcriptional regulatory protein CssR 
bf_rs_01029 0.94955754 Galactokinase 
bf_rs_03015 0.94822705 hypothetical protein 
bf_rs_01704 0.93246371 Oxygen regulatory protein NreC 
bf_rs_00793 0.93168683 Alkyl hydroperoxide reductase subunit C 
bf_rs_01838 0.92354425 hypothetical protein 
bf_rs_01329 0.88731815 7%2C8-dihydro-6-hydroxymethylpterin-pyrophosphokinase 
(HPPK) 
bf_rs_02390 0.88503445 30S ribosomal protein S9 
bf_rs_02023 0.87013396 hypothetical protein 
bf_rs_02230 0.86405934 Acetolactate synthase isozyme 2 large subunit 
bf_rs_00756 0.86104914 50S ribosomal protein L25 
bf_rs_00843 0.85771165 Alpha-xylosidase 
bf_rs_02908 0.85299383 putative type I restriction enzymeP M protein 
bf_rs_02534 0.85194894 30S ribosomal protein S12 
bf_rs_01908 0.84560935 Fructose-bisphosphate aldolase 
bf_rs_00150 0.84557721 Lactaldehyde reductase 
bf_rs_00893 0.82647446 hypothetical protein 
bf_rs_00021 0.82219587 hypothetical protein 
bf_rs_01900 0.80783599 Glutaconyl-CoA decarboxylase subunit beta 
bf_rs_02145 0.80663874 multifunctional tRNA nucleotidyl transferase/2'3'-cyclic 
phosphodiesterase/2'nucleotidase/phosphatase 
bf_rs_02388 0.80475804 Elongation factor Ts 
bf_rs_01440 0.80392404 LysM domain/BON superfamily protein 
bf_rs_02781 0.80238847 Type-1 restriction enzyme R protein 
bf_rs_00676 0.80123476 ECF RNA polymerase sigma factor SigW 
bf_rs_01629 -0.8022802 hypothetical protein 
bf_rs_02218 -0.8101734 Cytidylate kinase 
bf_rs_00915 -0.8115897 Cytidine deaminase 
bf_rs_03013 -0.8190102 Iron-binding zinc finger CDGSH type 
bf_rs_01610 -0.8238728 Superoxide dismutase [Mn/Fe] 
bf_rs_02914 -0.833247 hypothetical protein 
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bf_rs_01771 -0.8440513 ECF RNA polymerase sigma factor SigG 
bf_rs_01465 -0.8542414 Outer membrane efflux protein 
bf_rs_00667 -0.8587571 hypothetical protein 
bf_rs_01143 -0.8619834 Glycerate dehydrogenase 
bf_rs_02718 -0.867328 Miniconductance mechanosensitive channel MscM precursor 
bf_rs_00713 -0.8858522 GTPase Obg 
bf_rs_02803 -0.8956159 NADP-dependent alcohol dehydrogenase C 2 
bf_rs_02234 -0.901416 Serine dehydratase alpha chain 
bf_rs_02120 -0.9186621 hypothetical protein 
bf_rs_00418 -0.91889 Efflux pump membrane transporter BepE 
bf_rs_01800 -0.9265082 Quercetin 2%2C3-dioxygenase 
bf_rs_01486 -0.9302885 Multidrug export protein EmrB 
bf_rs_02308 -0.9336015 Glutathione peroxidase homolog BsaA 
bf_rs_02059 -0.9483879 Methylmalonyl-CoA carboxyltransferase 1.3S subunit 
bf_rs_01006 -0.950982 2-oxoisovalerate dehydrogenase subunit beta 
bf_rs_00796 -0.9578412 hypothetical protein 
bf_rs_00797 -0.9605315 hypothetical protein 
bf_rs_01709 -0.9715214 Thioredoxin-1 
bf_rs_00804 -0.99059 5-amino-6-(5-phosphoribosylamino)uracil reductase 
bf_rs_01397 -0.9999215 hypothetical protein 
bf_rs_00094 -1.0009305 putative oxidoreductase UxuB 
bf_rs_00417 -1.0044964 Outer membrane protein TolC precursor 
bf_rs_02086 -1.0142848 Membrane-bound lytic murein transglycosylase D precursor 
bf_rs_02536 -1.0237507 hypothetical protein 
bf_rs_01273 -1.0267843 Dihydroorotate dehydrogenase (quinone) 
bf_rs_00198 -1.0326919 ECF RNA polymerase sigma factor SigH 
bf_rs_00695 -1.0329689 hypothetical protein 
bf_rs_00273 -1.0403668 Glutaminase 1 
bf_rs_00133 -1.0426138 hypothetical protein 
bf_rs_00996 -1.0481186 metal-dependent hydrolase 
bf_rs_02722 -1.0489901 hypothetical protein 
bf_rs_02976 -1.0509659 hypothetical protein 
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bf_rs_01153 -1.0556578 LemA family protein 
bf_rs_02567 -1.0561453 Anaerobic C4-dicarboxylate transporter DcuA 
bf_rs_02050 -1.070767 hypothetical protein 
bf_rs_00557 -1.0770803 Alpha/beta hydrolase family protein 
bf_rs_00858 -1.0784808 VIT family protein 
bf_rs_02077 -1.0831795 Beta-lactamase type II precursor 
bf_rs_02111 -1.08887 Pyridoxine kinase 
bf_rs_02045 -1.0974955 Cupin domain protein 
bf_rs_00665 -1.1051248 ECF RNA polymerase sigma factor SigW 
bf_rs_00238 -1.1093411 hypothetical protein 
bf_rs_00844 -1.1187241 lipoprotein involved with copper homeostasis and adhesion 
bf_rs_00956 -1.1285733 hypothetical protein 
bf_rs_00878 -1.1336931 Sodium-dependent dicarboxylate transporter SdcS 
bf_rs_01325 -1.1429498 hypothetical protein 
bf_rs_02095 -1.1429531 Peptide methionine sulfoxide reductase MsrA/MsrB 
bf_rs_01094 -1.1488791 site-specific tyrosine recombinase XerD 
bf_rs_01989 -1.150831 Pyruvate dehydrogenase [ubiquinone] 
bf_rs_02538 -1.1514013 hypothetical protein 
bf_rs_02993 -1.1518235 LexA repressor 
bf_rs_01240 -1.154515 hypothetical protein 
bf_rs_00656 -1.1580733 Thioredoxin reductase 
bf_rs_00779 -1.1636445 H(+)/Cl(-) exchange transporter ClcA 
bf_rs_01487 -1.1673847 putative multidrug resistance protein EmrK 
bf_rs_01562 -1.1674059 acid-resistance membrane protein 
bf_rs_02537 -1.1718679 hypothetical protein 
bf_rs_00619 -1.1745272 RNA polymerase sigma factor SigM 
bf_rs_02659 -1.181242 Rhomboid family protein 
bf_rs_02058 -1.2097667 2-oxoglutarate carboxylase small subunit 
bf_rs_00311 -1.2125034 Chaperone protein Skp precursor 
bf_rs_02034 -1.2158301 bacterioferritin 
bf_rs_01957 -1.2235202 putative oxidoreductase/MSMEI_2347 
bf_rs_02470 -1.233513 PBP superfamily domain protein 
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bf_rs_01920 -1.2428509 Toluene efflux pump periplasmic linker protein TtgD precursor 
bf_rs_00331 -1.2440999 hypothetical protein 
bf_rs_01266 -1.2581519 Transcriptional activator protein Anr 
bf_rs_02114 -1.2751312 Lactate utilization protein A 
bf_rs_01396 -1.2754052 hypothetical protein 
bf_rs_01167 -1.2786394 Collagen triple helix repeat (20 copies) 
bf_rs_00272 -1.2798191 Glutamate decarboxylase 
bf_rs_00452 -1.2842719 hypothetical protein 
bf_rs_01395 -1.2880023 hypothetical protein 
bf_rs_01684 -1.2907739 Diaminopimelate epimerase 
bf_rs_00930 -1.2932448 Bifunctional aspartate aminotransferase and L-aspartate beta-
decarboxylase 
bf_rs_01503 -1.2942115 Ribonucleoside-diphosphate reductase subunit beta 
bf_rs_01960 -1.3016038 Oxygen-insensitive NAD(P)H nitroreductase 
bf_rs_02334 -1.3016943 P-protein 
bf_rs_00356 -1.3021361 hypothetical protein 
bf_rs_01295 -1.322733 inner membrane protein 
bf_rs_00980 -1.3254225 putative inner membrane protein 
bf_rs_01477 -1.3276994 Sirohydrochlorin cobaltochelatase 
bf_rs_01757 -1.3547535 hypothetical protein 
bf_rs_01357 -1.3565358 putative peroxiredoxin 
bf_rs_02906 -1.3577911 hypothetical protein 
bf_rs_00721 -1.3607892 hypothetical protein 
bf_rs_02083 -1.378718 Phosphotransferase RcsD 
bf_rs_02082 -1.3791335 hypothetical protein 
bf_rs_00330 -1.3858288 hypothetical protein 
bf_rs_01690 -1.3927457 Guanosine-5'-triphosphate%2C3'-diphosphate 
pyrophosphatase 
bf_rs_00958 -1.3980968 hypothetical protein 
bf_rs_02276 -1.4009092 Ribonucleoside-diphosphate reductase NrdZ 
bf_rs_02802 -1.4168218 Putative NAD(P)H-dependent FMN-containing oxidoreductase 
YwqN 
bf_rs_00960 -1.4225697 hypothetical protein 
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bf_rs_00999 -1.4252064 hypothetical protein 
bf_rs_01543 -1.4322056 hypothetical protein 
bf_rs_00854 -1.4373897 hypothetical protein 
bf_rs_00355 -1.4376383 hypothetical protein 
bf_rs_00931 -1.4384082 Aspartate/alanine antiporter 
bf_rs_00254 -1.4394472 hypothetical protein 
bf_rs_00236 -1.4453883 SusD family protein 
bf_rs_02075 -1.4465711 hypothetical protein 
bf_rs_02219 -1.4522683 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 
bf_rs_02051 -1.4625414 hypothetical protein 
bf_rs_00199 -1.4826842 hypothetical protein 
bf_rs_02905 -1.5008279 ISXO2-like transposase domain protein 
bf_rs_02707 -1.5012662 FKBP-type 22 kDa peptidyl-prolyl cis-trans isomerase 
bf_rs_00989 -1.5084547 DUF based on B. Theta Gene description 
bf_rs_02080 -1.518875 hypothetical protein 
bf_rs_02930 -1.5235038 fermentation/respiration switch protein 
bf_rs_02414 -1.5255661 Outer membrane protein 40 precursor 
bf_rs_00556 -1.5284233 LemA family protein 
bf_rs_00990 -1.5419876 hypothetical protein 
bf_rs_01544 -1.5552672 hypothetical protein 
bf_rs_02166 -1.5855451 Anaerobic ribonucleoside-triphosphate reductase 
bf_rs_01090 -1.5907614 ECF RNA polymerase sigma factor SigW 
bf_rs_00253 -1.5909689 Cytochrome c-type protein NrfH 
bf_rs_00233 -1.5950836 hypothetical protein 
bf_rs_02113 -1.6011148 Lactate utilization protein B 
bf_rs_01092 -1.6308183 hypothetical protein 
bf_rs_00332 -1.6386106 Malate dehydrogenase 
bf_rs_02244 -1.6620174 Choloylglycine hydrolase 
bf_rs_00235 -1.6642256 Periplasmic beta-glucosidase precursor 
bf_rs_00200 -1.6720026 putative TonB-dependent receptor precursor 
bf_rs_02568 -1.6946538 L-asparaginase 2 precursor 
bf_rs_00998 -1.7057636 hypothetical protein 
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bf_rs_00234 -1.716765 hypothetical protein 
bf_rs_00329 -1.7304116 Glutamate/gamma-aminobutyrate antiporter 
bf_rs_02569 -1.7390944 hypothetical protein 
bf_rs_00237 -1.7550649 TonB-dependent Receptor Plug Domain protein 
bf_rs_01414 -1.757573 Efflux pump membrane transporter BepE 
bf_rs_01412 -1.7893962 Outer membrane protein OprM precursor 
bf_rs_02197 -1.8030906 Outer membrane efflux protein 
bf_rs_01363 -1.8438535 Inner membrane protein YhiM 
bf_rs_00961 -1.8620409 hypothetical protein 
bf_rs_01307 -1.8783795 hypothetical protein 
bf_rs_01091 -1.9090812 hypothetical protein 
bf_rs_01000 -1.9486584 hypothetical protein 
bf_rs_00908 -1.9734855 Histidine decarboxylase proenzyme precursor 
bf_rs_00891 -2.0182707 Porin subfamily protein 
bf_rs_01711 -2.0210519 5-methyltetrahydropteroyltriglutamate--homocysteine 
methyltransferase 
bf_rs_02469 -2.1202025 tetratricopeptide repeat protein 
bf_rs_01274 -2.1584938 Acetylxylan esterase precursor 
bf_rs_00201 -2.2886939 hypothetical protein 
bf_rs_02471 -2.3649883 Gram-negative bacterial tonB protein 
bf_rs_01413 -2.3962242 Efflux pump periplasmic linker BepF 
bf_rs_02474 -2.5668838 colicin uptake protein TolQ 
bf_rs_02473 -2.8621158 Biopolymer transport protein ExbD/TolR 
bf_rs_02472 -2.9218949 Biopolymer transport protein ExbD/TolR 
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